<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003962" GROUP_ID="RENAL" ID="156302102023510041" MERGED_FROM="" MODIFIED="2011-02-16 22:27:49 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="019" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2011-02-16 22:27:49 +0100" MODIFIED_BY="Narelle Willis">
<TITLE>Non-immunosuppressive treatment for IgA nephropathy</TITLE>
<CONTACT MODIFIED="2011-02-16 22:27:49 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16154" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><MIDDLE_INITIALS>FM</MIDDLE_INITIALS><LAST_NAME>Strippoli</LAST_NAME><POSITION>Editor and Regional Coordinator</POSITION><EMAIL_1>Giovanni.Strippoli@diaverum.com</EMAIL_1><EMAIL_2>strippoli@negrisud.it</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Renal Group</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+39 080 5580776</PHONE_1><PHONE_2>+39 349 5705884</PHONE_2><FAX_1>+39 080 5580776</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-02-16 22:27:49 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="1FAF4EB782E26AA200831C196D3977EC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sharon</FIRST_NAME><LAST_NAME>Reid</LAST_NAME><EMAIL_1>sharon.reid@sydney.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>University of Sydney</ORGANISATION><ADDRESS_1>Edward Ford Building (A27)</ADDRESS_1><ADDRESS_2>Room 301C</ADDRESS_2><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 90369126</PHONE_1><FAX_1>+61 2 93515049</FAX_1></ADDRESS></PERSON><PERSON ID="F0B6373D82E26AA200CE015FE36A4BBC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peggy</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Cawthon</LAST_NAME><EMAIL_1>pcawthon@sfcc-cpmc.net</EMAIL_1><ADDRESS><DEPARTMENT>Research Institute</DEPARTMENT><ORGANISATION>California Pacific Medical Center</ORGANISATION><ADDRESS_1>185 Berry St</ADDRESS_1><ADDRESS_2>Suite 5700</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94107</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 415 6007426</PHONE_1><FAX_1>+1 415 5148159</FAX_1></ADDRESS></PERSON><PERSON ID="4552" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Craig</LAST_NAME><POSITION>Head of Clinical Research</POSITION><EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1><EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>a) Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead</DEPARTMENT><ORGANISATION>b) Sydney School of Public Health, The University of Sydney</ORGANISATION><CITY>Sydney</CITY><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON><PERSON ID="16145" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Joshua</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Samuels</LAST_NAME><POSITION>Assistant Professor of Medicine and Pediatrics</POSITION><EMAIL_1>Joshua.A.Samuels@uth.tmc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Nephrology / Pediatric Nephrology</DEPARTMENT><ORGANISATION>UT-Houston Health Science Center</ORGANISATION><ADDRESS_2>6431 Fannin Street, MSB 4-148</ADDRESS_2><CITY>Houston</CITY><ZIP>77030</ZIP><REGION>TX</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>713-500-6868</PHONE_1><PHONE_2>713-500-5670</PHONE_2><FAX_1>713-500-6882</FAX_1></ADDRESS></PERSON><PERSON ID="16131" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Donald</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Molony</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>Donald.A.Molony@uth.tmc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Internal Medicine</DEPARTMENT><ORGANISATION>UT-Houston Health Science Center</ORGANISATION><ADDRESS_1>Division of Renal Diseases and Hypertension</ADDRESS_1><ADDRESS_2>64312 Fannin St</ADDRESS_2><CITY>Houston</CITY><ZIP>77030</ZIP><REGION>TX</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>713-500-6868</PHONE_1><FAX_1>713-500-6882</FAX_1></ADDRESS></PERSON><PERSON ID="16154" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><MIDDLE_INITIALS>FM</MIDDLE_INITIALS><LAST_NAME>Strippoli</LAST_NAME><EMAIL_1>Giovanni.Strippoli@diaverum.com</EMAIL_1><EMAIL_2>strippoli@negrisud.it</EMAIL_2><ADDRESS><DEPARTMENT>a) Mario Negri Sud Consortium, Santa Maria Imbaro (Ch), Italy</DEPARTMENT><ORGANISATION>b) Sydney School of Public Health, University of Sydney, Australia, c) Diaverum Medical-Scientific Office</ORGANISATION><CITY>Lund</CITY><COUNTRY CODE="SE">Sweden</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-08-04 15:24:52 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="14" MONTH="7" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="7" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="9" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-08 09:59:12 +1100" MODIFIED_BY="Narelle S Willis"/>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-02-17 08:21:13 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2011-02-17 08:10:37 +1100" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2011-02-07 17:48:31 +1100" MODIFIED_BY="Narelle S Willis">Non-immunosuppressive treatment for IgA nephropathy</TITLE>
<SUMMARY_BODY MODIFIED="2011-02-09 15:45:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>IgA nephropathy (IgAN) is the most common primary glomerular disease with approximately 30% to 40% of patients progressing to end-stage kidney disease (ESKD) within 20 years. The most common regimens include immunosuppressive agents, however the risks of long-term treatment often outweigh the potential benefits. Non-immunosuppressive options, including fish oils, anticoagulants, antihypertensive agents and tonsillectomy have also been examined but not reviewed systematically.</P>
<P>We included 56 studies enrolling 2838 participants. Antihypertensive agents were the most beneficial non-immunosuppressive intervention for IgAN. The antihypertensives examined here were predominantly angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or combinations of both, compared with other antihypertensives and other agents. The benefits of antihypertensive agents appear to potentially outweigh the harms in patients with IgAN. The benefits were mostly reported as a reduction in 24 hour proteinuria. There is no evidence that treatment with any of the antihypertensive agents evaluated to date affect major renal and/or cardiovascular endpoints or long-term mortality risk beyond the benefit that arises from controlling hypertension in patients with IgAN. The RCT evidence is insufficiently robust to demonstrate efficacy for any of the other non-immunosuppressive therapies evaluated here.</P>
<P>IgAN remains a disease in search of adequately powered RCTs to reliably inform clinical practice. More and better evidence is needed to understand the magnitude of benefit and the possible risks of anti-hypertensive or more specifically of ACEi/ARB therapy alone or in combination and which specific types of patients with the IgAN might have the greatest potential for benefit. For other non-immunosuppressive therapies, where benefit nor significant harm has yet to be demonstrated, there remains some justification for further exploration of the potential benefits.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-02-09 14:04:31 +1100" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2011-02-07 17:04:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>IgA nephropathy (IgAN) is the most common primary glomerular disease with approximately 30% to 40% of patients progressing to end-stage kidney disease (ESKD) within 20 years. The most common regimens include immunosuppressive agents, however the risks of long-term treatment often outweigh the potential benefits. Non-immunosuppressive options, including fish oils, anticoagulants, antihypertensive agents and tonsillectomy have also been examined but not reviewed systematically.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-01-12 14:33:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>To assess the benefits and harms of non-immunosuppressive treatments for treating IgAN in adults and children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-02-09 14:00:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>In July 2010 we searched the Cochrane Renal Group's specialised register, CENTRAL (in <I>The Cochrane Library</I>)<I>, </I>MEDLINE (from 1966) and EMBASE (from 1980). We also searched reference lists of included studies, review articles and contacted local and international experts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-02-07 16:58:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Randomised controlled trials (RCTs) of non-immunosuppressive agents in adults and children with biopsy-proven IgAN were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-01-12 16:46:33 +1100" MODIFIED_BY="Narelle S Willis">
<P>Two authors independently reviewed search results, extracted data and assessed study quality. Results were expressed as mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI) using a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-09 14:04:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>We included 56 studies (2838 participants). Antihypertensive agents were the most beneficial non-immunosuppressive intervention for IgAN. The antihypertensives examined were predominantly angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or combinations of both, versus other antihypertensives and other agents. The benefits of antihypertensive agents, particularly inhibitors of the renin angiotensin system, appear to potentially outweigh the harms in patients with IgAN. The benefits are largely manifest as a reduction in proteinuria, a surrogate outcome. There is no evidence that treatment with any of the antihypertensive agents evaluated affect major renal and/or cardiovascular endpoints or long-term mortality risk beyond the benefit that arises from controlling hypertension in patients with IgAN. The RCT evidence is insufficiently robust to demonstrate efficacy for any of the other non-immunosuppressive therapies evaluated here.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-02-08 19:23:20 +1100" MODIFIED_BY="Narelle S Willis">
<P>IgAN remains a disease in search of adequately powered RCTs to reliably inform clinical practice. More and better evidence is needed to understand the magnitude of benefit and the possible risks of anti-hypertensive or more specifically of ACEi/ARB therapy alone or in combination and which specific types of patients with the IgAN might have the greatest potential for benefit. For other non-immunosuppressive therapies, where neither benefit nor significant harm has yet to be demonstrated, there remains some justification for further exploration of the potential benefits.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-02-17 08:21:13 +1100" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2011-02-09 15:46:27 +1100" MODIFIED_BY="Narelle S Willis">
<CONDITION MODIFIED="2011-02-09 15:45:53 +1100" MODIFIED_BY="Narelle S Willis">
<P>IgA nephropathy (IgAN) was first described in 1968 by Dr J Berger. Characterised by prominent diffuse mesangial IgA deposits at immunofluorescent microscopy, the condition was initially thought to be a rare and benign cause of recurrent haematuria (<LINK REF="REF-Berger-1968" TYPE="REFERENCE">Berger 1968</LINK>). It has since become apparent that IgAN is neither rare nor entirely benign. Although biopsy practices differ from region to region, affecting the frequency of diagnosis of IgAN, it is now known that IgAN is the most common primary glomerular disease worldwide (<LINK REF="REF-D_x0027_Amico-1987" TYPE="REFERENCE">D'Amico 1987</LINK>).</P>
<P>While about 20% of patients affected by IgAN experience lasting remission (<LINK REF="REF-Nolin-1999" TYPE="REFERENCE">Nolin 1999</LINK>), end-stage kidney disease (ESKD) will develop in 15% to 20% of patients within 10 years from the apparent onset of the disease and in up to 30% to 40% within 20 years (<LINK REF="REF-Schena-2001" TYPE="REFERENCE">Schena 2001</LINK>).</P>
<P>Most individuals who develop IgAN have degalctosylated IgA involving <I>0-</I>linked glycans in the hinge region of IgA1. This results in the potential for the generation of autoantibodies and the formation of circulating immune complexes which deposit in the glomerular mesangium and lead to the clinical manifestations of the disease (<LINK REF="REF-Glassock-2009" TYPE="REFERENCE">Glassock 2009</LINK>; <LINK REF="REF-Julian-1999" TYPE="REFERENCE">Julian 1999</LINK>; <LINK REF="REF-Mestecky-1993" TYPE="REFERENCE">Mestecky 1993</LINK>). Despite the progression in understanding of the pathogenesis of IgAN, a consensus on optimal treatment for IgAN has yet to be established.</P>
<P>Recent meta-analyses have examined the evidence for treatment of both adults and children (<LINK REF="REF-Nolin-1999" TYPE="REFERENCE">Nolin 1999</LINK>) with IgAN to find optimal regimens. These analyses included studies of variable methodological quality, mostly case series and other forms of non-randomised evaluations. These data have resulted in conflicting information regarding the optimal therapy. The most commonly used regimens include immunosuppressive agents, however the risks of long-term treatment often outweigh the potential benefits (<LINK REF="REF-Samuels-2003a" TYPE="REFERENCE">Samuels 2003a</LINK>).</P>
</CONDITION>
<THEORY MODIFIED="2011-02-08 19:24:41 +1100" MODIFIED_BY="Narelle S Willis">
<P>Non-immunosuppressive therapeutic options, including fish oils, anticoagulants, antihypertensive agents and tonsillectomy have also been examined. The rationale for administration of fish oils, anticoagulants and antihypertensive agents is an effect on the pathogenesis of renal damage with possible decrease of both renal inflammation and glomerulosclerosis. The potential benefits of tonsillectomy are proposed to be due to elimination of a source for the defective IgA1 (which is manufactured in the tonsils as well as in the bone marrow) (<LINK REF="REF-Glassock-2009" TYPE="REFERENCE">Glassock 2009</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-02-09 15:46:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Given the burden of disease and the known risks of progression, a systematic review of the benefits and harms of fish oil treatments, antihypertensive agents and other non-immunosuppressive treatments for patients with IgAN will aid healthcare providers in their management of this condition.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-02-09 15:46:38 +1100" MODIFIED_BY="Narelle S Willis">
<P>This review aims to assess the benefits and harms of non-immunosuppressive treatments (e.g. fish oils, antihypertensive agents, anticoagulants, tonsillectomy and other non-immunosuppressive agents) for the treatment of IgAN in adults and children.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-02-09 16:01:42 +1100" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2011-02-09 15:56:09 +1100" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES MODIFIED="2011-01-12 18:11:35 +1100" MODIFIED_BY="Narelle S Willis">
<P>Any randomised controlled trials (RCTs) and quasi-RCTs evaluating the benefits and harms of fish oil, antihypertensive agents, anticoagulant agents, tonsillectomy and other non-immunosuppressive agents versus placebo/no treatment or any other non-immunosuppressive treatment for IgAN patients were included. The first period of randomised, cross-over studies, where separate data was available, were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-02-09 15:46:56 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Adult and children with biopsy-proven IgAN (presence of IgA mesangial deposits evident as mesangial expansion by standard histopathology examination and IgA staining by immunofluorescence). Studies where chronic glomerulonephropathies were grouped together, but separate data for IgAN was not given, were included if &gt; 75% of included participants had IgAN.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Studies of non-immunosuppressive agents used in people with chronic nephropathies but not IgAN were excluded.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-02-07 17:50:57 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Fish oil supplements (any dose, type or duration) versus placebo/no treatment.</LI>
<LI>Fish oil supplements (any dose, type or duration) versus any other non-immunosuppressive treatment (including head to head comparisons).</LI>
<LI>Antihypertensive agents (any dose, type or duration) versus placebo/no treatment.</LI>
<LI>Antihypertensive agents (any dose, type or duration) versus any other non-immunosuppressive treatment (including head to head comparisons).</LI>
<LI>Antiplatelet agents/anticoagulants (any dose, type or duration), versus placebo/no treatment.</LI>
<LI>Antiplatelet agents/anticoagulants (any dose, type or duration) versus any other non-immunosuppressive treatment (including head to head comparisons).</LI>
<LI>Tonsillectomy versus placebo/no treatment.</LI>
<LI>Tonsillectomy versus any other non-immunosuppressive treatment (including head to head comparisons).</LI>
<LI>Other non-immunosuppressive treatment for IgAN (e.g. statins, phenytoin, herbal medicine, urokinase, vitamin E, sodium cromoglycate) versus placebo/no treatment.</LI>
<LI>Other non-immunosuppressive treatment for IgAN (e.g. statins, phenytoin, herbal medicine, urokinase, vitamin E, sodium cromoglycate) versus any other non-immunosuppressive treatment (including head to head comparisons).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-02-09 15:56:09 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Progression or improvement in kidney disease. Where possible, time to reach each end point was included in the analysis. End points include attainment of:</LI>
<UL>
<LI>ESKD requiring renal replacement therapy (RRT)</LI>
<LI>Doubling of serum creatinine (SCr) concentration</LI>
<LI>&gt; 50% increase in SCr</LI>
<LI>&gt; 50% decrease in creatinine clearance (CrCl)</LI>
<LI>Remission of haematuria</LI>
<LI>Remission of proteinuria</LI>
<LI>Absolute change in the SCr (mg/dL or &#956;mol/L)</LI>
<LI>Absolute change in CrCl (mL/min or mL/min/1.73 m²)</LI>
<LI>Changes in daily proteinuria (g/24 h)</LI>
</UL>
<LI>All-cause mortality</LI>
<LI>Any adverse event</LI>
<LI>Infection rate</LI>
<LI>Changes in any measure of bone density</LI>
<LI>Fractures</LI>
<LI>Changes in any measure of quality of life (QoL)</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-02-09 15:57:41 +1100" MODIFIED_BY="Narelle S Willis">
<ELECTRONIC_SEARCHES MODIFIED="2011-02-09 15:56:49 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>The Cochrane Renal Group&#8217;s specialised register using keywords relevant to this review. The register is populated using the following strategies:</LI>
<OL>
<LI>Screening of weekly Ovid MEDLINE AutoAlerts using a search strategy covering the scope of the Group (see the Renal Group&#8217;s module under Specialised Register at <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html">http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html</A>) plus the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>).</LI>
<LI>Quarterly searches of NEW records in the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> using a search strategy covering the scope of the Group.</LI>
<LI>Records handsearched by the Renal Group. The Renal Group has undertaken extensive handsearching of renal-related journals and conference proceedings, therefore we did not specifically search conference proceedings for this review. For a full list of journals and conference proceedings handsearched by the Renal Group use the link to its module (<LINK REF="REF-Renal-Group-2010" TYPE="REFERENCE">Renal Group 2010</LINK>).</LI>
</OL>
<LI>MEDLINE (from 1966) using the optimally sensitive strategy developed for The Cochrane Collaboration to identify RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) with a specific search strategy developed with input from the Trial Search Coordinator.</LI>
<LI>EMBASE (from 1980) using a search strategy adapted from that developed for The Cochrane Collaboration to identify RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) together with a specific search strategy developed with input from the Trial Search Coordinator.</LI>
</OL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-02-09 15:57:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Additional studies were located through reference lists of all included studies, review articles and through contact with local and international experts in the field.</LI>
<LI>Information about unpublished or incomplete studies was asked by email correspondence of investigators known to be involved in previous studies.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-02-09 16:01:42 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_SELECTION MODIFIED="2011-02-09 15:58:35 +1100" MODIFIED_BY="Narelle S Willis">
<P>The search strategy described was used to obtain titles and abstracts of studies that appeared relevant to the review. The titles and abstracts were screened independently by the two authors, who discarded studies that were not applicable based on our inclusion criteria. Two authors independently assessed retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria. Disagreements were resolved in consultation with other authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-01-12 18:28:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data extraction was carried out by the same authors independently using standard data extraction forms. Studies reported in non-English language journals were translated, where possible, before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Disagreements were resolved in consultation with other authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-01-19 17:43:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>The quality of studies to be included was assessed independently by two authors without blinding to authorship or journal using the checklist developed for the Cochrane Renal Group (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). Discrepancies were resolved by discussion with other authors. The items assessed were;</P>
<UL>
<LI>allocation concealment,</LI>
<LI>blinding of investigators, participants, outcome assessors and data analysts,</LI>
<LI>intention-to-treat analysis, and</LI>
<LI>completeness to follow-up.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-02-09 15:59:09 +1100" MODIFIED_BY="Narelle S Willis">
<P>For dichotomous outcomes (e.g. ESKD, &gt; 50% increase in SCr, &gt; 50% decrease in CrCl, remission of proteinuria/haematuria, all-cause mortality) results were expressed as risk ratios (RR) with 95% confidence intervals (CI) for individual studies.</P>
<P>Where continuous scales of measurement were used to assess the effects of treatment (e.g. SCr, CrCl, daily proteinuria) the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-02-09 16:00:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>For dichotomous outcomes, to avoid double counting where studies had multiple intervention groups, both the number of events and the total number of participants in the control group were divided up. For continuous outcomes, only the total numbers of participants in the control group were divided up (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-01-12 16:59:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>Any further information required from the original author was requested by written correspondence (email) and any relevant information obtained in this manner was included in the review.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-02-09 16:00:24 +1100" MODIFIED_BY="Narelle S Willis">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with a P of 0.05 used for statistical significance and the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-02-09 16:00:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data were pooled using a random effects model but the fixed effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-02-09 16:01:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>Subgroup analyses were performed wherever possible to explore how potential sources of heterogeneity (related to characteristics of the population: children versus adults, populations with different degrees of renal impairment, populations with different stage of IgAN based on renal biopsy; interventions: different types and doses of fish oil, different types and doses of antihypertensive agent, different types and doses of anticoagulant, different techniques of tonsillectomy) may influence treatment effect.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-02-09 16:22:13 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2011-02-09 16:02:56 +1100" MODIFIED_BY="Narelle S Willis">
<SEARCH_RESULTS MODIFIED="2011-02-09 16:02:03 +1100" MODIFIED_BY="Narelle S Willis">
<P>The combined search of MEDLINE, EMBASE, CENTRAL, the Cochrane Renal Group specialised registry, handsearching of reference lists and contact with experts, identified a total of 2872 potentially relevant articles. Duplicate publications (433) were excluded. Of the remaining 2439 reports, 2305 were excluded after title and abstract review. This left 134 reports of potentially eligible studies that underwent full text review. Of these 22 were excluded (not RCTs, not relevant population or intervention) leaving 112 reports of studies eligible for inclusion. Of these there were 56 studies, with 56 secondary publications, enrolling a total of 2838 participants (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-02-09 16:02:56 +1100" MODIFIED_BY="Narelle S Willis">
<P>The 56 studies were grouped according to the category of intervention and the comparisons made (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> <I>Key characteristics of included studies</I>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Fish oil (7 studies, 402 participants)</HEADING>
<UL>
<LI>Fish oil versus placebo/no treatment (4 studies, 265 participants: <LINK REF="STD-Bennett-1989" TYPE="STUDY">Bennett 1989</LINK>; <LINK REF="STD-Donadio-1994" TYPE="STUDY">Donadio 1994</LINK>; <LINK REF="STD-NA-IgAN-Study-2006" TYPE="STUDY">NA IgAN Study 2006</LINK>; <LINK REF="STD-Pettersson-1994" TYPE="STUDY">Pettersson 1994</LINK>)</LI>
<LI>Fish oil versus symptomatic treatment (1 study, 34 participants: <LINK REF="STD-Alexopoulos-2004" TYPE="STUDY">Alexopoulos 2004</LINK>)</LI>
<UL>
<LI>In <LINK REF="STD-Alexopoulos-2004" TYPE="STUDY">Alexopoulos 2004</LINK> the symptomatic treatment included angiotensin converting enzyme inhibitors (ACEi) ± beta-blockers (BB) or calcium channel blockers (CCB) to treat hypertension and diuretics if there was evidence of severe oedema or congestive heart failure.</LI>
</UL>
<LI>High versus low dose fish oil(1 study, 73 participants: <LINK REF="STD-Donadio-2001" TYPE="STUDY">Donadio 2001</LINK>)</LI>
<LI>Fish oil + other treatment versus other treatment (1 study, 30 participants: <LINK REF="STD-Costanzi-2006" TYPE="STUDY">Costanzi 2006</LINK>)</LI>
<UL>
<LI>Other treatment was ACEi + angiotensin receptor blockers (ARB)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antihypertensive agents (30 studies, 1587 participants)</HEADING>
<P>Antihypertensive agents used were ACEi, ARB, BB, and CCB. The effect of the antihypertensive agents was examined as a group and where possible antihypertensive type/class effect was examined in subgroup analysis.</P>
<UL>
<LI>Antihypertensive agents versus placebo/no treatment (4 studies, 251 participants: <LINK REF="STD-HKVIN-Study-2006" TYPE="STUDY">HKVIN Study 2006</LINK>; <LINK REF="STD-IgACE-Study-2001" TYPE="STUDY">IgACE Study 2001</LINK>; <LINK REF="STD-Maschio-1994" TYPE="STUDY">Maschio 1994</LINK>*; <LINK REF="STD-Nakamura-2000" TYPE="STUDY">Nakamura 2000</LINK>)</LI>
</UL>
<UL>
<LI>Antihypertensive agents versus other treatment (22 studies, 1060 participants: <LINK REF="STD-Bannister-1995" TYPE="STUDY">Bannister 1995</LINK>; <LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>; <LINK REF="STD-Hashizume-1998" TYPE="STUDY">Hashizume 1998</LINK>; <LINK REF="STD-Horita-2007" TYPE="STUDY">Horita 2007</LINK>; <LINK REF="STD-JLIGHT-Study-2003" TYPE="STUDY">JLIGHT Study 2003</LINK>; <LINK REF="STD-Kanno-2005" TYPE="STUDY">Kanno 2005</LINK>; <LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>*; <LINK REF="STD-Nakamura-2000" TYPE="STUDY">Nakamura 2000</LINK>; <LINK REF="STD-Nakamura-2007" TYPE="STUDY">Nakamura 2007</LINK>; <LINK REF="STD-Nakao-2001" TYPE="STUDY">Nakao 2001</LINK>*; <LINK REF="STD-Panichi-2000" TYPE="STUDY">Panichi 2000</LINK>*; <LINK REF="STD-Park--2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Perico-1998" TYPE="STUDY">Perico 1998</LINK>; <LINK REF="STD-Praga-2003" TYPE="STUDY">Praga 2003</LINK>; <LINK REF="STD-Roccatello-2000" TYPE="STUDY">Roccatello 2000</LINK>*; <LINK REF="STD-Russo-2001" TYPE="STUDY">Russo 2001</LINK>*; <LINK REF="STD-Shi-2002" TYPE="STUDY">Shi 2002</LINK>; <LINK REF="STD-Shimizu-2008" TYPE="STUDY">Shimizu 2008</LINK>; <LINK REF="STD-Tesar-1999" TYPE="STUDY">Tesar 1999</LINK>*; <LINK REF="STD-Woo-1990" TYPE="STUDY">Woo 1990</LINK>; <LINK REF="STD-Woo-2008" TYPE="STUDY">Woo 2008</LINK>)</LI>
<UL>
<LI>The other treatment was either another antihypertensive (generally comparisons were made with ACEi versus other antihypertensive such as CCB or BB), symptomatic treatment (non ACEi antihypertensives such as CCB, BB or alpha blockers (AB)), herbal medicine, or an anticoagulant/antiplatelet.</LI>
<LI>Where possible antihypertensive type effect was examined in subgroup analyses.</LI>
</UL>
</UL>
<UL>
<LI>Antihypertensive agents + other treatment versus other treatment (8 studies, 408 participants: <LINK REF="STD-Bang-1994" TYPE="STUDY">Bang 1994</LINK>; <LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>; <LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>; <LINK REF="STD-Guan-2005" TYPE="STUDY">Guan 2005</LINK>; <LINK REF="STD-Horita-2004" TYPE="STUDY">Horita 2004</LINK>; <LINK REF="STD-Horita-2007" TYPE="STUDY">Horita 2007</LINK>; <LINK REF="STD-Nakamura-2007" TYPE="STUDY">Nakamura 2007</LINK>; <LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>*)</LI>
<UL>
<LI>Other treatments were used in both comparison arms and included another antihypertensive, anticoagulants ± steroids and herbal medicine.</LI>
<LI>
<LINK REF="STD-Horita-2004" TYPE="STUDY">Horita 2004</LINK> and <LINK REF="STD-Nakamura-2007" TYPE="STUDY">Nakamura 2007</LINK> compared ACEi + ARB versus ACEi or ARB</LI>
<LI>Where possible antihypertensive type/class effect was examined in subgroup analysis.</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antiplatelets and anticoagulants (5 studies, 152 participants)</HEADING>
<P>Antiplatelet and anticoagulant agents used were warfarin, dipyridamole, aspirin, defibrotide and ticoplidine.</P>
<UL>
<LI>Antiplatelet/anticoagulant versus placebo/no treatment (2 studies, 33 participants: <LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK>*; <LINK REF="STD-Lee-1997" TYPE="STUDY">Lee 1997</LINK>)</LI>
<UL>
<LI>
<LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK> compared dipyridamole to placebo</LI>
<LI>
<LINK REF="STD-Lee-1997" TYPE="STUDY">Lee 1997</LINK> compared dipyridamole + warfarin to no treatment</LI>
</UL>
<LI>Antiplatelet/anticoagulant versus other treatment (1 study, 52 participants: <LINK REF="STD-Chan-1987" TYPE="STUDY">Chan 1987</LINK>)</LI>
<UL>
<LI>
<LINK REF="STD-Chan-1987" TYPE="STUDY">Chan 1987</LINK> compared aspirin + dipyridamole to vitamin B complex.</LI>
</UL>
</UL>
<UL>
<LI>Antiplatelet/anticoagulant + other treatment versus other treatment (2 studies, 67 participants: <LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>; <LINK REF="STD-Frasca-1997" TYPE="STUDY">Frasca 1997</LINK>)</LI>
<UL>
<LI>Other treatments were used in both comparator arms.</LI>
<LI>
<LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK> compared ticlopidine + ACEi to ACEi or BB.</LI>
<LI>
<LINK REF="STD-Frasca-1997" TYPE="STUDY">Frasca 1997</LINK> compared defibrotide + steroids to steroids.</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tonsillectomy (2 studies, 79 participants)</HEADING>
<UL>
<LI>Tonsillectomy + other treatment versus other treatment (<LINK REF="STD-Hotta-1993" TYPE="STUDY">Hotta 1993</LINK>; <LINK REF="STD-Kawasaki-2006" TYPE="STUDY">Kawasaki 2006</LINK>).</LI>
<UL>
<LI>
<LINK REF="STD-Hotta-1993" TYPE="STUDY">Hotta 1993</LINK> compared tonsillectomy + steroid pulse initially + cyclophosphamide + dipyridamole + warfarin during the steroid therapy versus steroid pulse initially + cyclophosphamide + dipyridamole + warfarin during the steroid therapy.</LI>
<LI>
<LINK REF="STD-Kawasaki-2006" TYPE="STUDY">Kawasaki 2006</LINK> compared tonsillectomy + methylprednisolone pulse + PWD (prednisolone, warfarin, dipyridamole) versus PWD + mizoribine.</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statins (2 studies, 51 participants)</HEADING>
<UL>
<LI>Statins (fluvastatin) versus placebo/no treatment (1 study, 21 participants: <LINK REF="STD-Buemi-2000" TYPE="STUDY">Buemi 2000</LINK>*)</LI>
<LI>Statins (fluvastatin) + other treatment versus other treatment (1 study, 30 participants: <LINK REF="STD-Kano-2003" TYPE="STUDY">Kano 2003</LINK>)</LI>
<UL>
<LI>
<LINK REF="STD-Kano-2003" TYPE="STUDY">Kano 2003</LINK> used dipyridamole both comparator arms.</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Phenytoin (3 studies, 100 participants)</HEADING>
<UL>
<LI>Phenytoin versus placebo/no treatment (<LINK REF="STD-Adamkova-1989" TYPE="STUDY">Adamkova 1989</LINK>*; <LINK REF="STD-Clarkson-1980" TYPE="STUDY">Clarkson 1980</LINK>; <LINK REF="STD-Houssin-1984" TYPE="STUDY">Houssin 1984</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Herbal medicines (5 studies, 358 participants)</HEADING>
<UL>
<LI>Herbal medicine versus placebo/no treatment (2 studies, 131 participants: <LINK REF="STD-Qian-1987" TYPE="STUDY">Qian 1987</LINK>; <LINK REF="STD-Yoshikawa-1997" TYPE="STUDY">Yoshikawa 1997</LINK>)</LI>
<UL>
<LI>
<LINK REF="STD-Qian-1987" TYPE="STUDY">Qian 1987</LINK> compared Tripterygium Wilfordii Glycoside (TWG) to no treatment</LI>
<LI>
<LINK REF="STD-Yoshikawa-1997" TYPE="STUDY">Yoshikawa 1997</LINK> compared Sairei-to with no treatment.</LI>
</UL>
</UL>
<UL>
<LI>Herbal medicine versus other treatment (1 study, 70 participants: <LINK REF="STD-Bo-2000" TYPE="STUDY">Bo 2000</LINK>)</LI>
<UL>
<LI>
<LINK REF="STD-Bo-2000" TYPE="STUDY">Bo 2000</LINK> compared Shenning Mixture to steroid + vitamin E + another drug (not translated).</LI>
</UL>
</UL>
<UL>
<LI>Herbal medicine + other treatment versus other treatment (2 studies, 157 participants: <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>*)</LI>
<UL>
<LI>
<LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK> compared Astragalus IV injection + dipyridamole + benazepril to dipyridamole + benazepril.</LI>
<LI>
<LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK> compared Dan Shao Tang + 'western medicine' (not specified) to 'western medicine'.</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Others (3 studies, 156 participants)</HEADING>
<UL>
<LI>Urokinase + ACEi versus ACEi (1 study, 71 participants: <LINK REF="STD-Chen--2004" TYPE="STUDY">Chen 2004</LINK>)</LI>
<LI>Vitamin E versus placebo/no treatment (1 study, 55 participants: <LINK REF="STD-Chan-2003" TYPE="STUDY">Chan 2003</LINK>)</LI>
<LI>Sodium cromoglycate versus placebo/no treatment (1 study, 30 participants: <LINK REF="STD-Sato-1990" TYPE="STUDY">Sato 1990</LINK>)</LI>
</UL>
<P>Some studies included more than 2 arms (e.g. ACEi versus CCB versus placebo) they were therefore considered in more than one comparator group.</P>
<P>Also in some studies (*) the data could not be included in the meta-analysis for various reasons, which are described in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
<I> Studies not included in meta-analyses.</I>
</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-02-09 16:22:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>The quality of most studies included in this review was suboptimal (see the Risk of bias tables under <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Allocation concealment was unclear in most of the studies with only 3/56 (5%) of the studies (<LINK REF="STD-HKVIN-Study-2006" TYPE="STUDY">HKVIN Study 2006</LINK>; <LINK REF="STD-IgACE-Study-2001" TYPE="STUDY">IgACE Study 2001</LINK>; <LINK REF="STD-Praga-2003" TYPE="STUDY">Praga 2003</LINK>) having adequate allocation concealment. One study concerning the effect of tonsillectomy (<LINK REF="STD-Hotta-1993" TYPE="STUDY">Hotta 1993</LINK>) was assumed to be a quasi-RCT (the authors stated that the participants were "divided into two groups" but did not clearly specify randomisation). Given the paucity of studies on tonsillectomy it was decided to include this study in the systematic review but the risk of bias must be considered in interpreting the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>The nature of blinding across participants, investigators, outcome assessors and data analysts was not clearly stated in 53/56 (94%) of the included studies.</P>
<UL>
<LI>In only one study (2%) participants, investigators, outcome assessors and data analysts were blinded (<LINK REF="STD-NA-IgAN-Study-2006" TYPE="STUDY">NA IgAN Study 2006</LINK>).</LI>
<LI>In two studies (4%) participants and investigators were blinded (<LINK REF="STD-Donadio-1994" TYPE="STUDY">Donadio 1994</LINK>; <LINK REF="STD-Maschio-1994" TYPE="STUDY">Maschio 1994</LINK>).</LI>
<LI>In one study (2%) participants and data analysts were blinded (<LINK REF="STD-Yoshikawa-1997" TYPE="STUDY">Yoshikawa 1997</LINK>).</LI>
<LI>In five studies (10%) only participants were blinded (<LINK REF="STD-Buemi-2000" TYPE="STUDY">Buemi 2000</LINK>; <LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK>; <LINK REF="STD-HKVIN-Study-2006" TYPE="STUDY">HKVIN Study 2006</LINK>; <LINK REF="STD-Nakamura-2007" TYPE="STUDY">Nakamura 2007</LINK>; <LINK REF="STD-Perico-1998" TYPE="STUDY">Perico 1998</LINK>).</LI>
<LI>In five studies (9%) "double blinding" was stated but the authors did not clarify who and how (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>; <LINK REF="STD-IgACE-Study-2001" TYPE="STUDY">IgACE Study 2001</LINK>; <LINK REF="STD-Nakao-2001" TYPE="STUDY">Nakao 2001</LINK>; <LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat analysis</HEADING>
<P>Intention-to-treat analysis was reported and confirmed on review of the studies in 8/56 studies (14%) (<LINK REF="STD-Donadio-1994" TYPE="STUDY">Donadio 1994</LINK>; <LINK REF="STD-Donadio-2001" TYPE="STUDY">Donadio 2001</LINK>; <LINK REF="STD-HKVIN-Study-2006" TYPE="STUDY">HKVIN Study 2006</LINK>; <LINK REF="STD-IgACE-Study-2001" TYPE="STUDY">IgACE Study 2001</LINK>; <LINK REF="STD-Lee-1997" TYPE="STUDY">Lee 1997</LINK>; <LINK REF="STD-NA-IgAN-Study-2006" TYPE="STUDY">NA IgAN Study 2006</LINK>; <LINK REF="STD-Praga-2003" TYPE="STUDY">Praga 2003</LINK>; <LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of follow-up</HEADING>
<P>The completeness of follow-up was not reported or assessable in 24/56 (43%) included studies. Eight studies (14%) reported total number of participants lost to follow-up but did not specify whether these participants were lost from the intervention or comparator arms. Overall incomplete follow-up ranged from 0% to 33% (<LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK>; <LINK REF="STD-Chan-1987" TYPE="STUDY">Chan 1987</LINK>; <LINK REF="STD-Hashizume-1998" TYPE="STUDY">Hashizume 1998</LINK>; <LINK REF="STD-Horita-2004" TYPE="STUDY">Horita 2004</LINK>; <LINK REF="STD-Horita-2007" TYPE="STUDY">Horita 2007</LINK>; <LINK REF="STD-Maschio-1994" TYPE="STUDY">Maschio 1994</LINK>; <LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>).</P>
<UL>
<LI>In the fish oil studies losses ranged from 0% to 33% with losses across arms slightly greater in the fish oil arm in two studies (<LINK REF="STD-Alexopoulos-2004" TYPE="STUDY">Alexopoulos 2004</LINK>; <LINK REF="STD-Bennett-1989" TYPE="STUDY">Bennett 1989</LINK>).</LI>
<LI>In the antihypertensive studies losses ranged from 0% to 33% with much greater losses in the nifedipine arm compared with an ACEi arm in one study (<LINK REF="STD-Bannister-1995" TYPE="STUDY">Bannister 1995</LINK>).</LI>
<LI>In the antiplatelet/anticoagulant studies losses ranged from 5% to 37%.</LI>
<LI>In the tonsillectomy studies losses ranged from 0% to 6%.</LI>
<LI>In the statins studies losses were nil in one study and not stated in the other.</LI>
<LI>In the other non-immunosuppressive treatments studies losses were not stated.</LI>
</UL>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-02-09 16:17:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>The effects of interventions are presented in <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> section. Some data not suitable for presentation in the forest plots are presented in 'other data' tables.</P>
<P>In the original protocol the outcomes: infection rate; decreased bone density or increased fractures or shorter stature; and QoL, were proposed but none of the included studies reported these outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="3">Fish oil</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Fish oil versus placebo/no treatment</HEADING>
<UL>
<LI>There was a significant reduction in the risk of a &gt; 50% increase in SCr with fish oil compared with placebo/no treatment (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (1 study, 106 participants): RR 0.20, 95% CI 0.06 to 0.65).</LI>
<LI>For the following outcomes there was no significant difference in the risk between fish oil and placebo/no treatment.</LI>
<UL>
<LI>&gt; 50% decrease in CrCl (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>)</LI>
<LI>all-cause mortality (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>)</LI>
<LI>SCr (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>)</LI>
<LI>change in SCr (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>)</LI>
<LI>CrCl (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>)</LI>
<LI>proteinuria (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>)</LI>
<LI>change in proteinuria (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>)</LI>
<LI>change in haematuria (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fish oil versus symptomatic treatment</HEADING>
<UL>
<LI>There was a significant decrease in SCr with fish oil compared to symptomatic treatment (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (1 study, 28 participants): MD -318.24, 95% CI -525.58 to -110.90).</LI>
<LI>For the following outcomes there was no significant difference in the risk between fish oil and symptomatic treatment.</LI>
<UL>
<LI>&gt; 50% increase in SCr (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>)</LI>
<LI>&gt; 50% decrease in CrCl (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>)</LI>
<LI>CrCl (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</LI>
<LI>proteinuria (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>)</LI>
<LI>&gt; 50% decrease in CrCl (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>)</LI>
<LI>CrCl (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</LI>
<LI>proteinuria (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">High versus low dose fish oil</HEADING>
<UL>
<LI>There was no significant difference between high dose and low dose fish oil for ESKD (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</LI>
<LI>Change in SCr and proteinuria could not be meta-analysed.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fish oil + other treatment versus other treatment</HEADING>
<P>When fish oil + ACEi + ARB was compared with ACEi + ARB:</P>
<UL>
<LI>There was a significant increase in CrCl (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (1 study, 30 participants): MD 26.20, 95% CI 1.01 to 51.39) in the fish oil arm.</LI>
<LI>There was a significant decrease in proteinuria (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> (1 study, 30 participants): MD -0.99 g/24 h, 95% CI -1.70 to -0.28) in the fish oil arm.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antihypertensive agents</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Antihypertensive agents versus placebo/no treatment</HEADING>
<P>The majority of antihypertensive agents used were either ACEi or ARB.</P>
<SUBSECTION>
<HEADING LEVEL="5">ACEi versus placebo</HEADING>
<UL>
<LI>There was a significant increase in the remission of proteinuria with ACEi compared to placebo (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> (1 study, 2 subgroups - complete and partial, 66 participants): RR 3.97, 95% CI 1.11 to 14.24; I² = 0%).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Any antihypertensive agent versus placebo/no treatment</HEADING>
<UL>
<LI>Overall there was a significant decrease in proteinuria (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK> (3 studies, 207 participants): MD -0.69 g/24 h, 95% CI -1.00 to -0.37; I² = 0%). These antihypertensive agent studies were analysed in subgroups according to type of antihypertensive.</LI>
<UL>
<LI>When ACEi or ARB was compared with placebo/no treatment there was a significant decrease in proteinuria in the ACEi or ARB group (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.1 (3 studies, 197 participants): MD -0.73 g/24 h, 95% CI -1.06 to -0.39; I² = 0%).</LI>
<LI>When CCB was compared with placebo/no treatment there was no significant difference in proteinuria (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.2 (1 study, 10 participants): MD -0.30 g/24 h, 95% CI -1.33 to 0.73)</LI>
<LI>When CCB was compared with placebo/no treatment there was no significant difference in proteinuria (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.2 (1 study, 10 participants): MD -0.30 g/24 h, 95% CI -1.33 to 0.73).</LI>
</UL>
<LI>No significant differences were detected for the following outcomes.</LI>
<UL>
<LI>ESKD (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)</LI>
<LI>SCr (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>)</LI>
<LI>CrCl (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>)</LI>
</UL>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antihypertensive agents versus other treatment</HEADING>
<P>Studies compared ACEi or ARB with other antihypertensive agents, and antihypertensive agents with other agents such as 'symptomatic treatment' (which involved other antihypertensive agents from a different class to control blood pressure), anticoagulants or herbal (including Chinese medicine) medicine.</P>
<SUBSECTION>
<HEADING LEVEL="5">ACEi versus ARB</HEADING>
<UL>
<LI>
<LINK REF="STD-Woo-2008" TYPE="STUDY">Woo 2008</LINK> had four intervention arms (ARB: 'high dose' and 'normal dose'; and ACEi: 'normal dose' and 'low dose'). When ACEi was compared with ARB there was a significant increase in the risk of ESKD (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.4 (1 study, 226 participants): RR 1.84, 95% CI 1.06 to 3.18).</LI>
<LI>There were no significant differences for the following outcomes.</LI>
<UL>
<LI>SCr (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.1)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.1)</LI>
<LI>Proteinuria (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.1)</LI>
<LI>Change in proteinuria (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.1)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined therapy (ACEi + ARB) versus monotherapy (ACEi or ARB)</HEADING>
<UL>
<LI>When combined therapy (ACEi + ARB) was compared to monotherapy (ACEi or ARB), there was a significant decrease in proteinuria with combination therapy (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.2 (2 studies, 67 participants): MD -0.49 g/24 h, 95% CI -0.72, to -0.25; I² = 20%).</LI>
<LI>There were no significant differences detected for these outcomes.</LI>
<UL>
<LI>SCr (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.2)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.2)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.2)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACEi or ARB or ACEi + ARB versus symptomatic treatment</HEADING>
<UL>
<LI>There was a significantly lower risk of &gt; 50% increase in SCr in the ACEi group compared to symptomatic treatment (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK> (1 study, 44 participants): RR 0.23, 95% CI 0.07 to 0.70).</LI>
<LI>There was a significant decrease in SCr in the ACEi or ARB or ACEi + ARB group compared to symptomatic treatment (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.4 (3 studies, 168 participants): MD -39.37, 95 % CI -71.95 to -6.80; I² = 0%).</LI>
<LI>There was a significant increase in CrCl in the ACEi or ARB or ACEi + ARB group compared to symptomatic treatment (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.4 (2 studies, 127 participants): MD 23.26, 95% CI 10.40 to 36.12; I² = 20%).</LI>
<LI>There was a significant decrease in proteinuria in the ACEi or ARB or ACEi + ARB group compared to symptomatic treatment (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.5 (3 studies, 168 participants): MD -1.16 g/24 h, 95% CI -1.52 to -0.81; I² = 0%)</LI>
<LI>There was no significant difference in the change in proteinuria between the ACEi or ARB or ACEi + ARB group compared to symptomatic treatment (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.2)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACEi or ARB versus CCB</HEADING>
<UL>
<LI>There was a significant decrease in proteinuria in the ACEi or ARB group compared to CCB (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.4 (3 studies, 40 participants): MD -0.32, 95% CI -0.79 to 0.14) and a significant change in proteinuria in the ACEi or ARB group compared to CCB (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.2 (1 study, 8 participants): MD 14.60, 95% CI 2.16 to 27.04).</LI>
<LI>There were no significant differences for the following outcomes.</LI>
<UL>
<LI>ESKD (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.1)</LI>
<LI>Doubling of SCr (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>)</LI>
<LI>SCr (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.4)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.4)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACEi versus BB</HEADING>
<UL>
<LI>There was no significant difference in ESKD between the ACEi and BB groups (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.3).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACEi + BB versus CCB + BB</HEADING>
<UL>
<LI>There was a significant decrease in proteinuria in the ACEi + BB group compared to the CCB + BB group (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.5 (1 study, 49 participants): MD -0.54, 95% CI -0.83 to -0.25).</LI>
<LI>There were no significant differences in the following outcomes.</LI>
<UL>
<LI>SCr (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.5)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.5)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACEi or ARB versus anticoagulants</HEADING>
<UL>
<LI>There were no significant differences between ACEi or ARB and anticoagulants for the following outcomes.</LI>
<UL>
<LI>ESKD (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.4)</LI>
<LI>SCr (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.6)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.6)</LI>
<LI>Proteinuria (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.6)</LI>
<LI>Haematuria (<LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACEi versus herbal medicine</HEADING>
<UL>
<LI>There were no significant differences between ACEi and herbal medicine for the following outcomes.</LI>
<UL>
<LI>SCr (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.7)</LI>
<LI>CrCl (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.7)</LI>
<LI>Proteinuria (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.7)</LI>
</UL>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antihypertensive agents + other treatment versus other treatment</HEADING>
<P>Other treatments included anticoagulants, steroids and herbal or Chinese medicines.</P>
<UL>
<LI>For the subgroup ARB + steroid + anticoagulant compared with steroid + anticoagulant there was significantly lower proteinuria (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>.1 (1 study, 38 participants): MD -0.20 g/24 h, 95% CI -0.26 to -0.14).</LI>
<LI>When ARB + Huobahuagen (a Chinese medicine) was compared with Huobahuagen haematuria was significantly lower (<LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK> (1 study, 62 participants): MD -7.00 RBC/HPF, 95% CI -11.08 to -2.92).</LI>
<LI>No other outcomes were significant.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antiplatelet and anticoagulants</HEADING>
<P>Anticoagulant agents used were warfarin and the antiplatelet agents used were aspirin, defibrotide, dipyridamole and ticlopidine. For the meta-analysis studies were grouped as anticoagulant versus placebo/no treatment, anticoagulant versus other and anticoagulant + other versus other.</P>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulant versus placebo/no treatment</HEADING>
<UL>
<LI>One study (<LINK REF="STD-Lee-1997" TYPE="STUDY">Lee 1997</LINK>) considered dipyridamole + warfarin versus no treatment. No significant differences were found for the outcomes ESKD, SCr, CrCl, proteinuria and haematuria.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulant versus other treatment</HEADING>
<UL>
<LI>One study (<LINK REF="STD-Chan-1987" TYPE="STUDY">Chan 1987</LINK>) considered aspirin + dipyridamole versus vitamin B complex. No significant differences were found for the outcomes SCr, CrCl and proteinuria.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anticoagulant + other treatment versus other treatment</HEADING>
<P>Two studies were included. <LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK> compared anticoagulant + ACEi versus ACEi and <LINK REF="STD-Frasca-1997" TYPE="STUDY">Frasca 1997</LINK> compared anticoagulant + steroid versus steroid.</P>
<UL>
<LI>The only significant outcome was a decrease in proteinuria for anticoagulant + steroid compared to steroid (<LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK> (1 study, 20 participants): MD -0.50 g/24 h, 95% CI -0.89 to -0.11).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other non-immunosuppressive treatments for IgAN</HEADING>
<P>Other treatments used for IgAN included tonsillectomy, statins, phenytoin, herbal medicines, urokinase, vitamin E and sodium cromoglycate. There was no significant difference in any of the outcomes for majority of the comparisons. The few exceptions are reported below.</P>
<SUBSECTION>
<HEADING LEVEL="4">Tonsillectomy</HEADING>
<P>Two studies of tonsillectomy were included in this analysis.</P>
<UL>
<LI>
<LINK REF="STD-Hotta-1993" TYPE="STUDY">Hotta 1993</LINK> compared tonsillectomy + steroid pulse initially + cyclophosphamide + dipyridamole + warfarin during the steroid therapy versus as above without tonsillectomy</LI>
<LI>
<LINK REF="STD-Kawasaki-2006" TYPE="STUDY">Kawasaki 2006</LINK>: tonsillectomy + methylprednisolone pulse + PWD (prednisolone, warfarin, dipyridamole) versus PWD + mizoribine.</LI>
</UL>
<P>The outcomes assessed were proteinuria remission, haematuria remission, SCr, CrCl and proteinuria. The only significant finding was a significant increase in the risk of haematuria remission in the tonsillectomy arm compared with non-tonsillectomy arm (<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK> (2 studies, 77 participants): RR 1.54, 95% CI 1.05 to 2.25; I² = 0%). This outcome had two subgroups. Microscopic haematuria was significant (<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>.1 (1 study, 45 participants): RR 1.83, 95% CI 1.04 to 3.22) and macroscopic haematuria was not significant (<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>.2 (1 study, 32 participants): RR 1.33, 95% CI 0.80 to 2.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statins</HEADING>
<P>There were two included studies.</P>
<UL>
<LI>
<LINK REF="STD-Buemi-2000" TYPE="STUDY">Buemi 2000</LINK> compared fluvastatin versus placebo</LI>
<LI>
<LINK REF="STD-Kano-2003" TYPE="STUDY">Kano 2003</LINK> compared fluvastatin + dipyridamole versus dipyridamole</LI>
</UL>
<P>Only <LINK REF="STD-Kano-2003" TYPE="STUDY">Kano 2003</LINK> was suitable for inclusion in the meta-analysis. The outcomes assessed were SCr, CrCl, proteinuria and haematuria. The only significant outcome was an increase in CrCl in the statin group (<LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK> (1 study, 30 participants): MD 22.60, 95% CI 11.83 to 33.37).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Herbal medicines</HEADING>
<P>The herbal medicines group included studies that looked at herbal versus placebo/no treatment, herbal versus other treatments (such as steroids, vitamins, and 'western medicine'), and herbal + other versus other (the other in this instance being anticoagulants and antihypertensives).</P>
<SUBSECTION>
<HEADING LEVEL="5">Herbal medicine versus placebo/no treatment</HEADING>
<P>There were two included studies.</P>
<UL>
<LI>
<LINK REF="STD-Qian-1987" TYPE="STUDY">Qian 1987</LINK> compared TWG versus no treatment</LI>
<LI>
<LINK REF="STD-Yoshikawa-1997" TYPE="STUDY">Yoshikawa 1997</LINK> compared Sairei-to versus no treatment.</LI>
</UL>
<P>The outcomes assessed for TWG versus no treatment were SCr and proteinuria. The only significant outcome was lower proteinuria with TWG compared with no treatment (<LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>.1 (1 study, 30 participants): MD -0.56 g/24 h, 95% CI -1.03 to -0.09).</P>
<P>The outcomes assessed for Sairei-to versus no treatment were proteinuria and haematuria. The only significant outcome was a decrease in for haematuria for the Sairei-to group (<LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK> (1 study, 94 participants): MD -0.80, 95% CI -1.27 to -0.33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Herbal medicine versus other treatment</HEADING>
<P>One study (<LINK REF="STD-Bo-2000" TYPE="STUDY">Bo 2000</LINK>), comparing Shenning Mixture versus steroid + vitamin E + dipyridamole assessing the outcomes SCr, proteinuria and haematuria was included.</P>
<UL>
<LI>Proteinuria was significantly lower for the Shenning Mixture group compared with the other treatment group (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK> (1 study, 70 participants): MD -0.90 g/24 h, 95% CI -1.23 to -0.57).</LI>
<LI>Haematuria was significantly lower for the Shenning Mixture group compared with the other treatment group (<LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK> (1 study, 70 participants): MD -18.17, 95% CI -22.39 to -13.95).</LI>
<LI>SCr was not significant (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Herbal medicine + other treatment versus other treatment</HEADING>
<P>Two studies compared herbal medicine + other treatment versus other treatment (<LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>). The data from <LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK> could not be meta-analysed. There were no significant differences for SCr and proteinuria.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urokinase</HEADING>
<P>One study compared urokinase + ACEi versus ACEi (<LINK REF="STD-Chen--2004" TYPE="STUDY">Chen 2004</LINK>).</P>
<UL>
<LI>There was a significant difference in the following outcomes</LI>
<UL>
<LI>&gt; 50% decrease in proteinuria (<LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK> (1 study, 71 participants): RR 1.61, 95% CI 1.05 to 2.45)</LI>
<LI>SCr (<LINK REF="CMP-018.03" TYPE="ANALYSIS">Analysis 18.3</LINK> (1 study, 71 participants): MD -39.49, 95% CI -47.69 to -31.29)</LI>
<LI>CrCl (<LINK REF="CMP-018.04" TYPE="ANALYSIS">Analysis 18.4</LINK> (1 study, 71 participants): MD 10.20, 95% CI 4.26 to 16.14)</LI>
<LI>Proteinuria (<LINK REF="CMP-018.05" TYPE="ANALYSIS">Analysis 18.5</LINK> (1 study, 71 participants): MD -0.67 g/24 h, 95% CI -0.74 to -0.60).</LI>
</UL>
<LI>There was no significant difference in &gt; 50% increase in SCr (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>)</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Adverse events data were reported in 23/56 (41%) of the included studies. None of this data could be pooled in a meta-analysis. The adverse events data that was reported in some of the included studies is presented in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> and in the 'other data' tables under each comparator group as follows:</P>
<UL>
<LI>Fish oil versus placebo/no treatment (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>)</LI>
<LI>Fish oil: high versus low dose (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>)</LI>
<LI>Antihypertensive agents versus placebo/no treatment (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>)</LI>
<LI>Antihypertensive agents versus other treatment (<LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>)</LI>
<LI>Antihypertensive agents + other treatment versus other treatment (<LINK REF="CMP-007.08" TYPE="ANALYSIS">Analysis 7.8</LINK>)</LI>
<LI>Anticoagulant versus placebo/no treatment (<LINK REF="CMP-008.08" TYPE="ANALYSIS">Analysis 8.8</LINK>)</LI>
<LI>Tonsillectomy + other treatment versus other treatment (<LINK REF="CMP-011.06" TYPE="ANALYSIS">Analysis 11.6</LINK>)</LI>
<LI>Phenytoin versus placebo/no treatment (<LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>)</LI>
<LI>Herbal medicine versus other treatment (<LINK REF="CMP-016.04" TYPE="ANALYSIS">Analysis 16.4</LINK>)</LI>
<LI>Urokinase + ACEi versus ACEi (<LINK REF="CMP-018.06" TYPE="ANALYSIS">Analysis 18.6</LINK>)</LI>
<LI>Vitamin E versus placebo/no treatment (<LINK REF="CMP-019.05" TYPE="ANALYSIS">Analysis 19.5</LINK>).</LI>
</UL>
<P>Most of the studies that reported adverse events did not identify many serious events and most effects noted were well known side effects of the treatments used. For example: the fish oil studies reported adverse events such as belching, fishy after taste and gastrointestinal intolerance; the antihypertensive agents studies (mostly related to ACEi or ARB use) reported instances of major adverse events such as allergy, heart failure, nephrotic syndrome and hyperkalaemia, and minor effects such as dizziness, headache, palpitations and cough; one of the tonsillectomy studies reported (presumably a result of the concurrent steroid use) incidents of glaucoma and growth retardation; one of the phenytoin studies noted rash, gingival hyperplasia and increased liver enzymes; one herbal medicine study noted 'GIT reaction'; and the urokinase study noted several nosebleeds in the intervention arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>Subgroup analyses were proposed a priori with the intention of investigating possible sources of heterogeneity in the meta-analyses. The pre-planned subgroup analyses included characteristics of the population: children versus adults, populations with different degrees of renal impairment, populations with different stages of biopsy-proven IgAN; and interventions: different types and doses of fish oil, different type and dose of antihypertensive agent, different types and doses of anticoagulant, different techniques of tonsillectomy that may influence treatment effect.</P>
<P>The only subgroup analyses actually performed were on the antihypertensive agent studies according to drug type/class and on the tonsillectomy studies for the macroscopic and microscopic haematuria outcomes. The results of these subgroup analyses are reported above. We were not able to perform subgroup analysis to explore potential effect modification by participants characteristics, populations with different degrees of renal impairment, such as the degree of baseline proteinuria, and other intervention characteristics, as data were either too few and sparse, not available or only available for very small numbers of studies.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-02-09 16:19:40 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="2">Key findings</HEADING>
<P>In this systematic review we found antihypertensive agents to be the most beneficial non-immunosuppressive intervention for people with IgAN. These benefits were consistently demonstrated across a range of outcomes and generally the 'antihypertensive' studies were among the higher quality studies included in this review. Other treatments evaluated in this review generally did not demonstrate significant effects and where significance was detected the studies tended to be of lower quality.</P>
<P>The antihypertensives examined in this review were predominantly ACEi or ARB. ACEi or ARB or combinations of both, were compared with other antihypertensives and other agents. When ACEi was compared with ARB there were no significant differences for the outcomes: SCr, CrCl, proteinuria, and proteinuria change. However, in one study (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.1) ARB compared with ACEi resulted in significantly less ESKD events. When the additional benefit of ACEi + ARB was examined (i.e. ACEi + ARB versus ACEi or ARB), a significant benefit was only shown in the 24 hour proteinuria (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.2) and not in the other outcomes examined (SCr and CrCl).</P>
<P>When ACEi or ARB was compared to placebo, proteinuria remission was more likely (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) and the 24 hour proteinuria was significantly less (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.1).</P>
<P>When ACEi or ARB or ACEi + ARB was compared with symptomatic treatment there was reduced risk of a &gt; 50% increase in SCr (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>), SCr was significantly reduced (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.3) as was 24 hour proteinuria (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.3). For the outcome change in proteinuria (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.2) the difference was not significant.</P>
<P>Comparisons of ACEi or ARB versus CCB showed mixed results. When ACEi was compared with CCB the 24 hour proteinuria was significantly reduced in the ACEi group (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>.4) and when ACEi or ARB was compared with CCB there was also a significant change (reduction) in proteinuria in the ACEi or ARB group (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.3). However no significant differences were apparent for a number of other outcomes (ESKD, doubling of SCr, SCr, CrCl, 24 hour proteinuria).</P>
<P>When ACEi or ARB were compared with BB (ESKD); anticoagulant (ESKD, CrCl, 24 hour proteinuria); and herbal medicines (SCr, CrCl, 24 hour proteinuria), no significant differences were detected.</P>
<P>The beneficial effect of ACEi or ARB in people with IgAN is also supported by the results of the comparisons: ARB + steroid + anticoagulant versus steroid + anticoagulant (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>.1) which showed significantly lower proteinuria in the ARB arm; and in the ARB + Huobahuagen versus Huobahuagen comparison (<LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK>) where haematuria was significantly lower in the ARB arm.</P>
<P>Overall ACEi or ARB appear to offer benefit in people with IgAN in terms of reduced proteinuria (24 hour and change in proteinuria), reduced SCr (overall SCr and a less likely &gt; 50% increase in SCr) and increased CrCl, when compared to placebo, and symptomatic treatment. When ACEi or ARB were compared with CCB the results were mixed. When ACEi or ARB were compared with BB, anticoagulant and herbal medicines no difference was detected.</P>
<P>The other interventions examined in this review offered fewer significant findings and less consistency in their results. For example, when fish oil was compared with placebo/no treatment only one significant result was found, a reduced risk of &gt; 50% increase in SCr (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The other nine outcomes examined in this group showed no significant differences. When fish oil was compared to symptomatic treatment the only significant finding was a lower SCr in the fish oil arm (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). The other five outcomes examined were not significant. When fish oil + ARB + ACEi was compared with ARB + ACEi there was a significantly higher CrCl (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and a significantly lower 24 hour proteinuria (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) in the fish oil arm.</P>
<P>When anticoagulant was compared to placebo/no treatment, no significant differences were detected for any of the five outcomes examined. However, when anticoagulants were compared as an additional treatment (anticoagulant + ACEi versus ACEi), one significant benefit was detected in the 24 hour proteinuria (<LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>). The other three outcomes examined were not significant.</P>
<P>In the other non-immunosuppressive treatments for IgAN, while significant results were found, the quality of the studies producing these results was generally suboptimal. Tonsillectomy + other treatment versus other treatment showed significant benefit only in haematuria remission (<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>). Note however the one 'study' by <LINK REF="STD-Hotta-1993" TYPE="STUDY">Hotta 1993</LINK> responsible for this result was assumed to be a quasi-RCT, and may not be an RCT at all. Statins + other treatment versus other treatment only showed significant benefit for CrCl (<LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>) with statins. Some of the herbal/Chinese medicines showed some significant results: Sairei-to versus no treatment showed significant benefit in haematuria (<LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>); TWG compared with no treatment (<LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>.1) showed significantly lower proteinuria, and another herbal medicine 'Shenning Mixture' versus steroid + vitamin E + dipyridamole showed significant benefit in 24 hour proteinuria (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>) and haematuria (<LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>); and urokinase + ACEi versus ACEi showed significant benefit in the outcomes &gt; 50% decrease in proteinuria (<LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK>), SCr (<LINK REF="CMP-018.03" TYPE="ANALYSIS">Analysis 18.3</LINK>), CrCl (<LINK REF="CMP-018.04" TYPE="ANALYSIS">Analysis 18.4</LINK>) and 24 hour proteinuria (<LINK REF="CMP-018.05" TYPE="ANALYSIS">Analysis 18.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Comparison with existing knowledge</HEADING>
<P>Comparison between our findings data and prior comprehensive analyses of the evidence (<LINK REF="REF-Nolin-1999" TYPE="REFERENCE">Nolin 1999</LINK>; <LINK REF="REF-Strippoli-2003" TYPE="REFERENCE">Strippoli 2003</LINK>; <LINK REF="REF-Samuels-2003a" TYPE="REFERENCE">Samuels 2003a</LINK>) is difficult since this is the first comprehensive systematic review of any non-immunosuppressive interventions for people with biopsy-proven IgAN.</P>
<P>The notion that antihypertensive agents reduce the progression of chronic kidney disease is not news and has been formally explored in several studies of people at high risk of renal and cardiac progression, as is the example of diabetic kidney disease and other chronic nephropathies (<LINK REF="REF-Jafar-2001" TYPE="REFERENCE">Jafar 2001</LINK>; <LINK REF="REF-Strippoli-2006" TYPE="REFERENCE">Strippoli 2006</LINK>). We confirm an effect of antihypertensive agents on proteinuria and SCr, surrogate markers of renal damage. Similarly, other sparse data relating to some of the immunosuppressive agents used in IgAN suggest that these may have an effect on these surrogate endpoints. Nonetheless, the notion of surrogates adoption in RCTs has been questioned recently, following the results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET)<B> </B>study (<LINK REF="REF-ONTARGET-Study-2008a" TYPE="REFERENCE">ONTARGET Study 2008a</LINK>; <LINK REF="REF-ONTARGET-Study-2008b" TYPE="REFERENCE">ONTARGET Study 2008b</LINK>), which compared ACEi, ARB and their combination in people with a previous major cardiovascular event or with diabetes and end organ damage. In this study, dual blockade of the renin angiotensin system resulted in a more prominent reduction of proteinuria compared to monotherapy with ACEi or ARB, but a higher risk of major renal events (including the need for RRT). A surrogate endpoint is a convenient outcome to use in RCTs as it occurs more rapidly and is more easily measurable than other major patient-centred end points, such as ESKD or the doubling of SCr concentration, and this is particularly true when the risk of these outcomes is low and occurs only after a prolonged time, as is the case with renal failure in people with IgAN. In these patients, the likelihood of reaching ESKD is low and requires a much longer time than would typically be feasible for a patient to be enrolled in a study. In this view, the nephrology community has become acquainted at following the effects of interventions in people with various forms of nephropathy by measuring changes in SCr, the glomerular filtration rate and proteinuria. For these surrogates to be valid, there needs to be evidence that they are associated with distal, major endpoints (e.g. ESKD, reduced survival) and also that an intervention which affects the surrogate (e.g. reduction of proteinuria) also reduces the risk of reaching the distal endpoints (e.g. ESKD, mortality). Unfortunately such evidence is not available in studies of IgAN, and neither in many others, as the recent ONTARGET study as shown (<LINK REF="REF-ONTARGET-Study-2008a" TYPE="REFERENCE">ONTARGET Study 2008a</LINK>; <LINK REF="REF-ONTARGET-Study-2008b" TYPE="REFERENCE">ONTARGET Study 2008b</LINK>). In light of this, the results of our analysis should be interpreted with caution, and the potential benefits of antihypertensive agents or other non-immunosuppressive therapies should be tested on major patient-level endpoints. Few studies are done in people with IgAN given the difficulties of recruitment and follow-up of these populations, which makes it a disease in search of a large scale clinical study to reliably inform practice, both in the area of immunosuppressive and non-immunosuppressive treatments (<LINK REF="REF-Strippoli-2009" TYPE="REFERENCE">Strippoli 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Strengths and limitations</HEADING>
<P>The strength of this study is that it explored all outcomes, both surrogate and patient-level, including all-cause mortality, adverse events and major renal endpoints, by means of a comprehensive systematic review based on a prespecified detailed published protocol (<LINK REF="REF-Samuels-2003b" TYPE="REFERENCE">Samuels 2003b</LINK>), with rigid inclusion criteria for RCTs only, and a comprehensive search strategy. Data extraction, data analysis, and methodological quality assessments were performed by two independent investigators. Furthermore, the possibility of publication bias was minimized by including both published and unpublished (e.g. abstracts to meetings) studies. Information about unpublished and ongoing RCTs was sought from authors of the included RCTs and from known experts in the field. According to the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) approach (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>), a system developed for grading the quality of evidence, our results, obtained from a meta-analysis of RCTs, should be considered as data of high quality level. However, there are many factors that decrease the quality level, such as publication bias, less than optimal design of included studies, unexplained heterogeneity and wide confidence intervals, which may be largely explained by the paucity and the relatively small size of existing studies.</P>
<P>The small number and suboptimal methodological quality of most of the included studies represents the major limitation of our systematic review. Most of the comparisons tested in this review involved only one to two studies. Only in the antihypertensive agents group were there frequently two or more studies in the meta-analysis. Most of the included studies were of suboptimal quality. Allocation concealment was unclear in most of the studies with only 3/56 (5%) of the studies reporting adequate allocation concealment. The nature of blinding across participants, investigators, outcome assessors and data analysts was not clearly stated in 53/56 (94%) of the included studies. Intention-to-treat analysis was reported and confirmed on review of the studies in only 8/56 studies (14%) and completeness of follow-up was not reported or determinable in 24/56 (43%) of included studies. Due to limited and sparse available data our review was also unable to identify effect modification by age, gender and ethnicity for any of the explored interventions. Such effect modification has been recurrently reported in existing non-randomised studies but remains unproven in the few and small available studies.</P>
<P>Some studies were also only reported in abstract form (<LINK REF="STD-Bang-1994" TYPE="STUDY">Bang 1994</LINK>), which made assessment of quality of methods problematic. Some study publications were in languages other than English (<LINK REF="STD-Adamkova-1989" TYPE="STUDY">Adamkova 1989</LINK>; <LINK REF="STD-Bo-2000" TYPE="STUDY">Bo 2000</LINK>; <LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>; <LINK REF="STD-Guan-2005" TYPE="STUDY">Guan 2005</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Shi-2002" TYPE="STUDY">Shi 2002</LINK>; <LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>; <LINK REF="STD-Yoshikawa-1997" TYPE="STUDY">Yoshikawa 1997</LINK>). Where possible they were translated but in others, where translation resources were lacking, they were either not translated or only an English-only abstract and partially translated tables were used to provide data for this analysis.</P>
<P>The majority of studies were not designed to answer research questions raised by this review. For example in the antihypertensive studies few were designed to evaluate the efficacy of within intervention differences, such as duration of treatment, dose variation and the effect of lowering blood pressure per se rather than the class of drug.</P>
<P>Considering the established practice pattern of managing proteinuria and renal surrogate endpoints in people with IgAN, and the notion that non-immunosuppressive agents should not pose a major risk for patients, studies included in our meta-analysis which have been completed to date have not been planned to evaluate the comparative efficacy of interventions on the risk of &#8220;hard&#8221; end points (e.g. survival, cardiovascular events, ESKD). Instead, most RCTs have focused attention on continuous renal end points only (such as proteinuria, SCr, glomerular filtration rate) during a short follow-up and have accounted for occasional major events which may have occurred and that could not be totally explained by the study&#8217;s and patients&#8217; characteristics as adverse events.</P>
<P>Finally, a limitation of our analysis was that although IgAN proven by biopsy was a criteria for inclusion of a study, the evidence of biopsy proof ranged from a simple declaration that IgA was 'biopsy-proven' to detailed descriptions of histopathology. Data on disease severity were generally not well reported in the studies included in this review and with the exception of one study (<LINK REF="STD-Bennett-1989" TYPE="STUDY">Bennett 1989</LINK>) all patients with IgAN, regardless of severity were analysed as a single group.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-02-17 08:21:13 +1100" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2011-02-17 08:21:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>In summary, based on existing knowledge, the benefits of antihypertensive agents, particularly inhibitors of the renin angiotensin system, appear to potentially outweigh the harms in patients with IgAN. The benefits are largely manifest as a reduction in proteinuria, a surrogate outcome. Whether the effect of ACEi/ARB therapy on proteinuria in IgAN is a consequence of a direct modulation of the pathogenesis of IgAN or a non-specific antiproteinuric effect of the ACEi/ ARB is unknown. Of greater clinical relevance is the finding in this systematic review that there is no evidence that treatment with any of the antihypertensive agents evaluated to date affect major renal and/or cardiovascular endpoints or long-term mortality risk beyond the benefit that arises from controlling hypertension in patients with IgAN. This latter view is supported by the finding that when compared to BB or CCB therapy, ACEi or ARB did not result in greater improvement in hard patient outcomes such as the long-term prevention of progression of renal dysfunction. It is equally likely that benefits from ACEi/ARB therapy on hard end points were not seen because of the paucity of long-term RCTs of sufficient rigor and power to demonstrate a true albeit small benefit or because of the absence of such benefit. Thus, although the use of ACEi/ARB agents has become customary practice in patients with chronic nephropathies, including those without hypertensive disease for the purpose of urinary protein reduction, clinicians and patients should remain informed regarding the limitations of this evidence, in particular, with respect to any potential benefit of a clinically relevant size on long-term patient-centred outcomes arising from these therapies. More and better evidence is needed to understand the magnitude of benefit and the possible risks of antihypertensive or more specifically of ACEi/ARB therapy alone or in combination and which specific types of patients with the IgAN might have the greatest potential for benefit.</P>
<P>Given the varied and chronic nature of the disorder, one of the major clinical questions in treating patients with IgAN is to know when to initiate treatment. As we already found in an analysis of immunosuppressive agents for IgAN, benefits are seen in some situations but not others (massive proteinuria, for instance). With non-immunosuppressive agents, the question still remains whether use of renin-angiotensin-aldosterone system (RAAS) blocking agents is indicated in all patients. There still is insufficient information from existing studies to state if we should recommend RAAS blockade:</P>
<OL>
<LI>For all patients with IgAN</LI>
<LI>Only for patients with a given degree of proteinuria</LI>
<LI>Only for patients with systolic hypertension.</LI>
</OL>
<P>There is also not enough evidence to support routine use over any other antihypertensive agent. Even if the data do not support an answer to the above question, optimal timing, duration, and use of RAAS blockade remains unclear.</P>
<P>The clinical studies evidence is insufficiently robust to demonstrate efficacy for any of the other non-immunosuppressive therapies evaluated in this systematic review. On the basis of the available evidence, the application of these other non-immunosuppressive therapies including fish oil supplementation, statin therapy, anticoagulation/anti-platelet therapy, or tonsillectomy is not supported.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-02-07 16:50:34 +1100" MODIFIED_BY="Narelle S Willis">
<P>Further research, in the form of good quality RCTs (with particular attention to adequate allocation concealment, appropriate blinding, and analysis by intention-to-treat), is required to ascertain the magnitude of the benefit of ACEi or ARB treatment, to determine whether patients of different disease severity and age will benefit differently, to determine optimal dosing, the effect of fixed dose versus dose targeted to reduction in proteinuria, and whether combination therapy offers added benefit, and to define better potential adverse effects of such treatment. Such clinical studies evidence would permit a more through interrogation of the potential risk benefit profile for patients with differing baseline severity of disease and allow for a better determination of individual patients&#8217; prognoses and optimal allocation of current and new therapies. Comparisons with other antihypertensive agents is still required, particular with CCBs to determine if the observed benefits are specific to ACEi/ARB therapies or can be obtained more generally with any effective anti-hypertensive strategy. </P>
<P>In all clinical research consistent use of internationally accepted patient-centred hard outcome measures and avoidance of 'combination or surrogate outcomes' is encouraged.</P>
<P>Unconvincing or sparse evidence for the benefits of fish oil, anticoagulants, tonsillectomy and other treatments was exposed through this systematic review of the totality of RCT clinical studies evidence. Moreover, this summation of the evidence, was based largely on studies that were of poorer quality. For many of these therapies for which neither benefit nor significant harm has yet to be demonstrated, equipoise persists there remains some justification for further exploration of the potential benefits of some of the non-hypertensive non-immunosuppressive treatments of IgAN that have been interrogated in this review with good quality RCTs with comparison to placebo in many cases. Importantly, the findings from these RCTs should be reported following guides such as those provided by the Cochrane Collaboration and the CONSORT statement (<LINK REF="REF-Consort-Statement-2001" TYPE="REFERENCE">Consort Statement 2001</LINK>).</P>
<P>IgAN is the most common form of glomerulonephritis worldwide and an important cause for renal failure for which current therapies are of uncertain benefits for patients with the most severe disease, for those patients most likely to progress to ESKD. IgAN remains a disease in search of adequately powered randomised studies, of sufficient duration, to reliably inform clinical practice. Despite the many challenges for obtaining adequate funding, for designing and conducting a robust randomised study a collaborative multicentre international effort should be pursued aggressively in order to provide more and better evidence to inform more effective management of this disease.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-12-21 18:59:47 +1100" MODIFIED_BY="[Empty name]">
<P>We thank Narelle Willis, Gail Higgins and Ruth Mitchell of the Cochrane Renal Group and Andrew Hayen, Petra Macaskill and Fiona Stanaway of the School of Public Health, University of Sydney, for their advice and support in the undertaking of this systematic review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-08-04 15:22:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-01-12 18:29:33 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Sharon Reid and Peggy Cawthon conducted the literature review and data extraction.</LI>
<LI>Giovanni FM Strippoli and Jonathan Craig provided assistance where there was disagreement about study inclusion and data interpretation and reviewed drafts of the manuscript.</LI>
<LI>Sharon Reid entered data, created the additional tables and appendices and wrote the first draft of the results and discussion.</LI>
<LI>Joshua A Samuels and Giovanni FM Strippoli equally contributed to the development of the study protocol and wrote the first draft of the background, objectives and methods of the review.</LI>
<LI>Donald Molony and all the above authors reviewed and commented on the final draft.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-02-03 16:13:01 +1100" MODIFIED_BY="[Empty name]">
<P>Additional interventions (phenytoin, herbal medicines and miscellaneous other treatments) were identified in systematic review of the literature and so were included in the review. Some of the outcomes identified in the original protocol were not identified in any of the included studies (e.g. bone density) and so were not included in the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-02-17 08:19:22 +1100" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2011-02-17 08:19:22 +1100" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2011-02-09 16:30:56 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Adamkova-1989" MODIFIED="2011-02-08 21:47:08 +1100" MODIFIED_BY="Narelle S Willis" NAME="Adamkova 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-02-08 21:47:08 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adamkova V, Matousovic K, Prat V</AU>
<TI>The effect of diphenylhydantoin on IgA nephropathy</TI>
<SO>Casopis Lekaru Ceskych</SO>
<YR>1989</YR>
<VL>128</VL>
<NO>17</NO>
<PG>524-6</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:28:30 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="2752395"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexopoulos-2004" MODIFIED="2010-12-29 14:20:58 +1100" MODIFIED_BY="Narelle S Willis" NAME="Alexopoulos 2004" YEAR="">
<REFERENCE MODIFIED="2010-01-28 13:32:48 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D</AU>
<TI>Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen</TI>
<SO>Renal Failure</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>4</NO>
<PG>453-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:32:45 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15462115"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:19:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexopoulos E, Stangou M, Pantzaki A, Kyrmizis D, Memmos D</AU>
<TI>Treatment of severe IgAN with omega-3 fatty acids: the effect of a "very lose dose" regime [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>28</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:19:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:19:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550426"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:20:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexopoulos E, Stangou M</AU>
<TI>The effect of fish oil in patients with IgA nephropathy and renal function impairment: a prospective study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>89A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:20:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:20:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00400046"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:29:42 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stangou M, Alexopoulos E, Diamantopoulou D, Pantzaki A, Papadimitriou M</AU>
<TI>The effect of fish-oil in the treatment of IGA nephropathy (IGAN) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>A63</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:29:42 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00447831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:20:58 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stangou M, Alexopoulos E, Diamantopoulou D, Papadimitriou M</AU>
<TI>The effect of fish-oil in human IgA nephropathy (IgAN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>115A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:20:58 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:20:58 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671809"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bang-1994" MODIFIED="2010-12-29 14:21:51 +1100" MODIFIED_BY="Narelle S Willis" NAME="Bang 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-29 14:21:51 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bang BK, Yang CW, Kim YS, Chang YS, Yoon YS</AU>
<TI>Effect of combination therapy of captopril and dipyridamole on proteinuria in patients with IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>346</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:21:51 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:21:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bannister-1995" MODIFIED="2010-12-29 14:22:42 +1100" MODIFIED_BY="Narelle S Willis" NAME="Bannister 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-01-28 13:33:55 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ</AU>
<TI>Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy</TI>
<SO>Contributions to Nephrology</SO>
<YR>1995</YR>
<VL>111</VL>
<PG>184-92</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:33:55 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7758341"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:22:42 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannister KM, Weaver A, Woodroffe AJ, Clarkson AR</AU>
<TI>Effect of nifedipine and enalapril on the progression of IgA glomerulonephritis (IgA GN) [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S128</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:22:42 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:22:42 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00460338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett-1989" MODIFIED="2010-01-28 13:34:52 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Bennett 1989" YEAR="">
<REFERENCE MODIFIED="2010-01-28 13:34:52 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett WM, Walker RG, Kincaid-Smith P</AU>
<TI>Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial</TI>
<SO>Clinical Nephrology</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>3</NO>
<PG>128-31</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:34:52 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="2539929"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bo-2000" MODIFIED="2011-02-08 19:42:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Bo 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-02-08 19:42:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bo S, Ju J, Chu D</AU>
<TI>Clinical study on Shenning Mixture in treating IgA nephropathy</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi</SO>
<YR>2000 Oct</YR>
<VL>20</VL>
<NO>10</NO>
<PG>729-30</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:35:28 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11938804"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buemi-2000" MODIFIED="2010-01-28 13:36:07 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Buemi 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-28 13:36:07 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, et al</AU>
<TI>Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>4</NO>
<PG>427-31</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:36:04 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="10801253"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camara-1991" MODIFIED="2010-12-29 14:24:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Camara 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-29 14:24:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camara S, de la Cruz JP, Frutos MA, Sanchez P, Lopez de Novales E, Sanchez E, et al</AU>
<TI>Effects of dipyridamole on the short-term evolution of glomerulonephritis</TI>
<SO>Nephron</SO>
<YR>1991</YR>
<VL>58</VL>
<NO>1</NO>
<PG>13-6</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:24:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:24:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1857478"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1987" MODIFIED="2010-01-28 13:37:04 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Chan 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-01-28 13:37:04 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan MK, Kwan SY, Chan KW, Yeung CK</AU>
<TI>Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1987</YR>
<VL>9</VL>
<NO>5</NO>
<PG>417-21</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:37:01 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="3555016"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2003" MODIFIED="2010-01-28 13:38:23 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Chan 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-28 13:38:23 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan JC, Mahan JD, Trachtman H, Scheinman J, Flynn JT, Alon US, et al</AU>
<TI>Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study</TI>
<SO>Pediatric Nephrology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>10</NO>
<PG>1015-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:38:20 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12920628"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen--2004" MODIFIED="2010-12-29 14:25:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chen  2004" YEAR="2004">
<REFERENCE MODIFIED="2010-12-29 14:25:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen X, Liu H, Wu J</AU>
<TI>The effect of long-term urokinase treatment combined with angiotensin-converting enzyme inhibitor on IgA nephropathy with glomerular sclerosis: a clinical control study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>67A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:25:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:25:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740473"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:39:06 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen X, Qiu Q, Tang L, Liu S, Cai G, Liu H, et al</AU>
<TI>Effects of co-administration of urokinase and benazepril on severe IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>4</NO>
<PG>852-7</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:39:03 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15031340"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2011-02-08 21:48:17 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chen 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-08 21:48:17 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen XM, Chen YP, Zhou ZL</AU>
<TI>Prospective, multi-centered, randomized and controlled trial on effect of Shenle Capsule in treating patients with IgA nephropathy of Fei-Pi qi-deficiency syndrome</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>12</NO>
<PG>1061-5</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:39:45 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17205814"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007" MODIFIED="2011-02-08 21:48:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chen 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-08 21:48:48 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen XM, Chen YP, Chen J</AU>
<TI>Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>2</NO>
<PG>101-5</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:40:40 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17342992"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1998" MODIFIED="2010-12-29 14:26:24 +1100" MODIFIED_BY="Narelle S Willis" NAME="Cheng 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-28 13:41:45 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng IKP, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HWD</AU>
<TI>A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy</TI>
<SO>Nephrology</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>1-2</NO>
<PG>19-26</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:41:45 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="EMBASE" VALUE="1998205046"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:26:24 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cheng IKP, Fang GX, Wong MC, Ji YL, Yeung H</AU>
<TI>A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993 June 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>45</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:26:24 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:26:24 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550664"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarkson-1980" MODIFIED="2010-01-28 13:42:39 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Clarkson 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-01-28 13:42:39 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarkson AR, Seymour AE, Woodroffe AJ, McKenzie PE, Chan YL, Wootton AM</AU>
<TI>Controlled trial of phenytoin therapy in IgA nephropathy</TI>
<SO>Clinical Nephrology</SO>
<YR>1980</YR>
<VL>13</VL>
<NO>5</NO>
<PG>215-8</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:42:36 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="6994960"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costanzi-2006" MODIFIED="2010-12-29 14:27:52 +1100" MODIFIED_BY="Narelle S Willis" NAME="Costanzi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-12-29 14:27:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costanzi S, Ferraro M, Sturniolo A, Passalacqua S, D'Alonzo S, Tullio T, et al</AU>
<TI>Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in IgA nephropathy: promising results on proteinuria at six months [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv295</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:27:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:27:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671823"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:27:52 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S</AU>
<TI>Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>1</NO>
<PG>156-60</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:27:52 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="18685141"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donadio-1994" MODIFIED="2011-02-08 19:44:01 +1100" MODIFIED_BY="Narelle S Willis" NAME="Donadio 1994" YEAR="">
<REFERENCE MODIFIED="2011-02-08 19:44:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Donadio JV Jr, Holub BJ, Bergstralh EJ</AU>
<TI>Effects of omega-3 fatty acids in IgA nephropathy: maintenance of lower proportions of n-6 eicosanoid precursors in plasma phospholipids in response to fish oil preserves renal function [abstract]</TI>
<SO>13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain</SO>
<YR>1995</YR>
<PG>64</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:28:58 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:28:58 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550676"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:58:56 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM</AU>
<TI>Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>7</NO>
<PG>1197-203</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:58:54 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12105241"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:59:04 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC</AU>
<TI>Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>2</NO>
<PG>65-71</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:59:01 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8004831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:29:48 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE, Mayo Nephrology Collaborative Group</AU>
<TI>A controlled trial of fish oil in IGA nephropathy (IGAN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>829</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:29:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:29:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550569"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:33:06 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE</AU>
<TI>A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>18</NO>
<PG>1194-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:59:15 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7935657"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:30:46 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Grande JP, Bergstrahl EJ, Dart RA, Larson TS, Mayo Nephrology Collaborative Group</AU>
<TI>The long-term outcome of patients with IgA nephropathy (IgAN) treated with fish oil in a placebo-controlled, randomized clinical trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>145A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:30:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:30:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445131"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:59:30 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC</AU>
<TI>The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>8</NO>
<PG>1772-7</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:59:27 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="10446945"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:32:34 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heilman RL, Bergstralh EJ, Holley KE, Donadio JV, Mayo Nephrology Collaborative Group</AU>
<TI>Morphology assessment does not correlate with subsequent change in renal function in IgA nephropathy (IgA) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>831</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:32:34 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:32:34 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donadio-2001" MODIFIED="2011-02-07 18:00:04 +1100" MODIFIED_BY="Narelle S Willis" NAME="Donadio 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-29 14:34:48 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Bibus DM, Grande JP</AU>
<TI>Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids (w-3 PUFA) in the treatment of patients with IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>675A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:34:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:34:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740498"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:22:37 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Bibus DM, Grande JP</AU>
<TI>Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>5</NO>
<PG>933-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:00:50 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17699310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:01:01 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM</AU>
<TI>Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>7</NO>
<PG>1197-203</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:00:58 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12105241"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:35:51 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Fervenza FC, Bergstralh EJ, Grande JP</AU>
<TI>Angiotensin-converting enzyme (ACE) genotype influences renal outcome in high-risk patients with IgA nephropathy (IgAN) treated with omega-3 fatty acids (n-3 FA) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>10A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:35:51 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:35:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583668"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-07 18:00:04 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Larson TS, Bergstralh EJ, Grande JP, Spencer DC</AU>
<TI>High-dose versus low-dose omega-3 fatty acids in patients with severe IgA nephropathy (IgAN): a randomized trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>59A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:36:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:36:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550684"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:01:15 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Larson TS, Bergstralh EJ, Grande JP</AU>
<TI>A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. [see comments]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>4</NO>
<PG>791-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:01:13 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11274240"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frasca-1997" MODIFIED="2010-01-28 13:56:49 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Frasca 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-28 13:56:35 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frasca GM, Cianciolo G, et al</AU>
<TI>A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>968</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:56:35 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00261099"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:56:40 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frasca GM, Martello M, Canova C, Isola E, Vangelista A, Bonomini V</AU>
<TI>Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>4</NO>
<PG>185-91</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:56:40 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="EMBASE" VALUE="1997135783"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:56:49 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frasca GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V</AU>
<TI>Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>392-3</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:56:45 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8700366"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guan-2005" MODIFIED="2011-02-08 21:49:43 +1100" MODIFIED_BY="Narelle S Willis" NAME="Guan 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-08 21:49:43 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guan XD, Wu YF, Zhao W</AU>
<TI>Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan</TI>
<SO>Zhong Xi Yi Jie He Xue Bao [Journal of Chinese Integrative Medicine]</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>5</NO>
<PG>366-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:55:14 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16159570"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hashizume-1998" MODIFIED="2010-12-29 14:38:01 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hashizume 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-12-29 14:38:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hashizume K, Sano T, Kokubo T, Hiki Y, Kamata K, Tateno S, et al</AU>
<TI>A randomized, prospective, controlled study of effect of angiotensin-converting enzyme inhibition on proteinuria and renal function in IGA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>149A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:38:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:38:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HKVIN-Study-2006" MODIFIED="2011-01-12 17:54:56 +1100" MODIFIED_BY="Narelle S Willis" NAME="HKVIN Study 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-28 14:11:24 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al</AU>
<TI>Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>5</NO>
<PG>751-60</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:11:22 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16632013"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:38:59 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li PKT, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al</AU>
<TI>Hong Kong study using Valsartan in IgA nephropathy (HKVIN) - a double-blind randomized placebo-controlled study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>352A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:38:59 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:38:59 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583348"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horita-2004" MODIFIED="2010-12-29 14:54:12 +1100" MODIFIED_BY="Narelle S Willis" NAME="Horita 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-28 14:08:19 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al</AU>
<TI>Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy</TI>
<SO>Hypertension Research - Clinical &amp; Experimental</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>12</NO>
<PG>963-70</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:08:17 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15894837"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 14:54:12 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horita Y, Tadokoro M, Taura K, Taguchi T, Miyazaki M, Kohno S</AU>
<TI>Aldosterone breakthrough during combined angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in patients with IgA nephropathy [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A37</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:54:12 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:54:12 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740497"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:08:26 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horita Y, Taura K, Taguchi T, Furusu A, Kohno S</AU>
<TI>Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy</TI>
<SO>Nephrology</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>5</NO>
<PG>462-6</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:08:23 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17014562"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horita-2007" MODIFIED="2011-02-07 18:00:58 +1100" MODIFIED_BY="Narelle S Willis" NAME="Horita 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-28 14:08:57 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horita Y, Tadokoro M, Taura K, Ashida R, Hiu M, Taguchi T, et al</AU>
<TI>Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy</TI>
<SO>Renal Failure</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>4</NO>
<PG>441-6</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:08:57 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17497466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-07 18:00:58 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horita Y, Tadokoro M, Taura K, Taguchi T, Kohno S</AU>
<TI>Effects of co-administration of prednisolone plus losartan in moderate proteinuric IgA nephropathy [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv332</PG>
<IDENTIFIERS MODIFIED="2010-12-29 14:55:06 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 14:55:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615873"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hotta-1993" MODIFIED="2011-02-09 16:30:56 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hotta 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-09 16:30:56 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hotta O, Taguma Y, Kurosawa K, Sudo K, Suzuki K, Horigome I</AU>
<TI>Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study</TI>
<SO>Japanese Journal of Nephrology</SO>
<YR>1993</YR>
<VL>35</VL>
<NO>8</NO>
<PG>967-73</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:01:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:01:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8255008"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houssin-1984" MODIFIED="2010-12-29 15:07:23 +1100" MODIFIED_BY="Narelle S Willis" NAME="Houssin 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-12-29 15:07:23 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houssin A, Denis J, Spiesser R</AU>
<TI>Phenytoin in treatment of Berger's Disease</TI>
<SO>Ouest Medical</SO>
<YR>1984</YR>
<VL>37</VL>
<NO>4</NO>
<PG>211-5</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:07:21 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:07:21 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1984118671"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IgACE-Study-2001" MODIFIED="2011-01-12 17:54:46 +1100" MODIFIED_BY="Narelle S Willis" NAME="IgACE Study 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-29 15:08:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amore A, Peruzzi L, Balegno S, Bertola L, Magnetti F, Camilla R, et al</AU>
<TI>Advanced oxidation protein products (AOPP) and degalactosylated IgA1 in patients with IgA nephropathy (IgA N): a prospective double blind randomized placebo controlled trial with ACE inhibitors [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1518</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:08:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:08:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00601964"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:43:51 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppo R, Chiesa M, Peruzzi L, Amore A</AU>
<TI>Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial</TI>
<SO>Journal of Nephrology</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>6</NO>
<PG>447-52</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:43:49 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11783600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:09:44 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppo R, Peruzzi L, Amore A, Camilla R, Mancuso D, Lin X, et al</AU>
<TI>Follow-up analysis of patients who reached the end-point during the IgACE, a placebo-controlled trial of ACE-inhibitors in children and young people with IgA nephropathy and moderate proteinuria [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts Issue</NO>
<PG>818A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:09:44 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:09:44 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00690387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:10:44 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppo R, Peruzzi L, Amore A, Mancuso D, Piccoli A, Cochat P, et al</AU>
<TI>IgACE: first multicentric prospective double blind randomized and placebo controlled study on ACE-inhibitors (ACE-I) administration in moderately proteinuric IgA nephropathy (IgAN) in the young [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1510</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:10:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:10:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00601977"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:44:25 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al</AU>
<TI>IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1880-8</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:44:22 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17513327"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:25:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al</AU>
<TI>IgACE: first multicentric prospective double blind randomized and placebo controlled study on ace-inhibitors (ACE-I) administration in moderately proteinuric IgA nephropathy (IgAN) in the young [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv293-iv29</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:45:38 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:26:49 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppo R, Peruzzi L, Amore A, Piccoli A</AU>
<TI>IgACE: first prospective double-blind randomized placebo-controlled multicenter trial of ACE-inhibitors (ACE-I) in moderately proteinuric IgA nephropathy (IgAN) in the young [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>553A-4A</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:45:58 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:28:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Coppo R</AU>
<TI>IgACE-BIOMED multicenter study on treatment of IgAN with ACE-I</TI>
<SO>European Society for Paediatric Nephrology</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2010-12-29 15:28:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:28:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00449901"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:36:37 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancuso D, Amore A, Peruzzi L, Balegno S, Bertola L, Roasio L, et al</AU>
<TI>Advanced oxidation protein products (AOPP) and degalactosylated IgA1 in patients with IgA nephropathy (IgAN): a prospective double blind randomized placebo controlled trial with ACE inhibitors [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv383</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:46:33 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:37:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancuso D, Peruzzi L, Amore A, Camilla R, Balegno S, Grillo C, et al</AU>
<TI>Systemic microinflammation in IgA nephropathy: down-modulation by ACE-inhibitors observed in a placebo-controlled trial [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 6</NO>
<PG>vi113</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:37:27 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:37:27 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671812"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:38:43 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancuso D, Peruzzi L, Amore A, Camilla R, Magnetti F, Balegno S, et al</AU>
<TI>ACE-inhibition (ACE-I) down modulates a microinflammatory syndrome detectable in patients with proteinuric IgA nephropathy (IgAN) during a prospective double blind trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>567A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:38:39 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:38:39 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671811"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:40:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peruzzi L, Amore A, Roasio L, Balegno S, Bertola L, Magnetti F, et al</AU>
<TI>Advanced oxidation protein products (AOPP) and a degalactosylated IgA1 in patients with IgA nephropathy (IgAN) during a prospective, double blind, placebo controlled trial of ACE-inhibitors [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>422A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:40:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:40:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00601982"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:41:24 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peruzzi L, Coppo R, Amore A, Camilla R, IgACE Trial Group</AU>
<TI>Proteinuria as early predictor of final outcome in IgACE trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>552A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:41:24 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:41:24 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740504"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:42:40 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peruzzi L, Coppo R, Amore A, Camilla R, Mancuso D, Mazzola G, et al</AU>
<TI>ACE gene insertion/deletion (I/D) polymorphism and ACE-inhibitors (ACE-I) response in the IgACE trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts Issue</NO>
<PG>819A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:42:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:42:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00688842"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:43:36 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peruzzi L, Mancuso D, Roasio L, Balegno S, Camilla R, Magnetti F, et al</AU>
<TI>Urinary cytokines and chemokines excretion (IL-6/EGF, MCP-1/EGF) in patients with IgA nephropathy (IgAN) during a prospective double blind trial with ACE-inhibitors [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv295</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:43:32 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:43:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00601983"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:44:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roasio L, Balegno S, Camilla R, Magnetti F, Dotti G, Conti G, et al</AU>
<TI>Urinary IL-6/EGF and MCP-1/EGF ratio in patients with IgA nephropathy (IgAN) during a prospective, double blind, placebo controlled trial of ACE-inhibitors [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>553A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:44:37 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:44:37 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00601984"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JLIGHT-Study-2003" MODIFIED="2011-01-12 17:55:07 +1100" MODIFIED_BY="Narelle S Willis" NAME="JLIGHT Study 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-28 13:51:50 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, et al</AU>
<TI>Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study</TI>
<SO>Clinical &amp; Experimental Nephrology</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>3</NO>
<PG>221-30</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:51:48 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="14586719"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:51:59 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, et al</AU>
<TI>Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study</TI>
<SO>Hypertension Research - Clinical &amp; Experimental</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>1</NO>
<PG>21-30</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:51:56 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15055252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:46:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iino Y, Kawaguchi Y, JLIGHT Study Group</AU>
<TI>Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension; a report from Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT study) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>785A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:46:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:46:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445840"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:47:30 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iino Y, Kawaguchi Y</AU>
<TI>Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension: a report from Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>363</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:47:30 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:47:30 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550556"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 15:48:21 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawamura T, Iino Y, Kawaguchi Y</AU>
<TI>Renoprotective effect of losartan in comparison to amlodipine in hypertensive patients with advanced IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>753A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:48:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:48:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanno-2005" MODIFIED="2010-12-29 15:49:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kanno 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-12-29 15:49:14 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanno Y, Okada H, Inoue T, Kobayashi T, Watanabe Y, Nakazata Y, et al</AU>
<TI>Tubulointerstitial fibrosis (TIF) predicts renal protective effects of ACE inhibitor in IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>74A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:49:14 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:49:14 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445999"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:49:50 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanno Y, Okada H, Yamaji Y, Nakazato Y, Suzuki H</AU>
<TI>Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation</TI>
<SO>Qjm</SO>
<YR>2005</YR>
<VL>98</VL>
<NO>3</NO>
<PG>199-203</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:49:47 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15728401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kano-2003" MODIFIED="2010-12-29 15:50:50 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kano 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-12-29 15:50:50 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kano K, Nishikura K, Yamada Y, Arisaka O</AU>
<TI>Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IGA nephropathy with mild histological findings and moderate proteinuria [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>524-5</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:50:33 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:50:40 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kano K, Nishikura K, Yamada Y, Arisaka O</AU>
<TI>Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria</TI>
<SO>Clinical Nephrology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>2</NO>
<PG>85-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:50:38 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12940609"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 13:50:45 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kano K, Nishikura K, Yamada Y, Arisaka O</AU>
<TI>No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria</TI>
<SO>Clinical Nephrology</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>2</NO>
<PG>74-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:50:43 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15730048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawasaki-2006" MODIFIED="2010-01-28 13:53:52 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Kawasaki 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-28 13:53:52 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawasaki Y, Takano K, Suyama K, Isome M, Suzuki H, Sakuma H, et al</AU>
<TI>Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy</TI>
<SO>Pediatric Nephrology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1701-6</PG>
<IDENTIFIERS MODIFIED="2010-01-28 13:53:49 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16932894"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1997" MODIFIED="2010-12-29 16:15:42 +1100" MODIFIED_BY="Narelle S Willis" NAME="Lee 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-29 15:52:33 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee G, Choong HL, Chian GSC, Woo KT</AU>
<TI>Stabilisation of elevated serum creatinine (CR) in dipyridamole (DYP) and warfarin (WAR) treated patients with IgA nephropathy (IGAN): a three year controlled trial [abstract]</TI>
<SO>9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea</SO>
<YR>1992</YR>
<PG>106</PG>
<IDENTIFIERS MODIFIED="2010-12-29 15:52:33 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 15:52:33 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00461145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:10:20 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee GSL, Choong HL, Chiang GSC, Woo KT</AU>
<TI>Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>1</NO>
<PG>117-21</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:10:20 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="EMBASE" VALUE="1997112670"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:15:42 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee GSL, Woo KT, Lim CH</AU>
<TI>Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment [abstract]</TI>
<SO>Clinical Nephrology</SO>
<YR>1989</YR>
<VL>31</VL>
<PG>276</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:15:42 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:15:42 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740470"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006" MODIFIED="2011-02-08 21:50:43 +1100" MODIFIED_BY="Narelle S Willis" NAME="Li 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-08 21:50:43 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li SM, Yan JX, Yang L</AU>
<TI>Effects of Astragalus injection on renal tubular function in patients with IgA nephropathy</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>6</NO>
<PG>504-7</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:12:39 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16841664"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007" MODIFIED="2011-02-08 16:46:33 +1100" MODIFIED_BY="Narelle S Willis" NAME="Liu 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-08 16:46:33 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Wang H, Chen W, Li H, Xu G, Liu H, et al</AU>
<TI>Comparison of therapeutic effect of higher-dose valsartan combined with higher dose of lotensin for IgA nephropathy</TI>
<SO>Journal of Xi'an Jiaotong University (Medical Sciences)</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>4</NO>
<PG>437-439, 45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="2007459059"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maschio-1994" MODIFIED="2010-12-29 16:16:55 +1100" MODIFIED_BY="Narelle S Willis" NAME="Maschio 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-01-28 14:24:55 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, et al</AU>
<TI>ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>3</NO>
<PG>265-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:24:55 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8052432"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:16:55 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maschio G, Zucchelli P, Cagnoli L, Sasdelli M, Fusaroli M, Sanna G</AU>
<TI>Ace inhibition reduced proteinuria in normotensive patients with IgA nephropathy (IGAN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>658</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:16:55 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:16:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00461260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NA-IgAN-Study-2006" MODIFIED="2011-02-08 16:47:17 +1100" MODIFIED_BY="Narelle S Willis" NAME="NA IgAN Study 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-08 16:47:17 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg R, Fitzgibbons L, Lee JD, Julian BA, Holub BJ</AU>
<TI>Omega-3 fatty acids (O3FA) for patients with IgA nephropathy (IgAN): Efficacy is dose-dependent. Report from the North American (NA) IgAN trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>337A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:20:55 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:20:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00676029"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:22:51 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group.</AU>
<TI>Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>6</NO>
<PG>1167-72</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:06:05 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17699343"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:23:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, et al</AU>
<TI>Clinical Trial to Evaluate Omega-3 Fatty Acids and Alternate Day Prednisone in Patients with IgA Nephropathy: Report from the Southwest Pediatric Nephrology Study Group</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>3</NO>
<PG>467-74</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:06:11 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17699247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:22:18 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Lee J, Nardelli NA, Cattran D, Hirschman G, Julian BA</AU>
<TI>Clinical trial of alternate-day prednisone or daily omega-3 fatty acids in patients with IgA nephropathy [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>9</NO>
<PG>C64</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:22:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:22:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583302"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:23:26 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Lee J, Nardelli NA, Cattran D, Hirschman G, Julian BA</AU>
<TI>Multicenter, placebo-controlled trial of alternate-day prednisone (QOD-PRED) or daily omega-3 fatty acids (OM-3 FA) in children and young adults with IgA nephropathy (IgAN). Report from the Southwest Pediatric Nephrology Study Group [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>751A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:23:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:23:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583125"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:06:47 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ</AU>
<TI>A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>5</NO>
<PG>792-6</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:06:45 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7485134"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-28 14:03:41 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-01-28 14:03:41 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00004448"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-2000" MODIFIED="2010-01-28 14:25:39 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Nakamura 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-28 14:25:39 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al</AU>
<TI>Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy</TI>
<SO>American Journal of Nephrology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>5</NO>
<PG>373-9</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:25:36 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11092994"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-2007" MODIFIED="2011-02-08 16:47:45 +1100" MODIFIED_BY="Narelle S Willis" NAME="Nakamura 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-08 16:47:45 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, et al</AU>
<TI>Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobulin A nephropathy</TI>
<SO>American Journal of Hypertension</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1195-201</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:26:12 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17954367"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakao-2001" MODIFIED="2010-12-29 16:24:35 +1100" MODIFIED_BY="Narelle S Willis" NAME="Nakao 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-29 16:24:35 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakao N, Takada M, Yoshimura A, Ideura T</AU>
<TI>Antiproteinuric effect on the combination therapy of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker is synergetic in IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>488A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:24:35 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:24:35 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740474"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panichi-2000" MODIFIED="2010-12-29 16:25:27 +1100" MODIFIED_BY="Narelle S Willis" NAME="Panichi 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-29 16:25:27 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panichi V, Migliori M, Taccola D, Ghiadoni L, Virdis A, Giovannini L, et al</AU>
<TI>Different antiproteinuric mechanisms of converting enzyme inhibitor and losartan in hypertensive patients with IgA nephropathy [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>9</NO>
<PG>A94</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:25:27 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:25:27 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00461463"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park--2003" MODIFIED="2010-12-29 16:26:15 +1100" MODIFIED_BY="Narelle S Willis" NAME="Park  2003" YEAR="2003">
<REFERENCE MODIFIED="2010-12-29 16:26:15 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park HC, Choi SR, Goo YS, Xu ZG, Choi HY, Kang SW, et al</AU>
<TI>Effects of losartan and amlodipine on proteinuria and urinary tgf-b1 excretion in patients with IgA nephropathy [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>44</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:26:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:26:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00520372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:27:33 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, et al</AU>
<TI>Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1115-21</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:27:31 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12748343"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perico-1998" MODIFIED="2011-02-08 16:48:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Perico 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-28 14:28:19 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, et al</AU>
<TI>The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>12</NO>
<PG>2308-17</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:28:17 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="9848785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-08 16:48:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Vendramini G, et al</AU>
<TI>The antiproteinuric effect of angiotensin antagonists in human IgA nephropathy is potentiated by indomethacin [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>96A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:27:22 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:27:22 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00447165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 14:28:31 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, et al</AU>
<TI>ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy</TI>
<SO>American Journal of Physiology</SO>
<YR>1999</YR>
<VL>276</VL>
<NO>3 (Pt 2)</NO>
<PG>F457-66</PG>
<IDENTIFIERS MODIFIED="2010-01-28 14:28:28 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="10070170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettersson-1994" MODIFIED="2010-12-29 16:31:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Pettersson 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-29 16:31:18 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, et al</AU>
<TI>Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>4</NO>
<PG>183-90</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:31:08 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:31:08 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8026109"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Praga-2003" MODIFIED="2010-12-29 16:32:40 +1100" MODIFIED_BY="Narelle S Willis" NAME="Praga 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-12-29 16:32:40 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Praga M, Gutiérrez E, González E, Morales E, Hernández E</AU>
<TI>Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>6</NO>
<PG>1578-83</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:32:37 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:32:37 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12761258"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qian-1987" MODIFIED="2011-02-08 19:47:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Qian 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-08 19:47:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Qian JQ, He Y, Hu P, Zhang Q</AU>
<TI>Treatment of IgA nephropathy with Tripterygium Wilfordii glycoside [abstract]</TI>
<SO>10th International Congress of Nephrology; 1987 Jul 26-31; London (UK)</SO>
<YR>1987</YR>
<PG>87</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:33:44 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:33:44 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roccatello-2000" MODIFIED="2011-02-08 16:48:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Roccatello 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-02-08 16:48:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roccatello D, Mengozzi G, Gigliola G, Cesano G, Mosso R, Cacace G, et al</AU>
<TI>Effects of short-term administration of an angiotensin receptor antagonist, and angiotensin converting enzyme inhibitor and a nitric oxide donor on renal hemodynamics, proteinuria and nitric oxide levels [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>A52</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:41:51 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:41:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00520381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:40:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roccatello D, Mengozzi G, Gigliola G, Mosso R, Cacace G, Polloni R, et al</AU>
<TI>Effects of short-term administration of an angiotensin receptor antagonist, an angiotensin converting enzyme inhibitor and a nitric oxide donor on renal hemodynamics, proteinuria and nitric oxide blood levels [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S129</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:37:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:37:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00461608"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:39:12 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roccatello D, Mengozzi G, Gigliola G, Rossi D, Mosso R, Cacace G, et al</AU>
<TI>Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>7</NO>
<PG>988-93</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:39:12 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:39:12 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00297613"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russo-2001" MODIFIED="2010-12-29 16:43:44 +1100" MODIFIED_BY="Narelle S Willis" NAME="Russo 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-29 16:43:44 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al</AU>
<TI>Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>1</NO>
<PG>18-25</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:43:44 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:43:44 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11431176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-1990" MODIFIED="2010-12-29 16:45:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sato 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-12-29 16:45:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato M, Takayama K, Kojima H, Koshikawa S</AU>
<TI>Sodium cromoglycate therapy in IgA nephropathy: a preliminary short-term trial</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>2</NO>
<PG>141-6</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:45:02 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:45:02 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2105638"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2002" MODIFIED="2010-12-29 16:46:37 +1100" MODIFIED_BY="Narelle S Willis" NAME="Shi 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-12-29 16:46:37 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi X, Chen X, Liu S, Zhuang Y, Zhang Y</AU>
<TI>The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors</TI>
<SO>Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine]</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>6</NO>
<PG>399-403</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:46:37 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:46:37 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12137603"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shimizu-2008" MODIFIED="2010-04-23 14:07:55 +1000" MODIFIED_BY="[Empty name]" NAME="Shimizu 2008" YEAR="2008 Sep">
<REFERENCE MODIFIED="2010-04-23 14:07:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K</AU>
<TI>Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy</TI>
<SO>Hypertension Research - Clinical &amp; Experimental</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1711-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18971549"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2003" MODIFIED="2010-12-29 16:49:32 +1100" MODIFIED_BY="Narelle S Willis" NAME="Song 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-12-29 16:49:32 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, et al</AU>
<TI>The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy</TI>
<SO>Clinical Nephrology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>5</NO>
<PG>318-26</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:49:32 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:49:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14640237"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tesar-1999" MODIFIED="2010-12-29 16:50:40 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tesar 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-12-29 16:50:40 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tesar V, Monhart V, Rysava R, Zima T, Mestek O</AU>
<TI>Losartan and enalapril in IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>372A-373A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:50:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:50:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583256"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 16:48:17 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tesar V, Monhart V, Rysavs R, Zima T, Mestek O, Merta M, et al</AU>
<TI>Losartan &amp; enalapril in IgA nephropathy [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A64</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:48:06 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:48:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00486135"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woo-2000" MODIFIED="2010-12-29 16:52:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Woo 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-29 16:52:14 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo KT, Lau YK, Wong KS, Chiang GS</AU>
<TI>ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis</TI>
<SO>Kidney international</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>6</NO>
<PG>2485-91</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:52:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:52:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11115082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woo-2008" MODIFIED="2011-02-08 21:51:47 +1100" MODIFIED_BY="Narelle S Willis" NAME="Woo 2008" YEAR="2009 Jan">
<REFERENCE MODIFIED="2010-12-29 16:53:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo KT, Chan CM, Fook-Chong S, Tan HK, Zhao Y, Chiang GS, et al</AU>
<TI>High dose ARB and ACE gene polymorphism in IgA nephritis [abstract]</TI>
<SO>Nephrology</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>A21</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:53:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:53:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00690457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-23 14:08:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo KT, Chan CM, Tan HK, Choong HL, Foo M, Vathsala A, et al</AU>
<TI>Beneficial effects of high-dose losartan in IgA nephritis</TI>
<SO>Clinical Nephrology</SO>
<YR>2009</YR>
<VL>71</VL>
<NO>6</NO>
<PG>617-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19473629"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-08 21:51:47 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo KT, Chan CM, Wong KS</AU>
<TI>Telmisartan is more effective than losartan in reducing proteinuria</TI>
<SO>Kidney International</SO>
<YR>2009</YR>
<VL>75</VL>
<NO>1</NO>
<PG>119-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19092821"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2003" MODIFIED="2011-02-08 19:48:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Wu 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-08 19:48:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu X, Li J, Liu B</AU>
<TI>Clinical study on dan shao tang in treating IgA nephropathy of deficiency of yin with damp-heat symptom</TI>
<SO>Zhong Yao Cai [Journal of Chinese Medicinal Materials]</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>11</NO>
<PG>844-6</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:55:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:55:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14989068"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshikawa-1997" MODIFIED="2010-12-29 16:56:59 +1100" MODIFIED_BY="Narelle S Willis" NAME="Yoshikawa 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-29 16:56:59 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al</AU>
<TI>A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/mesangial proliferation</TI>
<SO>Nippon Jinzo Gakkiai shi</SO>
<YR>1997</YR>
<VL>39</VL>
<NO>5</NO>
<PG>503-6</PG>
<IDENTIFIERS MODIFIED="2010-12-29 16:56:59 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 16:56:59 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9283216"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-02-17 08:19:22 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-_x0032_nd-NA-IgAN-Study-2005" MODIFIED="2011-02-17 08:19:22 +1100" MODIFIED_BY="Narelle S Willis" NAME="2nd NA IgAN Study 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-12-29 17:01:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg R, Bay C</AU>
<TI>Reduction of proteinuria observed in response to high dose ACE inhibition and Omega-3 fatty acids in pts with IgA nephropathy. Report from the second North American IgA nephropathy trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>48A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:01:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:01:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740507"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:02:08 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Bay C</AU>
<TI>Dose-dependency of the effect of Omega-3 fatty acids (O3FA) on proteinuria in patients with IgA nephropathy: report from the 2nd North American IgA nephropathy trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>523A-4A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:02:08 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:02:08 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615826"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:23:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group.</AU>
<TI>Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>6</NO>
<PG>1167-72</PG>
<IDENTIFIERS MODIFIED="2010-01-29 12:32:27 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17699343"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-17 08:19:22 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Hogg RJ, SouthWest Pediatric Nephrology Study Group</AU>
<TI>A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy: study protocol</TI>
<SO>Personal communication</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2010-01-29 12:32:05 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:03:38 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ, Wyatt RJ, Scientific Planning Committee of the North American IgA Nephropathy Study</AU>
<TI>A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]</TI>
<SO>BMC Nephrology</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>3</PG>
<IDENTIFIERS MODIFIED="2010-01-29 12:32:18 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15043759"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:04:33 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RJ</AU>
<TI>Preliminary report from the second North American IgA nephropathy (IgAN) trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>567A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:04:33 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:04:33 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615827"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1999" MODIFIED="2011-02-09 16:30:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Anonymous 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-09 16:30:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Fish oil supplements</TI>
<SO>Geneesmiddelenbulletin</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>4</NO>
<PG>37-42</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:08:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:08:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1999132078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belovezhdov-1982" MODIFIED="2011-02-09 16:30:25 +1100" MODIFIED_BY="Narelle S Willis" NAME="Belovezhdov 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-02-09 16:30:25 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belovezhdov N, Robeva R</AU>
<TI>Controlled therapeutic trial in IgA glomerulonephritis</TI>
<SO>Vutreshni Bolesti</SO>
<YR>1982</YR>
<VL>21</VL>
<NO>3</NO>
<PG>49-53</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:08:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:08:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7051564"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-2003" MODIFIED="2010-12-29 17:09:46 +1100" MODIFIED_BY="Narelle S Willis" NAME="Campbell 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-12-29 17:09:46 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, et al</AU>
<TI>Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>3</NO>
<PG>1094-103</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:09:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:09:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12631093"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dal-Canton-2005" MODIFIED="2010-04-23 15:33:37 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Dal Canton 2005" YEAR="2005 Mar">
<REFERENCE MODIFIED="2010-04-23 15:33:37 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dal Canton A, Amore A, Barbano G, Coppo R, Emma F, Grandaliano G, et al</AU>
<TI>One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study</TI>
<SO>Journal of Nephrology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>136-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15944996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deliyska-2003" MODIFIED="2011-02-09 16:30:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Deliyska 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-09 16:30:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deliyska B, Angelova P, Nedialkov A, Shurliev V, Rapondzieva A</AU>
<TI>Antioxidant therapy with triovit and lipid peroxidation in IgA nephropathy</TI>
<SO>Nephrology, Hemodialysis &amp; Transplantation</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>2-3</NO>
<PG>35-7</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:11:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:11:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="2004200036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deteix-1984" MODIFIED="2010-12-29 17:13:06 +1100" MODIFIED_BY="Narelle S Willis" NAME="Deteix 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-12-29 17:13:06 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deteix P, Colon S, Leitienne P, Cochat P, Laville M, Zech P, et al</AU>
<TI>Prospective controlled therapeutic trial with diaminodiphenylsulfone-dapsone (DDS) in primitive IGA nephropathy (IgAN) [abstract]</TI>
<SO>Kidney International</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>4</NO>
<PG>493</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:13:06 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:13:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00677749"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuiano-2004" MODIFIED="2010-12-29 17:14:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Fuiano 2004" YEAR="2004 Aug">
<REFERENCE MODIFIED="2010-04-30 17:01:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuiano G, Mancuso D, Cianfrone P, Comi N, Mazza G, Marino F, et al</AU>
<TI>Can young adult patients with proteinuric IgA nephropathy perform physical exercise?</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>2</NO>
<PG>257-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15264183"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:14:14 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancuso D, Cianfrone P, Mazza G, Vecchi ML, Comi N, Caglioti A, et al</AU>
<TI>Post-exercise proteinuria in patients (pts) with IgA nephropathy in baseline conditions and after treatment with ramipril (r) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>209-10</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:14:14 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:14:14 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583600"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamazaki-1984" MODIFIED="2010-12-29 17:15:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hamazaki 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-12-29 17:15:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamazaki TS, Tateno S, Shishido H</AU>
<TI>Eicosapentaenoic acid and IgA nephropathy</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>1</VL>
<NO>8384</NO>
<PG>1017-8</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:14:57 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:14:57 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6143935"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez-1993" MODIFIED="2011-02-08 16:53:15 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hernandez 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-08 16:53:15 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hernandez E, Praga M, Ruilope LM, Sanchez R, Mazuecos A, Morales JM, et al</AU>
<TI>Effect of antihypertensive therapy with angiotensin converting enzyme inhibitors (ACEi) on progression of renal failure (rf) in patients with IgA nephropathy (IgAN) [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993 June 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>45</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:16:08 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:16:08 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615854"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hotta-1990" MODIFIED="2010-12-29 17:17:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hotta 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-12-29 17:17:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hotta O, Taguma Y, Matsubara M, Kurosawa K, Takahashi H</AU>
<TI>Effect of tonsillectomy combined with prednisolone therapy on active IgA nephropathy [abstract]</TI>
<SO>11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan</SO>
<YR>1990</YR>
<PG>114A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:17:16 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:17:16 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740471"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ihm-1999" MODIFIED="2010-12-29 17:19:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ihm 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-12-29 17:19:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ihm CG, Lee TW, Kim MJ, Cho BS</AU>
<TI>Comparison of immunosuppressive therapy (IST), ace inhibitor (ACEi), and AT1 receptor antagonist (AIIA) in the treatment of IgA nephropathy (IgAN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>104A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:18:51 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:18:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671813"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamei-2008" MODIFIED="2010-12-29 17:20:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kamei 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-12-29 17:20:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamei K, Iijima K, Honda M, Nakanishi K, Yoshikawa N</AU>
<TI>Long term prognosis of severe childhood IgA nephropathy showing diffuse mesangial proliferation [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>332A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:20:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:20:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanjanabuch-2007" MODIFIED="2010-12-29 17:20:58 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kanjanabuch 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-12-29 17:20:58 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanjanabuch T, Sukhato W, Prakash S, Avihingsanon Y, Tungsanga K, Eiam-Ong S</AU>
<TI>Effect of peroxisome proliferator-activated receptor-gamma (PPAR-g) on inflammatory markers and renal outcome in IgA nephropathy (IgAN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>47A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:20:58 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:20:58 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740505"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanno-2003" MODIFIED="2010-12-29 17:21:12 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kanno 2003" YEAR="2003 Mar">
<REFERENCE MODIFIED="2010-12-29 17:21:12 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H, et al</AU>
<TI>A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial</TI>
<SO>Clinical &amp; Experimental Nephrology</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>48-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14586743"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanno-2006" MODIFIED="2011-02-09 16:30:11 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kanno 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-09 16:30:11 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanno Y, Takenaka T, Nakamura T, Suzuki H</AU>
<TI>Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>4</NO>
<PG>730-7</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:22:20 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:22:20 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17699280"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerst-2003" MODIFIED="2011-02-08 21:52:43 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kerst 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-08 21:52:43 +1100" MODIFIED_BY="Narelle S Willis" NOTES="Excluded - Not &amp;gt;75% IgA (about 50%) - unable to separate data thus exclude" NOTES_MODIFIED="2011-02-08 21:52:43 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerst AJ</AU>
<TI>Combination treatment of angiotensin II receptor antagonist and ACE inhibitor protects against renal insufficient in non-diabetic kidney disease</TI>
<SO>Geneesmiddelenbulletin</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>9</NO>
<PG>111-2</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:24:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:24:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="2003424989"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konishi-2001" MODIFIED="2010-04-23 15:36:40 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Konishi 2001" YEAR="2001 Jul">
<REFERENCE MODIFIED="2010-04-23 15:36:40 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konishi Y, Okada N, Okamura M, Morikawa T, Okumura M, Yoshioka K, et al</AU>
<TI>Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin A nephropathy</TI>
<SO>Hypertension</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>1</NO>
<PG>81-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11463764"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurent-1987" MODIFIED="2010-12-29 17:25:23 +1100" MODIFIED_BY="Narelle S Willis" NAME="Laurent 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-12-29 17:25:23 +1100" MODIFIED_BY="Narelle S Willis" NOTES="12/29 IgA not analysed separately - thus excluded study" NOTES_MODIFIED="2010-12-29 17:25:23 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurent J, Belghiti D, Bruneau C, Lagrue G</AU>
<TI>Diclofenac, a nonsteroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study</TI>
<SO>American Journal of Nephrology</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>3</NO>
<PG>198-202</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:25:23 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:25:23 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3307414"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenzi-1996" MODIFIED="2010-12-29 17:25:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Lenzi 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-30 10:37:57 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenzi S, Caprioli R, Rindi P, Lazzerini G, Bernini W, Pardini E, et al</AU>
<TI>Omega-3 fatty acid supplementation and lipoprotein(a) concentrations in patients with chronic glomerular diseases</TI>
<SO>Nephron</SO>
<YR>1996</YR>
<VL>72</VL>
<NO>3</NO>
<PG>383-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8852484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lv-2009" MODIFIED="2010-12-29 17:26:36 +1100" MODIFIED_BY="Narelle S Willis" NAME="Lv 2009" YEAR="2007">
<REFERENCE MODIFIED="2010-12-29 17:25:40 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al</AU>
<TI>Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>1</NO>
<PG>26-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18930568"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:26:36 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lv J, Zhang H, Chen Y, Li G, Wang H</AU>
<TI>Addition of steroids to ACE inhibitors is more preferred to patients with IgA nephropathy: a prospective randomized controlled trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>57A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:26:36 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:26:36 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740506"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manno-2001" MODIFIED="2011-02-08 19:50:01 +1100" MODIFIED_BY="Narelle S Willis" NAME="Manno 2001" YEAR="2001 Jul">
<REFERENCE MODIFIED="2010-04-23 15:38:39 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP</AU>
<TI>Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy</TI>
<SO>Journal of Nephrology</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>4</NO>
<PG>248-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11506246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-08 19:50:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Manno C, Torres DD, Pesce F, Rossini M, Schena FP</AU>
<TI>Long-term prospective randomized controlled multicentre trial on steroids plus ramipril in proteinuric IgA nephropathy [abstract]</TI>
<SO>American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia, PA</SO>
<YR>2008</YR>
<IDENTIFIERS MODIFIED="2010-12-29 17:28:07 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:28:07 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-23 15:38:39 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manno C, Torres DD, Rossini M, Pesce F, Schena FP</AU>
<TI>Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>12</NO>
<PG>3694-701</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19628647"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:29:12 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Torres D, Rossini M, Manno C, Gesualdo L, Grandaliano G, Schena FP, et al</AU>
<TI>Steroids plus ramipril versus ramipril alone in the treatment of IgA nephropathy: interim analysis of a prospective, controlled, randomized, multicenter trial [abstract]</TI>
<SO>41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal</SO>
<YR>2004</YR>
<PG>222-3</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:29:12 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:29:12 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00636151"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mao-2008" MODIFIED="2010-12-29 17:34:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="Mao 2008" YEAR="2008 Jan">
<REFERENCE MODIFIED="2010-12-29 17:34:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mao LM, Cheng XX, Xu YY</AU>
<TI>[Effect of Yishen Tiaojing Recipe on hypogonadism induced by Tripterygium glycosides in women patients with nephropathy] [Chinese]</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1</NO>
<PG>70-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18418976"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogura-2004" MODIFIED="2010-12-29 17:36:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ogura 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-12-29 17:36:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogura M, Ito Y, Utsunomiya Y, Kawamura T, Hosoya T</AU>
<TI>Combined therapy with steroid, ACE inhibitor and anticoagulant improved the long-term prognosis of advanced IgA nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>332A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:36:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:36:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740476"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rychlik-1999" MODIFIED="2010-12-29 17:38:12 +1100" MODIFIED_BY="Narelle S Willis" NAME="Rychlik 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-12-29 17:37:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rychlik I, Tesar V, Jirsa M, Serakova M, Vernerova Z</AU>
<TI>Urinary eicosanoids and adhesion molecules in IgA nephropathy (IGAN) during the treatment with fish oil (FO) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A91</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:37:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:37:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00485692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:38:12 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rychlik I, Tesar V, Jirsa M</AU>
<TI>Urinary eicosanoids and serum interleukins in IgA nephropathy during fish oil treatment [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>114A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:38:12 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:38:12 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740472"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schena-2000" MODIFIED="2010-12-29 17:39:47 +1100" MODIFIED_BY="Narelle S Willis" NAME="Schena 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-29 17:39:47 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schena FP, Grandaliano G, Manno C, D'Altri C, Pontrelli P, Gesualdo L</AU>
<TI>Urinary EGF/MCP-1 ratio is a prognostic marker in IgA nephropathy (IgAN). A prospective randomized clinical trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>76A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:39:47 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:39:47 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulimani-2001" MODIFIED="2010-12-29 17:40:40 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sulimani 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-29 17:40:40 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulimani FM, Alhomssi M, Mitwalli A, al Wakeel J, Alam A, Tarif N, et al</AU>
<TI>Difficult nephropathies: a multicenter randomized trial on the treatment [abstract]</TI>
<SO>Saudi Journal of Kidney Diseases and Transplantation</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>2</NO>
<PG>229</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:40:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:40:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00402775"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1995" MODIFIED="2010-12-29 17:42:37 +1100" MODIFIED_BY="Narelle S Willis" NAME="Wolf 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-29 17:42:37 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf SC, Erley CM, Kenner S, Berger ED, Risler T</AU>
<TI>Does L-arginine alter proteinuria and renal hemodynamics in patients with chronic glomerulonephritis and hypertension?</TI>
<SO>Clinical Nephrology</SO>
<YR>1995</YR>
<VL>43 Suppl 1</VL>
<PG>S42-6</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:42:37 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:42:37 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7781205"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:41:40 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf SC, Erley CM, et al</AU>
<TI>Does L-arginine alter proteinuria and renal haemodynamics in patients with chronic glomerulonephritis and hypertension? [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>7</NO>
<PG>932</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:41:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:41:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00260999"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woo-1990" MODIFIED="2010-12-29 17:43:54 +1100" MODIFIED_BY="Narelle S Willis" NAME="Woo 1990" YEAR="July 15-20, 1990">
<REFERENCE MODIFIED="2010-12-29 17:43:54 +1100" MODIFIED_BY="Narelle S Willis" NOTES="Excluded - abstract refers to 3 studies - 2 not RCT and 1 RCT not non-immunosuppressive" NOTES_MODIFIED="2010-12-29 17:43:54 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Woo KT, Lee GSL, Lau YK, Chiang GSC, Lim CH</AU>
<TI>Anti platelet therapy in IgA nephritis [abstract]</TI>
<SO>XIth International Congress of Nephrology, ICN Joint Meeting; Tokyo, Japan</SO>
<YR>July 15-20, 1990</YR>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:43:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:43:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00448412"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshikawa-1999" MODIFIED="2010-12-29 17:46:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Yoshikawa 1999" YEAR="1999 May">
<REFERENCE MODIFIED="2010-04-23 15:41:47 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al</AU>
<TI>A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>101-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9890315"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-23 15:41:47 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Ito H</AU>
<TI>Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>5</NO>
<PG>1097-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10344344"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:45:51 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Ito H</AU>
<TI>Corticosteroids and immunosuppressive drugs [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>8</NO>
<PG>C31</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:45:51 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:45:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00448482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:46:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Itoh H, Japanese Pediatric IgA Nephropathy Treatment Study Group</AU>
<TI>A controlled trial of prednisolone (P), azathioprine (A), heparin-warfarin (H-W) and dipyridamole (D) in newly diagnosed severe childhood IgA nephropathy (IGAN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1401</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:46:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:46:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583182"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshikawa-2000" MODIFIED="2010-12-29 17:49:10 +1100" MODIFIED_BY="Narelle S Willis" NAME="Yoshikawa 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-29 17:47:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al</AU>
<TI>Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>3</NO>
<PG>511-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17699253"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:48:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N, Ito H</AU>
<TI>Prednisolone therapy versus combined therapy with prednisolone, azathioprine, warfarin and dipyridamole for newly diagnosed severe childhood IgA nephropathy: a controlled trial by the Japanese Pediatric IgA Nephropathy Treatment study group [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>79A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:48:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:48:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550736"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:49:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshikawa N</AU>
<TI>Treatment of IGA nephropathy in children [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>9</NO>
<PG>C57</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:49:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:49:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" MODIFIED="2011-01-12 17:56:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Zhang 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-12-29 17:50:23 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XZ, He Q, Luo TC, Lin ST</AU>
<TI>Efficacy and safety of leflunomide in the treatment of IgA nephropathy: preliminary results from a randomized, corticosteroid controlled, multi-center clinical trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>337A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:50:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:50:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583916"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-29 17:51:20 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XZ, He YC, Luo Q, Yang TC, Li XG, Lin SY</AU>
<TI>Efficacy and safety of leflunomide in the treatment of IgA nephropathy: a perspective, corticosteroid controlled, multi-center clinical trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>567A</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:51:17 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:51:17 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644205"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-04-30 17:02:14 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2011-01-19 18:16:50 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Pozzi-2006" MODIFIED="2010-12-29 17:52:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="Pozzi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-12-29 17:52:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pozzi C, Del Vecchio L, Casartelli D, Pozzoni P, Andrulli S, Amore A, et al</AU>
<TI>ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study</TI>
<SO>Journal of Nephrology</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>4</NO>
<PG>508-14</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:52:16 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:52:16 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17048209"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOP-Study-2008" MODIFIED="2011-01-19 18:16:50 +1100" MODIFIED_BY="Narelle S Willis" NAME="STOP Study 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-23 15:40:12 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eitner F, Ackermann D, Hilgers RD, Floege J</AU>
<TI>Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol</TI>
<SO>Journal of Nephrology</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>284-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18587715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-01-19 18:16:50 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-01-19 18:16:50 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT00554502"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-02-17 08:12:19 +1100" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2011-02-07 17:45:13 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2011-01-12 17:57:31 +1100" MODIFIED_BY="Narelle S Willis" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490-4</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:57:59 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:57:59 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15205295"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berger-1968" MODIFIED="2008-06-11 15:16:33 +1000" MODIFIED_BY="Narelle S Willis" NAME="Berger 1968" TYPE="JOURNAL_ARTICLE">
<AU>Berger J, Hinglais N</AU>
<TI>Intercapillary deposits of IgA-IgG</TI>
<SO>Journal d Urologie et de Nephrologie</SO>
<YR>1968</YR>
<VL>74</VL>
<NO>9</NO>
<PG>694-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4180586"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Consort-Statement-2001" MODIFIED="2010-12-29 17:52:51 +1100" MODIFIED_BY="Narelle S Willis" NAME="Consort Statement 2001" TYPE="OTHER">
<TI>Consort statement</TI>
<SO>http://www.consort-statement.org/consort-statement/</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-1987" MODIFIED="2008-06-11 15:16:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="D'Amico 1987" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G</AU>
<TI>The commonest glomerulonephritis in the world: IgA nephropathy</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1987</YR>
<VL>64</VL>
<NO>245</NO>
<PG>709-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3329736"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glassock-2009" MODIFIED="2010-12-29 17:55:20 +1100" MODIFIED_BY="Narelle S Willis" NAME="Glassock 2009" TYPE="JOURNAL_ARTICLE">
<AU>Glassock RJ</AU>
<TI>Analyzing antibody activity in IgA nephropathy</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2009</YR>
<VL>119</VL>
<NO>6</NO>
<PG>1450-2</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:55:20 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:55:20 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19504718"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-12-29 17:58:44 +1100" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins J, Thompson S, Deeks J, Altman D</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2010-12-29 17:58:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 17:58:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-12-29 18:01:38 +1100" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>16.5.4 How to include multiple groups from one study. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008)</TI>
<SO>The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jafar-2001" MODIFIED="2010-12-29 18:03:43 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jafar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al</AU>
<TI>Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>2</NO>
<PG>73-87</PG>
<IDENTIFIERS MODIFIED="2010-12-29 18:03:43 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:03:43 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11453706"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Julian-1999" MODIFIED="2008-06-11 15:16:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="Julian 1999" TYPE="JOURNAL_ARTICLE">
<AU>Julian BA, Tomana M, Novak J, Mestecky J</AU>
<TI>Progress in the pathogenesis of IgA nephropathy</TI>
<SO>Advances in Nephrology From the Necker Hospital</SO>
<YR>1999</YR>
<VL>29</VL>
<PG>53-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10561737"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2011-01-12 18:04:42 +1100" MODIFIED_BY="Narelle S Willis" NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mestecky-1993" MODIFIED="2008-06-11 15:16:47 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mestecky 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S</AU>
<TI>Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy</TI>
<SO>Contributions to Nephrology</SO>
<YR>1993</YR>
<VL>104</VL>
<PG>172-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8325028"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nolin-1999" MODIFIED="2008-06-11 15:16:56 +1000" MODIFIED_BY="Narelle S Willis" NAME="Nolin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nolin L, Courteau M</AU>
<TI>Management of IgA nephropathy: evidence-based recommendations</TI>
<SO>Kidney International - Supplement</SO>
<YR>1999</YR>
<VL>70</VL>
<PG>56-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10369196"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ONTARGET-Study-2008a" MODIFIED="2011-01-12 17:57:54 +1100" MODIFIED_BY="Narelle S Willis" NAME="ONTARGET Study 2008a" TYPE="JOURNAL_ARTICLE">
<AU>ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al</AU>
<TI>Telmisartan, ramipril, or both in patients at high risk for vascular events</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>15</NO>
<PG>1547-59</PG>
<IDENTIFIERS MODIFIED="2010-12-29 18:08:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:08:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18378520"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ONTARGET-Study-2008b" MODIFIED="2011-01-12 17:58:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="ONTARGET Study 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al</AU>
<TI>Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9638</NO>
<PG>547-53</PG>
<IDENTIFIERS MODIFIED="2010-12-29 18:11:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:11:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18707986"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renal-Group-2010" MODIFIED="2011-01-12 18:04:10 +1100" MODIFIED_BY="Narelle S Willis" NAME="Renal Group 2010" TYPE="OTHER">
<AU>Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC</AU>
<TI>Cochrane Renal Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2010, Issue 12. Art. No.: RENAL</SO>
<YR>(accessed December 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Samuels-2003a" MODIFIED="2011-02-07 16:41:33 +1100" MODIFIED_BY="Narelle S Willis" NAME="Samuels 2003a" TYPE="COCHRANE_REVIEW">
<AU>Samuels J, Strippoli GFM, Craig JC, Schena F, Molony DA</AU>
<TI>Immunosuppressive agents for treating IgA nephropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-12-29 18:16:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:16:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD003965"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schena-2001" MODIFIED="2008-06-11 15:16:59 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schena 2001" TYPE="JOURNAL_ARTICLE">
<AU>Schena FP</AU>
<TI>Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists</TI>
<SO>American Journal of Medicine</SO>
<YR>2001</YR>
<VL>110</VL>
<NO>6</NO>
<PG>499-500</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11331065"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2003" MODIFIED="2010-12-29 18:18:07 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GFM, Manno C, Schena FP</AU>
<TI>An &#8220;evidence-based&#8221; survey of therapeutic options for IgA nephropathy: assessment and criticism</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1129-39</PG>
<IDENTIFIERS MODIFIED="2010-12-29 18:17:42 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:17:42 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12776264"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2006" MODIFIED="2010-12-29 18:22:15 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2006" TYPE="COCHRANE_REVIEW">
<AU>Strippoli GFM, Bonifati C, Craig ME, Navaneethan SD, Craig JC</AU>
<TI>Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-12-29 18:22:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:22:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD006257"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2009" MODIFIED="2010-12-29 18:23:47 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2009" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GFM, Maione A, Schena FP, Tognoni G, Craig JC</AU>
<TI>IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS MODIFIED="2010-12-29 18:23:47 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-12-29 18:23:47 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19101396"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-02-07 16:42:18 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Samuels-2003b" MODIFIED="2011-02-07 16:42:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Samuels 2003b" TYPE="COCHRANE_PROTOCOL">
<AU>Samuels JA, Strippoli GFM, Craig JC, Schena FP, Molony DA</AU>
<TI>Non-immunosuppressive treatment for IgA nephropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-02-07 16:42:08 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-02-07 16:42:08 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD003962"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-02-17 08:12:19 +1100" MODIFIED_BY="Narelle S Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-02-08 21:46:28 +1100" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-02-08 19:34:10 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-01-09 14:40:31 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Adamkova-1989">
<CHAR_METHODS MODIFIED="2010-12-30 21:54:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-31 16:50:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: NS</LI>
<LI>Country: Czech Republic</LI>
<LI>"Diagnosis of IgA nephropathy"</LI>
<LI>Number: 17</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): 89/11 (%)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:40:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Phenytoin: Diphenylhydantoin</LI>
<UL>
<LI>Dose: 2 to 3 mg/kg for 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-30 17:45:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Haematuria</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:11:36 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Journal paper with only abstract in English, unable to translate full article.</LI>
<LI>Additional data (SE versus SD) requested from authors: no response.</LI>
<LI>Unable to meta-analyse data</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:50:06 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Alexopoulos-2004">
<CHAR_METHODS MODIFIED="2011-01-03 21:11:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: enrolment 1994 to 1996</LI>
<LI>Follow-up period: 4 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:20 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Greece</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 1 g/24 h; SCr &gt; 1.5 mg/dL</LI>
<LI>Number: 34</LI>
<LI>Mean age: 41 years</LI>
<LI>Sex (M/F): 79/21 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Previous treatment with PFA or immunosuppressive; diabetes; CLD; autoimmune disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:50:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil: MaxEPA</LI>
<UL>
<LI>Dose: 6 g/d (equivalent to 0.85 g/d EPA and 0.58 g/d DHA)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatment: e.g. ACEi ± BB, CCB, diuretics</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-30 18:05:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>ESKD</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-31 17:23:22 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 13:58:52 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bang-1994">
<CHAR_METHODS MODIFIED="2011-01-03 11:13:24 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-31 17:43:22 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Korea</LI>
<LI>Setting: NS</LI>
<LI>Biopsy-proven IGAN: NS; normotensive (MAP &lt; 110 mmHg); normal renal function (SCr &lt; 1.3 mg/dL)</LI>
<LI>Number: 45</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 13:58:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Captopril</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-31 16:42:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Remission - partial</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:12:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only</LI>
<LI>No response from attempt to contact authors: assumed SD used.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 13:59:24 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bannister-1995">
<CHAR_METHODS MODIFIED="2011-01-03 12:00:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow- up period: 3 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:12:15 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Australia</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy; hypertensive; GFR 30 to 90 mL/min</LI>
<LI>Number: 52</LI>
<LI>Mean age: 53 years</LI>
<LI>Sex (M/F): 74/26 (%)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 13:59:24 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Enalapril ACEi</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>CCB: Nifedipine</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-31 16:52:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-31 17:18:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>1995 Journal article and 1997 abstract.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:50:10 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bennett-1989">
<CHAR_METHODS MODIFIED="2011-01-03 11:13:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Australia</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; group A (SCr &gt; 0.12 mmol/L), group B (SCr &lt; 0.12 mmol/L with proteinuria; urine RBC &gt; 200,000/mL or &gt; 10% crescents)</LI>
<LI>Number: 27</LI>
<LI>Mean age (group A/group B): 52/28 years</LI>
<LI>Sex (M/F): 57/43 (%)</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:50:10 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil: MaxEPA</LI>
<UL>
<LI>Dose: 10g/d (equivalent to 1.8 g/d EPA and 1.2 g/d DHA)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-31 17:26:39 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>CrCl</LI>
<LI>Haematuria</LI>
<LI>ESKD</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-31 17:26:00 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-12 12:26:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bo-2000">
<CHAR_METHODS MODIFIED="2011-01-03 21:12:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1996 to 1999</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:53:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: NS</LI>
<LI>Biopsy-proven IGAN; haematuria; ± albuminuria; not hypertensive</LI>
<LI>Number: 70</LI>
<LI>Mean age: 30 years</LI>
<LI>Sex (M/F): 53/47 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>SLE; purpuric nephritis; cirrhosis or other progressive forms of nephropathy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-12 12:26:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Herbal medicine: Shenning Mixture</LI>
<UL>
<LI>Dose: 30 mL 3 times/day for 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Steroid: Prednisolone</LI>
<UL>
<LI>Dose: 30 mg initially then tapered over 7 weeks</LI>
</UL>
<LI>Vitamin E</LI>
<UL>
<LI>Dose: 0.1 g/d</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 150 mg</LI>
</UL>
</UL>
<P>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-31 17:36:18 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
<LI>Side effects: GIT reaction, irregular menstruation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-31 17:36:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Translated (Chinese)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-12 17:03:19 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Buemi-2000">
<CHAR_METHODS MODIFIED="2010-12-31 17:40:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-12 17:03:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; SCr &lt; 1.8 µmol/L (stable renal function); serum cholesterol &lt; 6.73 mmol/L; no indicators of poor prognosis (nephritic syndrome, severe lesions on biopsy)</LI>
<LI>Number: 21</LI>
<LI>Mean age: 36 years</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Cholesterol lowering treatment in the last year; severe hypertension; diabetes; smoking; alcoholism; secondary causes of IgAN</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:39:29 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Statin: Fluvastatin</LI>
<UL>
<LI>Dose: 40 mg/d for 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo for 6 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-31 17:45:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>GFR</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-31 17:39:40 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:33:30 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Camara-1991">
<CHAR_METHODS MODIFIED="2010-12-31 17:49:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-31 17:50:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Spain</LI>
<LI>Setting: single centre</LI>
<LI>Proteinuria &gt; 500 mg/24 h; CrCl &gt; 40 mL/min</LI>
<LI>Number: 12</LI>
<LI>Mean age: 35 years</LI>
<LI>Sex (M/F): 58/42 (%)</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:33:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 300 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-31 17:47:36 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>UP/UCr</LI>
<LI>Side effects: headache</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:53:30 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Numbers in treatment groups: NS</LI>
<LI>Attempt to contact authors: no response.</LI>
<LI>Unable to use data in meta-analyses</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 21:20:46 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chan-1987">
<CHAR_METHODS MODIFIED="2011-01-03 11:06:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: mean 33.2 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN</LI>
<LI>Number: 52</LI>
<LI>Mean age: 29 years</LI>
<LI>Sex (M/F): 63/37 (%)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 21:20:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Antiplatelet: Aspirin SR</LI>
<UL>
<LI>Dose: 650 mg/d</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 75 to 225 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Vitamin B complex</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 11:00:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:00:18 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-03 21:51:23 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chan-2003">
<CHAR_METHODS MODIFIED="2011-01-03 11:07:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: enrolment 1997 to 2000</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; children &lt; 21 years; haematuria (&gt; 3 RBC/HPF on 2 occasions); GFR 20 to 100% normal</LI>
<LI>Number: 55</LI>
<LI>Mean age: 11 years</LI>
<LI>Sex (M/F): 67/33 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Secondary IGAN, previous treatment with medications and procedures used in IGAN (see list in article p1016); pregnancy; hypertension</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-03 11:09:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Vitamin E (Hoffman-La Roche Inc)</LI>
<LI>Dose</LI>
<UL>
<LI>&lt; 30 kg: 400 IU/d</LI>
<LI>&#8805; 30 kg: 800 IU/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 11:10:01 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>UP/UCr</LI>
<LI>Haematuria</LI>
<LI>ESKD</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:10:22 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Numbers in each group at follow-up unclear</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:44:25 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chen--2004">
<CHAR_METHODS MODIFIED="2011-01-03 11:15:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: enrolment 1999 to 2000</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:24 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; &#8805; Lee grade III; IF glomerular fibrogen deposits; SCr &lt; 354 µmol/L; not prone to haemorrhage</LI>
<LI>Number: 71</LI>
<LI>Mean age: 30 years</LI>
<LI>Sex (M/F): 68/32 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>No systemic disease; no prior ACEi or urokinase treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:44:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Urokinase</LI>
<UL>
<LI>Dose: 100,000 IU in 250 mL 5% glucose IV/d for 10 days/month</LI>
</UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose:10 mg/d</LI>
</UL>
</UL>
<P>Duration: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:54:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>CrCl</LI>
<LI>Side effects: hyperkalaemia; bleeding</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:21:00 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-12 12:26:15 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chen-2006">
<CHAR_METHODS MODIFIED="2011-01-03 11:26:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS in abstract (not translated)</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 11:26:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: multicentre</LI>
<LI>IGAN patients of Fei-Pi Qi-Deficiency syndrome</LI>
<LI>Number: 70</LI>
<LI>Age: NS in abstract (not translated)</LI>
<LI>Sex (M/F): NS in abstract (not translated)</LI>
</UL>
<P>Exclusion: NS in abstract (not translated)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-12 12:26:15 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Fosinopril</LI>
<UL>
<LI>Dose: NS in abstract (not translated)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Herbal medicine: Shenle capsule</LI>
<UL>
<LI>Dose: NS in abstract (not translated)</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 11:22:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>CrCl</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:22:23 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only in English, data tables partly in English, remainder not translated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-12 12:26:16 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chen-2007">
<CHAR_METHODS MODIFIED="2011-01-03 11:35:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: enrolment date NS in abstract (not translated)</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 11:33:01 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: multicentre</LI>
<LI>IGAN patients of TCM Qi-yin Deficiency syndrome type</LI>
<LI>Number: 131</LI>
<LI>Age: NS in abstract (not translated)</LI>
<LI>Sex (M/F): NS in abstract (not translated)</LI>
</UL>
<P>Exclusion: NS in abstract (not translated)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-12 12:26:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Fosinopril</LI>
<UL>
<LI>Dose: NS in abstract (not translated)</LI>
</UL>
<LI>Herbal medicine: Compound Shenhua tablet</LI>
<UL>
<LI>Dose: NS in abstract (not translated)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Herbal medicine: Compound Shenhua tablet</LI>
<UL>
<LI>Dose: NS in abstract (not translated)</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 11:29:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>CrCl</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:29:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only in English, data tables partly in English, remainder not translated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-08 16:17:12 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Cheng-1998">
<CHAR_METHODS MODIFIED="2011-01-03 11:50:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 11:47:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: single centre</LI>
<LI>Number: 47</LI>
<LI>Mean age: 32 years</LI>
<LI>Sex (M/F): 74/26 (%)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-08 16:17:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>BB: Nadolol</LI>
<UL>
<LI>Dose: 80 mg</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ACEi: Captopril</LI>
<UL>
<LI>Dose: 75 mg</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi: Captopril</LI>
<UL>
<LI>Dose: 75 mg</LI>
</UL>
<LI>Anticoagulant: Ticlopidine</LI>
<UL>
<LI>Dose: 250 mg twice daily</LI>
</UL>
</UL>
<P>Dose titrated to target dose (above) to normalise BP in hypertensives and reduce 5 to 10 mmHg in normotensives</P>
<P>Duration: minimum 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 11:52:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>ESKD</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:52:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Some data (SCr, CrCl) not useable in meta-analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-03 21:51:24 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Clarkson-1980">
<CHAR_METHODS MODIFIED="2011-01-03 11:59:44 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:24 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Australia</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN</LI>
<LI>Number: 47</LI>
<LI>Mean age: 32 years</LI>
<LI>Sex (M/F): 74/26 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Clinical features of systemic disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-03 21:13:09 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Phenytoin</LI>
<UL>
<LI>Dose: 5 to 6 mg/kg/d in 3 divided doses (blood level 40 to 80 µmol/L or 10 to 20 µg/mL)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 11:53:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 11:53:09 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-19 17:24:54 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Costanzi-2006">
<CHAR_METHODS MODIFIED="2011-01-03 12:06:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: Nov 2004 to Feb 2006</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 200 mg/d; on renin-angiotensin system blockers</LI>
<LI>Number: 30</LI>
<LI>Mean age: 39.5 years</LI>
<LI>Sex (M/F): 47/53 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Dialysis; kidney transplant; diabetes mellitus; SLE; HSP; current or past immunosuppressive treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-19 17:24:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil: PUFA (85% EPA + DHA)</LI>
<UL>
<LI>Dose 3 x 1g/d</LI>
</UL>
<LI>ACEi: Ramipril</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>ARB: Irbesartan</LI>
<UL>
<LI>Dose: 300 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>ACEi: Ramipril</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>ARB: Irbesartan</LI>
<UL>
<LI>Dose: 300 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-23 14:26:03 +1000" MODIFIED_BY="[Empty name]">
<P>CrCl<BR/>Proteinuria<BR/>Haematuria</P>
<P>S/E</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-23 14:07:08 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 13:49:58 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Donadio-1994">
<CHAR_METHODS MODIFIED="2011-01-03 21:56:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: enrolment 1988 to 1991</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:56:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; proteinuria &#8805; 1 g/d or SCr increase by 25% during preceding 6 months; SCr &#8804; 265 µmol/L; expected survival &#8805; 2 years</LI>
<LI>Number: 106</LI>
<LI>Mean age: 37 years</LI>
<LI>Sex (M/F): 74/26 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>SLE, CLD; anti-glomerular basement membrane glomerulonephritis; pregnant or lactating</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 13:49:58 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil</LI>
<UL>
<LI>MaxEPA</LI>
<LI>Dose: 12 g/d (1.87 g/d EPA and 1.36 g/d DHA)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:56:32 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>ESKD</LI>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>All-cause mortality</LI>
<LI>Side effects: fishy aftertaste</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 13:53:12 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Donadio-2001">
<CHAR_METHODS MODIFIED="2011-01-03 12:28:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: enrolment 1995 to 1998</LI>
<LI>Follow-up period: 2 years minimum</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; &#8805; 18 years; SCr 1.5 to 4.9 mg/dL</LI>
<LI>Number: 73</LI>
<LI>Mean age: 46 years</LI>
<LI>Sex (M/F): 84/16 (%)</LI>
</UL>
<P>Exclusion: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 13:53:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Fish oil: Omacor</LI>
<UL>
<LI>High dose: 8 x 1 g capsules (EPA 3.76g/d + DHA 2.94 g/d)</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Fish oil: Omacor</LI>
<UL>
<LI>Low dose: 4 x 1 g capsules (EPA 1.88 g/d + DHA 1.47 g/d)</LI>
</UL>
</UL>
<P>Duration: 2 years<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 12:30:30 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>ESKD</LI>
<LI>SCr</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 12:30:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Some SCr data not useable in meta-analysis</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:35:25 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Frasca-1997">
<CHAR_METHODS MODIFIED="2011-01-03 12:38:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; SCr &gt; 1.4 mg/dL</LI>
<LI>Number: 20</LI>
<LI>Mean age: 30 years</LI>
<LI>Sex (M/F): 90/10 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Systemic disease or hepatic dysfunction; previous treatment for IGAN</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:35:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Antiplatelet: Defibrotide</LI>
<UL>
<LI>Dose: 10 mg/kg/d for 2 years</LI>
</UL>
<LI>Steroid: Prednisone</LI>
<UL>
<LI>Dose: 0.5 mg/kg/alternate days for 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Steroid: Prednisone</LI>
<UL>
<LI>Dose: 0.5 mg/kg/alternate days for 6 months</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 12:40:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 12:40:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding: 1996 MURST and University of Bologna Grant</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:04:25 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Guan-2005">
<CHAR_METHODS MODIFIED="2011-01-03 12:46:57 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:57:10 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: single centre</LI>
<LI>'diagnosed as IgA nephropathy'</LI>
<LI>Number: 62</LI>
<LI>Age: NS in abstract</LI>
<LI>Sex (M/F): NS in abstract</LI>
</UL>
<P>Exclusion criteria: NS in abstract</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:04:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ARB: Irbesartan</LI>
<UL>
<LI>Dose: 150 to 300 mg/d</LI>
</UL>
<LI>Huobahuagen tablets</LI>
<UL>
<LI>Dose: 5 x three times/day</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Herbal medicine: Huobahuagen tablets</LI>
<UL>
<LI>Dose: 5 x three times/day</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 12:49:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 12:50:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Chinese, abstract and tables in English. Remainder of paper not translated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:04:56 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hashizume-1998">
<CHAR_METHODS MODIFIED="2011-01-03 13:14:39 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 5 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:57:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: NS</LI>
<LI>'patients with IGAN'</LI>
<LI>Number: 47</LI>
<LI>Mean age: 42 years</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:04:56 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Cilazapril</LI>
<UL>
<LI>Dose: 1 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Antiplatelet drug: NS</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 12:56:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>ESKD</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 12:57:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:17:24 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-HKVIN-Study-2006">
<CHAR_METHODS MODIFIED="2011-01-03 13:14:39 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 2000 to 2003</LI>
<LI>Follow-up period: 104 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; at least 18 years; either proteinuria (&#8805; 1g/d) + SCr (&lt; 2.8 mg/dL) or SCr 1.4 to 2.8 mg/dL</LI>
<LI>Number: 109</LI>
<LI>Mean age: 41 years</LI>
<LI>Sex (M/F): 28/72 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Accelerated or malignant hypertension; expected survival &lt; 2 years; secondary IGAN including HSP; pregnant or lactating; clinically significant hepatic disease; allergy or reactions to ARB; recent treatment (&lt; 4 weeks) with ACEi or ARB</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:17:24 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ARB: Valsartan</LI>
<UL>
<LI>Dose: 80 to 160 mg/d (to achieve target BP)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 12:58:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>ESKD</LI>
<LI>Proteinuria</LI>
<LI>CrCl</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:13:53 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding: Novartis Pharmaceuticals provided study medication and cost of administrative support: not involved in study design; collection, analysis or interpretation of data; or preparation of the manuscript</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:14:20 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Horita-2004">
<CHAR_METHODS MODIFIED="2011-01-03 13:11:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: Jan 2000 to Mar 2003</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; normotensive (&lt; 140/90); proteinuria &#8805; 0.4 g/d; CrCl &gt; 50 mL/min; on antiplatelet agents for 3 months before without ACEi or ARB</LI>
<LI>Number: 46</LI>
<LI>Mean age: 43 years</LI>
<LI>Sex (M/F): 56/44 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Systemic diseases such as diabetes; lupus; HSP; CLD; kidney allografts</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:14:20 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Temocapril</LI>
<UL>
<LI>Dose: 1 mg</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 12.5 mg</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi: Temocapril</LI>
<UL>
<LI>Dose: 1 mg</LI>
</UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 12.5 mg</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 13:07:01 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>GFR</LI>
<LI>Proteinuria</LI>
<LI>Side effects: cough, postural hypotension</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 13:12:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>3, 6 and 12 month data from 2004 and 2006 papers</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-07 17:54:21 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Horita-2007">
<CHAR_METHODS MODIFIED="2011-01-03 13:17:52 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 2000 to 2003</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:58:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; BP &lt; 140/90 mm Hg; MAP &lt; 107 mm Hg; mild to moderate proteinuria (mean 1.6 g/d); CrCl &gt; 50 mL/min/1.73 m², renal glomerular score (Katafuchis's scale) 1 to 4.</LI>
<LI>Number: 40</LI>
<LI>Mean age: 34 years</LI>
<LI>Sex (M/F): 53/47 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Systemic disease such as diabetes, lupus, HSP, CLD; kidney allografts</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-07 17:54:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Losartan</LI>
<UL>
<LI>Dose: 50 mg/d</LI>
</UL>
<LI>Steroid: Prednisolone</LI>
<UL>
<LI>Dose: 30 mg/d tapered to 5 mg/d over 2 years</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 300 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Steroid: Prednisolone</LI>
<UL>
<LI>Dose: 30 mg/dL tapered to 5 mg/d over 2 years</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 300 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 13:23:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Side effects: postural hypotension</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:36:56 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hotta-1993">
<CHAR_METHODS MODIFIED="2011-01-03 21:59:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: ?quasi-RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:59:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Single centre</LI>
<LI>Biopsy-proven IGAN, 'active IGAN in which cellular crescents present' and chronic tonsillitis (pus in tonsillar crypts)</LI>
<LI>Number: 45</LI>
<LI>Mean age: 29 years</LI>
<LI>Sex (M/F): 38/62 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Systemic disease such as SLE, HSP or CLD</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:36:51 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Tonsillectomy</LI>
<LI>Steroid: Methylprednisolone</LI>
<UL>
<LI>Dose</LI>
<UL>
<LI>pulse initially: 1 to 3 courses of 1000 mg/d for 3 days</LI>
<LI>30 mg/d for 4 weeks then tapered over 1 to 2 years</LI>
</UL>
</UL>
<LI>Cytotoxic: Cyclophosphamide</LI>
<UL>
<LI>Dose: 50 mg/d for 4 months</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 150 to 300 mg/d for 36 months</LI>
</UL>
<LI>Anticoagulant: Warfarin</LI>
<UL>
<LI>Thrombotest: 20 to 40% during the steroid therapy</LI>
</UL>
</UL>
<P>Control group<BR/>
</P>
<UL>
<LI>Steroid: Methylprednisolone</LI>
<UL>
<LI>Dose</LI>
<UL>
<LI>pulse initially: 1 to 3 courses of 1000 mg/d for 3 days</LI>
<LI>30 mg/d for 4 weeks then tapered over 1 to 2 years</LI>
</UL>
</UL>
<LI>Cytotoxic: Cyclophosphamide</LI>
<UL>
<LI>Dose: 50 mg/d for 4 months</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 150 to 300 mg/d for 36 months</LI>
</UL>
<LI>Anticoagulant: Warfarin</LI>
<UL>
<LI>Thrombotest: 20 to 40% during the steroid therapy</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 14:27:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-09 14:36:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Haematuria data not useable</LI>
<LI>?Quasi RCT or cohort</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-03 21:14:16 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Houssin-1984">
<CHAR_METHODS MODIFIED="2011-01-03 14:44:43 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 14:45:53 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: France</LI>
<LI>Setting: multicentre</LI>
<LI>Moderate kidney failure; proteinuria &gt; 0.5 g/24 h and/or haematuria &gt;100,000 RBC/mL</LI>
<LI>Number: 36</LI>
<LI>Mean age: 34 years</LI>
<LI>Sex (M/F): 83/17 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Pregnant</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-03 21:14:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Phenytoin</LI>
<UL>
<LI>Dose: 200 to 300 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 14:45:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
<LI>Side effects: gastric, skin rash, gingival hyperplasia, increased liver enzyme</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 14:40:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Partially translated (French)</LI>
<LI>SE used?</LI>
<LI>Unable to use haematuria data</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:03:47 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-IgACE-Study-2001">
<CHAR_METHODS MODIFIED="2011-01-03 14:53:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: enrolment 1998 to 2003</LI>
<LI>Follow-up period: 3 years (38 months median)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:59:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Countries: Italy, France, Germany, Sweden, Portugal</LI>
<LI>Setting: international multicentre</LI>
<LI>Biopsy-proven IGAN; children and young people (3 to 35 years); proteinuria 1 to 3.4g/d/1.73 m², CrCl &gt; 50mL/min/1.73 m²</LI>
<LI>Number: 66</LI>
<LI>Mean age: 20.5 years; range 9 to 35 years</LI>
<LI>Sex (M/F): 73/27 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>HSP; lupus; celiac disease; CLD; diabetes; pregnancy; hypertension &gt; 140/90 in adults and &gt; 95th percentile in children (despite non-intervention drug treatment); treatment in last 6 months with steroids, cytotoxic drugs, or ACEi.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:03:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: 0.2 mg/kg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 14:53:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Side effects: cough</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 14:51:45 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:17:06 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-JLIGHT-Study-2003">
<CHAR_METHODS MODIFIED="2011-01-03 14:58:38 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; hypertensive; proteinuria &#8805; 0.5 g/d; SCr 1.3 to 3 mg/dL</LI>
<LI>Number: 24</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:17:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 25 to 100 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CCB: Amlodipine</LI>
<UL>
<LI>Dose: 2.5 to 5 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 14:59:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 14:58:06 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-07 17:54:37 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kanno-2005">
<CHAR_METHODS MODIFIED="2011-01-03 15:09:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame NS</LI>
<LI>Follow-up period: 3 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN</LI>
<LI>Number: 49</LI>
<LI>Mean age: 35 years</LI>
<LI>Sex (M/F): 31/60 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Diabetes; hyperlipidaemia; liver disease; SLE; HSP; past treatment with ACEi or steroids</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-07 17:54:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Temocapril or Trandolapril</LI>
<UL>
<LI>Dose: 1 to 2 mg/d</LI>
</UL>
<LI>BB: Arotinolol (if need for BP control)</LI>
<UL>
<LI>Dose: 10 to 20 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CCB: Amlodipine</LI>
<UL>
<LI>Dose: 2.5 to 5 mg/d</LI>
</UL>
<LI>BB: Arotinolol (if need for BP control)</LI>
<UL>
<LI>Dose: 10 to 20 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 15:05:43 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:39:58 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kano-2003">
<CHAR_METHODS MODIFIED="2011-01-03 15:24:50 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;children ?subgroup&lt;/p&gt;" NOTES_MODIFIED="2011-01-03 15:24:50 +1100" NOTES_MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN (minor lesion or focal mesangial proliferation without glomerulosclerosis, crescent formation or adhesion to the Bowman's capsule); children; normocholesterolaemic; moderate proteinuria (0.5 to 2.0 g/24 h/1.73 m²)</LI>
<LI>Number: 30</LI>
<LI>Mean age: 13 years</LI>
<LI>Sex (M/F): 47/53 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Cholesterol lowering drugs or antiplatelet drugs in last year; hypertension; kidney failure (CrCl &lt; 103 mL/min/1.73 m²); SLE; HSP</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:39:58 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Statin: Fluvastatin</LI>
<UL>
<LI>Dose: 20 mg</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 5 mg/kg</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 5 mg/kg</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 15:26:31 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:38:51 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kawasaki-2006">
<CHAR_METHODS MODIFIED="2011-01-03 21:14:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 2001 to 2004</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting; single centre</LI>
<LI>Biopsy-proven IGAN; age &lt; 15 years</LI>
<LI>Number: 34</LI>
<LI>Mean age: 13 years</LI>
<LI>Sex (M/F): 53/47 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>systemic disease such as HSP, SLE; previous treatment with corticosteroids or immunosuppressive drugs</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:38:51 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Tonsillectomy</LI>
<LI>Steroid</LI>
<UL>
<LI>Methylprednisolone pulse</LI>
<UL>
<LI>Dose: 10 days after surgery 20 to 25 mg/kg/d for 3 days</LI>
</UL>
<LI>Prednisolone</LI>
<UL>
<LI>Dose: 2 mg/kg/d (max 60 mg) reduced over 12 months to 0.5 mg/kg every 2 days for 21 months</LI>
</UL>
</UL>
<LI>Anticoagulant: Warfarin</LI>
<UL>
<LI>Dose:1 to 2 mg/d</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 5 mg/kg/d (max 300 mg)</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Cytotoxic: Mizoribine</LI>
<UL>
<LI>Dose: 5 mg/kg/d</LI>
</UL>
</UL>
<UL>
<LI>Steroid: Prednisolone</LI>
<UL>
<LI>Dose: 2 mg/kg/d (max 60 mg) reduced over 12 months to 0.5 mg/kg every 2 days for 21 months</LI>
</UL>
<LI>Anticoagulant: Warfarin</LI>
<UL>
<LI>Dose:1 to 2 mg/d</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 5 mg/kg/d (max 300 mg)</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 15:30:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
<LI>Side effects: glaucoma, growth retardation, hypertension, hyperuricaemia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 15:26:42 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-08 16:32:34 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lee-1997">
<CHAR_METHODS MODIFIED="2011-01-03 15:39:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Singapore</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; SCr 1.6 to 3 mg/dL</LI>
<LI>Number: 21</LI>
<LI>Mean age: 36 years</LI>
<LI>Sex (M/F): 76/24 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>SLE; liver disease; HSP; other systemic vasculitis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:34:49 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: 75 mg 3 times/d</LI>
</UL>
<LI>Anticoagulant: Warfarin</LI>
<UL>
<LI>Dose: INR 1.3 to 1.5</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Duration: 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 15:40:53 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-08 16:32:34 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>NB: patients withdrawn if SCr &gt; 6 mg/dL. When withdrawn the last values of SCr and UP (when SCr &lt; 6 mg/dL) was recorded as the last value</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-08 16:33:55 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Li-2006">
<CHAR_METHODS MODIFIED="2011-02-07 18:02:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: possible parallel RCT</LI>
<LI>Time frame: enrolment date NS in abstract</LI>
<LI>Follow-up period: NS in abstract</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-09 20:57:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: NS in abstract</LI>
<LI>IGAN</LI>
<LI>Number: 67</LI>
<LI>Age: NS in abstract</LI>
<LI>Sex (M/F): NS in abstract</LI>
</UL>
<P>Exclusion: NS in abstract</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-08 16:33:55 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Herbal medicine: Astragalus IV injection</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Antiplatelet: Dipyridamole</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 15:52:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 15:52:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only in English, data tables partly in English, remainder not translated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 20:54:56 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Liu-2007">
<CHAR_METHODS MODIFIED="2011-01-09 20:54:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Enrolment date NS in abstract</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-09 20:54:56 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: NS in abstract</LI>
<LI>IGAN</LI>
<LI>Number: 61</LI>
<LI>Age: NS in abstract</LI>
<LI>Sex (M/F): NS in abstract</LI>
</UL>
<P>Exclusion criteria: NS in abstract</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:18:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ARB: Valsartan</LI>
<UL>
<LI>Dose:160 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ARB: Valsartan</LI>
<UL>
<LI>Dose:160 mg/d</LI>
</UL>
</UL>
<UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 15:56:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
<LI>"total effective rate" (what this means is not clear from abstract)</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 15:56:01 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only in English, data tables partly in English, remainder not translated</LI>
<LI>Groups not clearly specified in abstract and tables</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-08 16:34:41 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Maschio-1994">
<CHAR_METHODS MODIFIED="2011-01-03 16:08:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 x 4 month sequences</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:33 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; proteinuria &#8805; 1 g/24 h; BP &lt; 140/90; SCr &lt; 1.4 mg/dL; CrCl &gt; 90 mL/min/1.73 m²</LI>
<LI>Number: 44</LI>
<LI>Mean age: 33 years</LI>
<LI>Sex (M/F): 67/33 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Systemic disease; purpura; liver cirrhosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-08 16:34:41 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Fosinopril</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>2 x 4 month sequences</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 16:07:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 16:09:00 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Data not useable, not able to distinguish groups</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-08 16:34:54 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-NA-IgAN-Study-2006">
<CHAR_METHODS MODIFIED="2011-01-03 16:20:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-08 16:34:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Biopsy-proven IGAN; GFR &#8805; 50 mL/min/1.73 m²; proteinuria: severe (1st morning UP/Cr &#8805; 1.0) or moderate (UP/Cr &#8805; 0.5) + biopsy suggesting risk of progression; age &#8804; 40 years</LI>
<LI>Number: 98</LI>
<LI>Mean age: 20 years</LI>
<LI>Sex (M/F): 66/34 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>SLE; HSP; abnormal LFTs; diabetes or other conditions exacerbated by prednisone; prednisone and/or fish oils for &gt; 3 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 13:54:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Fish oil: O3FA</LI>
<UL>
<LI>Dose: 4 g/d (1.88 g/d EPA + 1.48 g/d DHA) for 2 years</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Steroid: Prednisone</LI>
<UL>
<LI>Dose : 60 mg/m² alternate days for 3 months; 40 mg/m² for 9 months; 30 mg/m² for 12 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-08 16:34:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Time to failure (eGFR &lt; 60% baseline)</LI>
<LI>UP/Cr</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:15:24 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>no SD provided; unable to include data in meta-analyses</LI>
<LI>Medications donated by Merck and Co. Inc, Pharmacia, Upjohn and Pronova Biocare</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:20:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nakamura-2000">
<CHAR_METHODS MODIFIED="2011-01-03 16:26:51 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:34 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; CrCl &gt; 80 mL/min</LI>
<LI>Number: 32</LI>
<LI>Mean age: 33 years</LI>
<LI>Sex (M/F): 44/56 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Liver disease; HSP; other systemic diseases; infection or macro haematuria in previous 4 weeks; previous immunosuppressive, anti-hypertensive or anti-inflammatory drugs; BP &gt; 140/90; proteinuria &gt; 3 g/d</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:20:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>CCB: Verapamil</LI>
<UL>
<LI>Dose: 120 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ACEi: Trandolapril</LI>
<UL>
<LI>Dose: 2 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ARB: Candesartan</LI>
<UL>
<LI>Dose: 8 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 16:28:38 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:21:25 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nakamura-2007">
<CHAR_METHODS MODIFIED="2011-01-03 16:31:53 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:35 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; normotensive; all patients on antiplatelet aggregation drugs</LI>
<LI>Number: 23</LI>
<LI>Mean age: 32 years</LI>
<LI>Sex (M/F): 54/46 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients were not taking steroids, immunosuppressive agents, statins or antihypertensive agents</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:21:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Temocapril</LI>
<UL>
<LI>Dose: 2 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Olmesartan</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi: Temocapril</LI>
<UL>
<LI>Dose: 2 mg/d</LI>
</UL>
</UL>
<UL>
<LI>ARB: Olmesartan</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 16:29:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:22:12 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nakao-2001">
<CHAR_METHODS MODIFIED="2011-01-03 18:29:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT (4 arms)</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:35 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Single centre</LI>
<LI>Biopsy-proven IGAN; normal renal function</LI>
<LI>Number: 40</LI>
<LI>Mean age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:22:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Trandolapril</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>dose: NS</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ACEi: Trandolapril</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
<LI>Placebo</LI>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
<LI>Placebo</LI>
</UL>
<P>Treatment group 4</P>
<UL>
<LI>Other antihypertensive treatment</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 18:29:58 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-23 14:07:40 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:22:55 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Panichi-2000">
<CHAR_METHODS MODIFIED="2011-01-03 18:36:39 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 x 4 weeks with 4 week washout</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria mean 1.9 ± 0.9 g/d; CrCl 101.3 ± 17.6</LI>
<LI>Number: 10</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:22:55 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose:10 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 18:36:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 18:36:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Data not useable, not included in MA</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:23:19 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Park--2003">
<CHAR_METHODS MODIFIED="2011-01-03 18:40:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 18:39:51 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Korea</LI>
<LI>Setting: single centre</LI>
<LI>Number: 36</LI>
<LI>Mean age: 39 years</LI>
<LI>Sex (M/F): 50/50 (%)</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:23:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CCB: Amlodipine</LI>
<UL>
<LI>Dose: 5 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 18:38:44 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 18:38:38 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding: Brain Korea 21 project for Medical Sciences Yonsei University &amp; MSD Korea</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:24:32 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Perico-1998">
<CHAR_METHODS MODIFIED="2011-01-03 18:44:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 4 weeks + 3 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: Single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria 0.5 to 4 g/24 h; SCr &lt; 2.5 mg/dL</LI>
<LI>Number: 20</LI>
<LI>Age range: 20 to 65 years</LI>
<LI>Sex (M/F): 80/20 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Previous immunosuppressive agent; NSAID 3 months before enrolment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:24:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
</UL>
<LI>Indomethacin</LI>
<UL>
<LI>Dose: 75 mg twice daily for 3 days at 4 weeks</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Irbesartan</LI>
<UL>
<LI>Dose: 100 mg/d</LI>
</UL>
<LI>Indomethacin</LI>
<UL>
<LI>Dose: 75 mg twice daily for 3 days at 4 weeks</LI>
</UL>
</UL>
<P>Duration: 31 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 18:49:59 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 18:50:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>ACEi versus ARB for 28 days then for 3 additional days NSAID added to both arms. In meta-analyses 28 day data (without NSAID) only used</LI>
<LI>Funding: in part Sanofi Winthrop (Gentilly Cedex France)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-11 16:28:14 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Pettersson-1994">
<CHAR_METHODS MODIFIED="2011-01-03 18:54:38 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Sweden</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 0.5 g/24 h</LI>
<LI>Number: 34</LI>
<LI>Mean age: 39 years</LI>
<LI>Sex (M/F): 78/22 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Rapidly progressive renal insufficiency; poorly controlled hypertension; malignant disease; other systemic disease; steroids, NSAIDs, immunosuppressive or cytotoxic treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-11 16:28:14 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil</LI>
<UL>
<LI>Dose: 6 g/d K85 + 55% EPA + 30% DHA (5.1 g omega-3-PUFA)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Corn oil</LI>
<UL>
<LI>Dose: 6 g/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 18:56:03 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Side effects: belching</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 18:56:07 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:26:00 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Praga-2003">
<CHAR_METHODS MODIFIED="2011-01-03 22:04:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1990 to 1995</LI>
<LI>Follow-up period: (mean) 78 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Spain</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 0.5 g/d; SCr &#8804; 1.5 mg/dL; BP controlled with treatment other than ACEi</LI>
<LI>Number: 44</LI>
<LI>Mean age: 28 years</LI>
<LI>Sex (M/F): 61/39 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Severe hypertension (&gt; 2 medications to control or malignant); secondary IgAN; HSP; diabetes mellitus; liver disease; systemic disease; previous treatment with ACEi, steroids, immunosuppressives or fish oil</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:26:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 5 to 40 mg/d (aim BP &lt; 140/90)</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatment: Antihypertensives other than ACEi or ARB if necessary for BP &lt; 140/90</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 19:04:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Side effects: mild K<SUP>+</SUP> increase</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:42:07 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Qian-1987">
<CHAR_METHODS MODIFIED="2011-01-03 19:06:31 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:38 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; untreated nephropathy</LI>
<LI>Number: 30</LI>
<LI>Mean age: NS</LI>
<LI>Sex (M/F): 60/40 (%)</LI>
</UL>
<P>Exclusion: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:42:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Herbal medicine: Tripterygium Wilfordii Glycoside</LI>
<UL>
<LI>Dose: 20 to 60 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No specific treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 19:07:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 19:07:32 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:26:35 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Roccatello-2000">
<CHAR_METHODS MODIFIED="2011-01-03 19:10:25 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 1 g/d; 'clinical and histological features of poor prognosis'</LI>
<LI>Number: 8</LI>
<LI>Mean age: 49 years</LI>
<LI>Sex (M/F): 88/12 (%)</LI>
</UL>
<P>Exclusion: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:26:35 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>Nitric oxide donor isosorbide 5 mononitrate</LI>
</UL>
<P>3 x 7 day sequences with 7 day washout periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 19:11:31 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 19:11:40 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Data not useable, not able to distinguish groups</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:27:17 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Russo-2001">
<CHAR_METHODS MODIFIED="2011-01-03 20:39:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; BP &lt; 140/90; proteinuria 1 to 3 g/d; CrCl &gt; 90 mL/min/1.73 m²</LI>
<LI>Number: 10</LI>
<LI>Mean age:(%) 25 years</LI>
<LI>Sex (M/F): 40/60 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Drug treatment during previous 12 weeks</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:27:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 10 to 20 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 to 100 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 10 to 20 mg/d</LI>
</UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 to 100 mg/d</LI>
</UL>
</UL>
<P>Duration: 6 x 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 20:41:33 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 20:41:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Data not useable, not able to distinguish groups</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-03 22:05:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sato-1990">
<CHAR_METHODS MODIFIED="2011-01-03 20:50:51 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame NS</LI>
<LI>Follow-up period: 16 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 1 g/d; CrCl &gt; 50 mL/min; BP &lt; 150/90</LI>
<LI>Number: 30</LI>
<LI>Mean age: 39 years</LI>
<LI>Sex (M/F): 37/63 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>SLE; purpura; hepatic disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-03 22:05:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Sodium cromoglycate</LI>
<UL>
<LI>dose: 1200 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 20:50:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:27:51 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Shi-2002">
<CHAR_METHODS MODIFIED="2011-01-03 20:54:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 18 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 22:05:22 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 500 mg/d; SCr &lt; 354 µmol/L</LI>
<LI>Number: 131</LI>
<LI>Mean age: 29 years</LI>
<LI>Sex (M/F): 66/34 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Porphyric nephritis; cirrhosis and other progressive nephropathies; narrowing renal vasculature; increased serum K<SUP>+</SUP>; vascular oedema</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:27:51 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ACEi: Benazepril</LI>
<UL>
<LI>Dose: 10 to 20 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatment: non-ACEi antihypertensive e.g. CCB, BB or AB</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 20:56:33 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 20:56:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Translated (Chinese)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:28:23 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Shimizu-2008">
<CHAR_METHODS MODIFIED="2011-01-03 21:01:31 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:41 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; normotensive; eGFR &gt; 50 mL/min/1.73 m²</LI>
<LI>Number: 36</LI>
<LI>Mean age: 36 years</LI>
<LI>Sex (M/F): 47/53 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Treatment with steroids or immunosuppressives; active infection; diabetes; SLE; CLD; kidney allograft; HSP</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:28:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 6.25 to 25 mg/d (titrate to BP)</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Antiplatelet: NS</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:03:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-23 16:47:47 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-08 16:36:43 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Song-2003">
<CHAR_METHODS MODIFIED="2011-01-03 21:07:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-08 16:36:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Korea</LI>
<LI>Setting: NS</LI>
<LI>Biopsy-proven IGAN + diabetic nephropathy; on ACEi (Ramipril 5 to 7.5 mg/d) with optimal BP control; proteinuria &#8805; 1g/d, CrCl 25 to 75 mL/min</LI>
<LI>Number: 14 with IgA, 20 with diabetic nephropathy</LI>
<LI>Mean age: 31 years</LI>
<LI>Sex (M/F): 43/57 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Treatment with steroid or cytotoxic</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-08 16:36:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>ARB: Candesartan</LI>
<UL>
<LI>Dose: 4 to 8 mg/d</LI>
</UL>
<LI>ACEi: Ramipril</LI>
<UL>
<LI>Dose: 5 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
<LI>ACEi: Ramipril</LI>
<UL>
<LI>Dose: 5 mg/d</LI>
</UL>
</UL>
<P>Duration: 2 x 16 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:07:51 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:16:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Crossover RCT; data not separate thus not useable</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:29:26 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tesar-1999">
<CHAR_METHODS MODIFIED="2011-01-03 21:20:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame NS</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Czech Republic</LI>
<LI>Setting: NS</LI>
<LI>Biopsy-proven IGAN; proteinuria &gt; 0.5 g/24 h; SCr &lt; 150 µmol/L; normal BP</LI>
<LI>Number: 23</LI>
<LI>Mean age: 35 years</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>No antihypertensive treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:29:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 mg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:21:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
<LI>SCr</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 22:06:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Complete data not given, qualitative results only "it was possible to demonstrate the antiproteinuric effect of both drugs only in patients with proteinuria higher than ± 1.25 g/24 hr, P &lt; 0.05. Therapy with losartan and enalapril had no influence on serum creatinine and creatinine clearance".</LI>
<LI>Data not included in meta-analyses</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-11 16:35:54 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Woo-2000">
<CHAR_METHODS MODIFIED="2011-01-03 21:26:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: recruitment 1997 to 1999</LI>
<LI>Follow-up period: 13 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Singapore</LI>
<LI>Setting: single centre</LI>
<LI>Biopsy-proven IGAN; proteinuria &#8805; 1 g; SCr &gt; 1.4 mg/dL; well controlled BP</LI>
<LI>Number: 41</LI>
<LI>Mean age: 39 years</LI>
<LI>Sex (M/F): 78/22 (%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>SCr &gt; 5 mg/dL; treatment with aspirin, warfarin, dipyridamole, steroids, cytotoxics, immunosuppressants, CCB</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-11 16:35:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 5 to 10 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 to 100 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Dose: 5 mg/d</LI>
</UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Dose: 50 mg/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatment: antihypertensives (i.e. atenolol, hydralazine or methyldopa)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:29:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SCr</LI>
<LI>Proteinuria</LI>
<LI>Side effects: cough, dizziness, hypotension</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:32:40 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Woo-2008">
<CHAR_METHODS MODIFIED="2011-01-03 21:32:47 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT (4 arms)</LI>
<LI>Time frame: recruitment: 2001 to 2007</LI>
<LI>Follow-up period: 6 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Singapore</LI>
<LI>Setting: single setting</LI>
<LI>Biopsy-proven IGAN primary IgA; proteinuria &gt; 1 g and/or CKD stage 3</LI>
<LI>Number: 226</LI>
<LI>Mean age: 34 years</LI>
<LI>Sex (M/F): 53/47 (%)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:32:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>High dose: 200 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>ARB: Losartan</LI>
<UL>
<LI>Normal dose: 100 mg/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Normal dose: 20 mg/d</LI>
</UL>
</UL>
<P>Treatment group 4</P>
<UL>
<LI>ACEi: Enalapril</LI>
<UL>
<LI>Low dose: 10 mg/d</LI>
</UL>
</UL>
<P>All groups: Symptomatic treatment (antihypertensives i.e. atenolol, hydralazine or methyldopa) and low salt diet</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:37:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>ESKD</LI>
<LI>CrCl</LI>
<LI>Proteinuria</LI>
<LI>Side effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-23 17:52:00 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:33:01 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wu-2003">
<CHAR_METHODS MODIFIED="2011-01-03 21:46:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS in abstract</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:45:49 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: China</LI>
<LI>Setting: NS in abstract</LI>
<LI>Number: 90</LI>
<LI>Age: NS in abstract</LI>
<LI>Sex (M/F): NS in abstract</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:33:01 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Herbal medicine: Dan Shao Tang</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
<LI>Western medicine: NS in abstract</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Western medicine: NS</LI>
<UL>
<LI>Dose: NS</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 22:06:36 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Kidney function</LI>
<LI>Haematuria</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:38:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Chinese, abstract only in English, unable to translate</LI>
<LI>Not included in meta-analyses</LI>
<LI>Western medicine not defined</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-09 14:44:00 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoshikawa-1997">
<CHAR_METHODS MODIFIED="2011-01-03 21:49:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS in abstract</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 21:51:45 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: NS in abstract</LI>
<LI>Biopsy-proven IGAN "focal/minimal mesangial proliferation" children; newly diagnosed with IgAN</LI>
<LI>Number: 101</LI>
<LI>Age: NS in abstract</LI>
<LI>Sex (M/F)L NS in abstract</LI>
</UL>
<P>Exclusion criteria: NS in abstract</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-09 14:44:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Herbal medicine: Sairei-to (TJ 114) for 2 years</LI>
<UL>
<LI>Dose: NS in abstract</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 21:49:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Proteinuria</LI>
<LI>Haematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 21:50:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Only abstract and tables in English. Unable to translate</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AB - alpha blockers; BB - beta blockers; BP - blood pressure; ACEi - angiotensin converting enzyme inhibitor; ARB - angiotensin receptor blocker; CCB - calcium channel blocker; CLD - chronic liver disease; Cr - creatinine; DHA - docosahexanoic acid; eGFR - estimated glomerular filtration rate; EPA - eicosapentanoic acid; HPF - high powered field; HSP - Henoch Schonlein purpura; IGAN - IgA nephropathy; LFT - liver function test; MAP - mean arterial pressure; MaxEPA (Seven Seas Health Care Ltd, UK); NS - not stated; O3FA - omega-3 fatty acid; PFA - polyunsaturated fatty acid; PUFA - polyunsaturated fatty acid; RBC - red blood cell; SCr - serum creatinine; SLE - systemic lupus erythematosus; UP - urinary protein</P>
<P>
<BR/>IF immunofluorescence<BR/>MI myocardial infarction<BR/>HS Henoch Schonlein Purpura<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-01-19 17:58:42 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-01-19 17:55:43 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-_x0032_nd-NA-IgAN-Study-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 17:55:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>RCT (MMF versus placebo). Fish oil and lisinopril only given in the pre-randomisation phase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 17:55:59 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Anonymous-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 17:55:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not RCT/quasi-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 17:56:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Belovezhdov-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 17:56:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not RCT/quasi-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 17:03:27 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Campbell-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 17:03:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not &gt;75% IgAN</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:34:13 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Dal-Canton-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:34:13 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 17:56:09 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Deliyska-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 17:56:09 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not RCT/quasi-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:35:01 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Deteix-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:35:01 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:14:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fuiano-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:14:58 +1000" MODIFIED_BY="[Empty name]">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-13 16:06:50 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hamazaki-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-13 16:06:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:15:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hernandez-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:15:11 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:15:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hotta-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:15:18 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:35:51 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Ihm-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:35:51 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-19 14:24:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kamei-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-19 14:24:45 +1000" MODIFIED_BY="[Empty name]">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:36:16 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Kanjanabuch-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:36:16 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:15:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanno-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:15:37 +1000" MODIFIED_BY="[Empty name]">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 17:03:28 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kanno-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 17:03:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not &gt;75% IgAN</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 17:03:29 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kerst-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 17:03:29 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not &gt;75% IgAN</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:36:51 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Konishi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:36:51 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 17:03:30 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Laurent-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 17:03:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not &gt;75% IgAN</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:16:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lenzi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:16:11 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:37:30 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Lv-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:37:30 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:38:46 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Manno-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:38:46 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:39:33 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Mao-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:39:33 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not treatment of IgA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:17:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ogura-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:17:14 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:16:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rychlik-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:16:30 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-30 17:20:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schena-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-30 17:20:14 +1000" MODIFIED_BY="[Empty name]">
<P>Not non-immunosuppressive intervention (examines modulating effect of urinary EGF/MCP-1 ratio) </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 17:03:31 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sulimani-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 17:03:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not &gt;75% IgAN</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-03 20:46:07 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wolf-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-03 20:46:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>IgA data NS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 17:56:23 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Woo-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 17:56:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not RCT/quasi-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:41:55 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Yoshikawa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:41:55 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:41:15 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Yoshikawa-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:41:15 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-23 15:42:24 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-Zhang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-23 15:42:24 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Not non-immunosuppressive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>MMF - mycophenolate mofetil</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-04-30 17:01:57 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-02-08 21:46:28 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-02-08 16:37:40 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Pozzi-2006">
<CHAR_STUDY_NAME MODIFIED="2009-08-18 11:47:20 +1000" MODIFIED_BY="[Empty name]">
<P>ACEi inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2011-01-19 17:53:33 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<P>Biopsy-proven IGAN; age 3-60 years; proteinuria 0.3-0.9 g/24 h; SCr &lt; 1.3 mg/dL in males and &lt; 1.2 mg/dL in females; eGFR at least 70 mL/min; BP &#8804; 135/85 (&lt; 90th percentile in children)</P>
<P>Exclusion criteria</P>
<P>Diabetes; hepatic disease; infections or malignancies; pregnant; treatment with ACEi in previous 3 months or steroids, NSAIDs, immunosuppressives in previous month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-08 16:37:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>ACEi (ramipril) 5 mg/d ± ARB (irbesartan) 150-300 mg/d</P>
<P>ARB (irbesartan) 150-300 mg/d ± ACEi (ramipril) 2.5-5 mg/d (dose/m² for children)</P>
<P>Supportive therapy (antihypertensives other than ACEi or ARB if needed)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-19 17:54:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Primary: Proteinuria &gt; 1.3 g/24 h or 50% increase in SCr from baseline.</P>
<P>Secondary: hypertension &gt; 140/90, remission or proteinuria &lt; 0.2 g/24 h, safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-06-13 16:08:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Enrolment for 3 years from October 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-02-08 16:37:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Claudio Pozzi<BR/>Dept of Nephrology and Dialysis A. Manzoni Hospital, Via dell'Eremo, 9, 23900 Lecco Italy, c.pozzi@ospedale.lecco.it</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-02-08 21:46:28 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-STOP-Study-2008">
<CHAR_STUDY_NAME MODIFIED="2011-01-19 18:10:58 +1100" MODIFIED_BY="Narelle S Willis">
<P>Supportive versus immunosuppressive therapy for the treatment of progressive IgA nephropathy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-02-07 17:57:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Allocation: randomised<BR/>Control: Active Control<BR/>Endpoint Classification: Safety/Efficacy Study<BR/>Intervention Model: Parallel Assignment<BR/>Masking: Open Label<BR/>Primary Purpose: Treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-07 17:57:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion Criteria:</P>
<UL>
<LI>Male or female patients from 18-70 years with histologically proven primary IgAN with typical mesangioproliferative features. Diagnosis has to be made by a neuropathologist.</LI>
<LI>Proteinuria above 0.75 g/day within 12 weeks prior to or at the first visit in the run-in phase (month -6) and presence of at least one further risk factor for the development of end stage renal disease arterial hypertension, defined as ambulatory blood pressure &gt;140/90 mm Hg or the use of antihypertensive medication or impaired renal function, defined as creatinine clearance or estimated GFR &lt;90 ml/min.</LI>
</UL>
<P>Exclusion Criteria:</P>
<UL>
<LI>Known allergy or intolerance to study medication (except in case of ACE-inhibitor, in which case a change to an angiotensin receptor blocker is possible).</LI>
<LI>Women who are pregnant or breastfeeding and women without sufficient contraception.</LI>
<LI>Any prior immunosuppressive therapy.</LI>
<LI>Variants of primary IgAN (e.g. rapidly progressive IgAN with crescents in &gt;50% of glomeruli or minimal change GN with glomerular IgA deposits).</LI>
<LI>Significant liver dysfunction (more than three fold increased GPT compared to norm)</LI>
<LI>Contraindication for immunosuppressive therapy, like acute or chronic infectious disease incl. hepatitis and HIV positive patients any malignancy leukocytopenia, thrombocytopenia or known allergy against prednisolone, cyclophosphamide or azathioprine active intestinal bleeding, active gastric or duodenal ulcer. Need of permanent immunosuppression, (e.g. transplanted patients, steroid-dependent inflammatory diseases)</LI>
</UL>
<UL>
<LI>Secondary IgAN or diseases associated with glomerular deposits of IgA.</LI>
<LI>Additional other chronic renal disease.</LI>
<LI>Creatinine clearance below 30 ml/min (mean of 3 measurements).</LI>
<LI>Alcohol or drug abuse</LI>
<LI>Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study</LI>
<LI>Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study</LI>
<LI>Participation in a parallel clinical trial or participation in another clinical trial within the last 3 months.</LI>
<LI>Subjects who are in any state of dependency to the sponsor or the investigators.</LI>
<LI>Employees of the sponsor or the investigators.</LI>
<LI>Subjects who have been committed to an institution by legal or regulatory order.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-07 17:58:24 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Drug: supportive therapy with: ACE-inhibitor / ARB / Statin Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)Other antihypertensive medications depending on the clinical decision and following current guidelines. Statin therapy Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.</LI>
</UL>
<UL>
<LI>Drug: supportive and immunosuppressive therapy supportive therapy as outlined above depending on GFR: methylprednisolone and prednisolone cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone</LI>
<LI>Concomitant medication with the immunosuppressive treatment following current clinical practice</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-08 21:46:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patients reaching full clinical remission of their disease</LI>
<LI>GFR loss of 15 ml/min or higher from baseline GFR</LI>
<LI>-Absolute GFR-change</LI>
<LI>GFR loss &gt;=30 ml/min from baseline GFR</LI>
<LI>-Onset of end stage renal disease</LI>
<LI>Mean annual change in one over serum creatinine concentration </LI>
<LI>Proteinuria at 12 and 36 months</LI>
<LI>Disappearance of microhematuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-01-19 18:15:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>February 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-01-19 18:15:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Contact: Juergen Floege, Prof. Dr. 49-241-808-9530; <A HREF="mailto:STOP-IgAN%40ukaachen.de">STOP-IgAN@ukaachen.de</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-04-23 15:40:12 +1000" MODIFIED_BY="Gail Y Higgins"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-02-08 19:34:10 +1100" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-02-08 19:34:10 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:54:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:58:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:56:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:06:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 13:54:19 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>Not clear from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 13:54:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>Not clear from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:52:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-23 14:27:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>Random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>"randomised within strata"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:25:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:34:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:45:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 15:30:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>"randomly assigned by means of a computer-generated list using 1-to-1 ratio in permuted blocks stratified by centre..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-18 11:45:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>"randomly divided according to age, amounts of proteinuria, creatinine clearance values, histological severity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 16:16:23 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>"divided into two groups" randomisation not specified ?pseudo-randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-08 19:34:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>'through an appropriate software in the Coordinating centre...This concealed randomisation is done... according to two strata, on the basis of CrCl..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:49:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Authors say "randomly divided" the unequal size groups suggest randomisation was inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:03:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>'patients were assigned to three groups at random'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:16:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>"randomisation of patients was performed using block randomisation within each stratum...patient groups were stratified on the basis of presence or absence of hypertension"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:29:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-18 15:36:25 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>"randomisation was performed with a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 22:04:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>"randomised trial", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-23 18:08:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>"simple randomisation method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:46:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-23 18:02:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>"list of random numbers generated via computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-01-09 20:54:59 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:54:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:59:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:56:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:05:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 13:54:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>Not clear from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 13:54:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>Not clear from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:52:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:25:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:34:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:45:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-18 14:55:49 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>"The randomisation list was used for packaging of tablets and then maintained by a third party who was not involved in the conduction of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:53:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:51:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>"This concealed randomisation is done..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 14:02:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Not clear from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:54:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:15:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:29:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-18 15:37:07 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>"Allocation concealment was performed by enclosing assignments in sequentially numbered, opaque closed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:05:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-23 16:48:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>"sequence kept concealed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:46:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:46:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:46:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-12-30 17:35:49 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-12-30 17:35:49 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-12-30 17:35:49 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-12-30 17:35:49 +1100" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2011-01-09 20:57:54 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Blinding of participants?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:54:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:59:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:56:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:05:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>Participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:23:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:33:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:53:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:34:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>No 'open label'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:35:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:45:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:58:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:54:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:51:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>'Double blind'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:15:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:28:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>'Double blind' details not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:59:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:06:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:49:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:54:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:00:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>"open label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:06:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>"double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:20:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:25:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:31:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2011-01-09 20:57:55 +1100" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Blinding of investigators?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:35:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:59:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:56:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:05:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:23:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:33:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:53:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:25:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:35:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:45:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:58:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:54:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:50:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>'Double blind'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:15:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:28:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>'Double blind' details not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:59:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:06:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:49:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:54:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:00:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>"open label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:06:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>"double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:19:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:25:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:31:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2011-01-09 20:57:56 +1100" MODIFIED_BY="Narelle S Willis" NO="9">
<NAME>Blinding of outcome assessors?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:54:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:59:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:56:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:05:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:23:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:33:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:53:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:25:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:35:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:45:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:58:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:54:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:51:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>'Double blind'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:15:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:29:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>'Double blind' details not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:59:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:06:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:49:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:54:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:00:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>"open label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:06:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>"double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:20:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:25:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:31:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2011-01-09 20:57:56 +1100" MODIFIED_BY="Narelle S Willis" NO="10">
<NAME>Blinding of data assessors?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:54:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:59:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:56:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:05:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>Biostatisticians blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:23:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:33:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>"double blinded" according to authors in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:53:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:25:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:35:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:45:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:58:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:54:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:51:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>'Double blind'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:15:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:29:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>'Double blind' details not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:59:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:06:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:49:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:54:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:00:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>"open label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:06:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>"double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:20:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:25:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:32:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2011-01-09 20:57:57 +1100" MODIFIED_BY="Narelle S Willis" NO="11">
<NAME>Intention to treat analysis?</NAME>
<DESCRIPTION>
<P>Was intention to treat analysis performed and confirmed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:51:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:47:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:51:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:32:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:46:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 10:55:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:06:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:24:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:33:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:49:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:53:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:25:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:35:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:46:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:58:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:54:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:06:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:52:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:38:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:15:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:29:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:53:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:59:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:06:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:49:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:54:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:00:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:06:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:20:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:25:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:32:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:48:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2011-02-08 16:36:53 +1100" MODIFIED_BY="Narelle S Willis" NO="12">
<NAME>Completeness of follow-up?</NAME>
<DESCRIPTION>
<P>Was completeness of follow-up reported or able to be determined?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 17:45:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Adamkova-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-30 21:53:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Alexopoulos-2004">
<DESCRIPTION>
<P>All patients accounted for: 33% lost to follow-up in fish oil group and 22% in symptomatic treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:37:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bang-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 16:46:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Bannister-1995">
<DESCRIPTION>
<P>73% completed study at 12 months (81% ACEi, 67% CCB) and 62% completed study at 3 years (73% ACEi, 53% CCB)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:27:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Bennett-1989">
<DESCRIPTION>
<P>1 drop out from EPA group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:31:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bo-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:39:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Buemi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-31 17:45:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Camara-1991">
<DESCRIPTION>
<P>95% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chan-1987">
<DESCRIPTION>
<P>73% completed study, number NS for each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chan-2003">
<DESCRIPTION>
<P>69% completed study to at least 1 year; number NS for each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:10:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen--2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:55:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:12:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chen-2007">
<DESCRIPTION>
<P>None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-08 16:17:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>90% complete (94% Nadolol; 80% Captopril; 95% Captopril+Ticlopidine)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:53:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Clarkson-1980">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 11:57:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Costanzi-2006">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:17:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Donadio-1994">
<DESCRIPTION>
<P>87% complete study (87% fish oil, 86% placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:24:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Donadio-2001">
<DESCRIPTION>
<P>74% completed study (76% low, 72% high). 1 lost (low dose), 13 left early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:35:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Frasca-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:46:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Guan-2005">
<DESCRIPTION>
<P>100% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:58:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-HKVIN-Study-2006">
<DESCRIPTION>
<P>88% completed study (91% valsartan, 85% placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hashizume-1998">
<DESCRIPTION>
<P>72% completed study, number in groups NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:57:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Horita-2004">
<DESCRIPTION>
<P>93% completed 12 months (numbers in groups NS)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 13:13:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Horita-2007">
<DESCRIPTION>
<P>95% completed study (2 patients from Losartan group dropped out because of postural hypotension)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:34:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Hotta-1993">
<DESCRIPTION>
<P>100% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:40:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houssin-1984">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:53:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-IgACE-Study-2001">
<DESCRIPTION>
<P>14% lost to follow-up (all of these from the ACEi group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 14:57:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-JLIGHT-Study-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:08:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kanno-2005">
<DESCRIPTION>
<P>100% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:15:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kano-2003">
<DESCRIPTION>
<P>100% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:29:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kawasaki-2006">
<DESCRIPTION>
<P>94% completed study (tonsillectomy group 100%; mizoribine group 89%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:39:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lee-1997">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 15:48:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>None lost</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007">
<DESCRIPTION>
<P>NS in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:06:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maschio-1994">
<DESCRIPTION>
<P>87% completed study (5 lost, arm NS)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:19:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-NA-IgAN-Study-2006">
<DESCRIPTION>
<P>72% completed 2 years (67% prednisone, 80% O3FA, 83% placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:26:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Nakamura-2000">
<DESCRIPTION>
<P>100% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 16:29:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:29:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Nakao-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:35:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Panichi-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:40:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Park--2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:43:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Perico-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:54:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pettersson-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 18:59:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Praga-2003">
<DESCRIPTION>
<P>89% completed study (87% ACEi, 90% control)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:06:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Qian-1987">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 19:09:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roccatello-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:37:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:45:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sato-1990">
<DESCRIPTION>
<P>?100% complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 20:53:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Shi-2002">
<DESCRIPTION>
<P>63% completed study (68% ACEi, 59% control)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:00:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shimizu-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:06:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>94% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:20:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tesar-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:25:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2000">
<DESCRIPTION>
<P>? 100% completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-09 20:55:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Woo-2008">
<DESCRIPTION>
<P>207/226 (92%) completed study, groups NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 21:42:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2003">
<DESCRIPTION>
<P>Abstract only in English, not translated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-08 16:36:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshikawa-1997">
<DESCRIPTION>
<P>93% completed study (92% Sairei-to, 94% control)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2010-12-31 16:47:44 +1100" MODIFIED_BY="Narelle S Willis" NO="13">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Where there any other potential biases?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-02-09 16:25:15 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;deleted additional table 1 as other table can used (e.g. appendix 3)&lt;/p&gt;" NOTES_MODIFIED="2011-02-09 16:25:15 +1100" NOTES_MODIFIED_BY="Narelle S Willis"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-17 08:11:41 +1100" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-01 18:47:29 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Fish oil versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.041876559636924715" CI_END="2.9655577518132192" CI_START="0.3411278197242148" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0058003033118887" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.47210638598175636" LOG_CI_START="-0.46708286147783806" LOG_EFFECT_SIZE="0.002511762251959121" METHOD="MH" MODIFIED="2010-12-29 21:10:08 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8378553653195318" P_Q="0.0" P_Z="0.9916355842556848" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="71" WEIGHT="100.0" Z="0.010483432524133342">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.483996521444045" CI_START="0.1849390283676453" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8741335769682707" LOG_CI_START="-0.732971428396856" LOG_EFFECT_SIZE="0.07058107428570728" ORDER="103" O_E="0.0" SE="0.9440214354495533" STUDY_ID="STD-Bennett-1989" TOTAL_1="17" TOTAL_2="20" VAR="0.8911764705882352" WEIGHT="34.152123806387884"/>
<DICH_DATA CI_END="3.5148420861092626" CI_START="0.24462968454312306" EFFECT_SIZE="0.9272727272727272" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5459058179271266" LOG_CI_START="-0.6114908447197416" LOG_EFFECT_SIZE="-0.03279251339630749" MODIFIED="2008-09-25 12:21:38 +1000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.6798605288446499" STUDY_ID="STD-Donadio-1994" TOTAL_1="55" TOTAL_2="51" VAR="0.4622103386809269" WEIGHT="65.84787619361212"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-29 21:09:30 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6513937215335093" CI_START="0.06061189231703651" EFFECT_SIZE="0.1987012987012987" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.1861564317037407" LOG_CI_START="-1.2174421570060254" LOG_EFFECT_SIZE="-0.7017992943548831" MODIFIED="2008-09-25 13:38:07 +1000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.6057823399892338" STUDY_ID="STD-Donadio-1994" TOTAL_1="55" TOTAL_2="51" VAR="0.3669722434428317" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 15:14:55 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% decrease in creatinine clearance</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.5547267547110115" CI_START="0.6301876664580021" EFFECT_SIZE="1.8709677419354838" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7446627002093947" LOG_CI_START="-0.20053010075206554" LOG_EFFECT_SIZE="0.2720662997286646" MODIFIED="2008-09-25 13:22:08 +1000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.5552109300645849" STUDY_ID="STD-NA-IgAN-Study-2006" TOTAL_1="31" TOTAL_2="29" VAR="0.30825917686318133" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-29 21:10:59 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.439807444877799" CI_START="0.05954613411751617" EFFECT_SIZE="0.9272727272727272" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1595614019465976" LOG_CI_START="-1.2251464287392126" LOG_EFFECT_SIZE="-0.03279251339630749" MODIFIED="2008-09-25 13:42:32 +1000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="1.4007891842389872" STUDY_ID="STD-Donadio-1994" TOTAL_1="55" TOTAL_2="51" VAR="1.962210338680927" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2010-12-29 21:11:24 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="45.40571089929029" CI_START="-9.405710899290291" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="121.0" ORDER="155" SD_1="39.0" SD_2="40.0" SE="13.982762497404565" STUDY_ID="STD-Pettersson-1994" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.06" MODIFIED="2010-12-29 21:13:09 +1100" MODIFIED_BY="Narelle S Willis" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Serum creatinine: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:13:09 +1100" MODIFIED_BY="Narelle S Willis" ORDER="7" STUDY_ID="STD-NA-IgAN-Study-2006">
<TR>
<TD>
<P>n = 24; median = 1.1 mg/dL (97.24 µmol/L)</P>
</TD>
<TD>
<P>n = 24; median = 1.1 mg/dL (97.24 µmol/L)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="1.1432365720224604" CI_END="101.38254414519048" CI_START="-74.88090273104908" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="13.250820707070705" ESTIMABLE="YES" I2="12.529040404040394" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2011-02-01 18:44:32 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.28496950431622325" P_Q="1.0" P_Z="0.7682342248096246" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="507.4261363636358" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.2946853906662946">
<NAME>Change in serum creatinine</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="84.03466839643325" CI_START="-144.03466839643323" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="190.0" MEAN_2="220.0" MODIFIED="2011-02-01 18:44:32 +1100" MODIFIED_BY="Narelle S Willis" ORDER="104" SD_1="141.0" SD_2="99.5" SE="58.182022371800784" STUDY_ID="STD-Bennett-1989" TOTAL_1="8" TOTAL_2="11" WEIGHT="51.94353254769921">
<FOOTNOTE>Group A (SCr &gt; 0.12 mmol/L). Change over 2 years</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="179.2199548589424" CI_START="-59.219954858942415" EFFECT_SIZE="60.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="10.0" MODIFIED="2011-02-01 18:35:05 +1100" MODIFIED_BY="Narelle S Willis" ORDER="18" SD_1="180.0" SD_2="30.0" SE="60.8276253029822" STUDY_ID="STD-Bennett-1989" TOTAL_1="9" TOTAL_2="9" WEIGHT="48.05646745230078">
<FOOTNOTE>Group B (SCr &lt; 0.12 mmol/L but active disease). Change over 2 years</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.08" MODIFIED="2010-12-29 21:15:54 +1100" MODIFIED_BY="Narelle S Willis" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in serum creatinine: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:15:54 +1100" MODIFIED_BY="Narelle S Willis" ORDER="10" STUDY_ID="STD-Donadio-1994">
<TR>
<TD>
<P>Annual median change = 0.03 mg/dL (2.7 µmol/L)</P>
</TD>
<TD>
<P>Annual median change = 0.14 mg/dL (12.4 µmol/L)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.797136067337521" CI_END="3.7909630591379653" CI_START="-34.93579020415146" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.572413572506747" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2011-02-01 18:45:09 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.37195107067460775" P_Q="1.0" P_Z="0.11497001587993802" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.5762421159848854">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="45.162730395504546" CI_START="-41.162730395504546" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="57.0" MEAN_2="55.0" MODIFIED="2011-02-01 18:45:09 +1100" MODIFIED_BY="Narelle S Willis" ORDER="22" SD_1="70.09" SD_2="62.61" SE="22.02220588539721" STUDY_ID="STD-Bennett-1989" TOTAL_1="17" TOTAL_2="20" WEIGHT="20.12539285224206">
<FOOTNOTE>Groups A &amp; B</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.6658995507785725" CI_START="-41.665899550778576" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="99.0" MODIFIED="2008-09-25 14:51:16 +1000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="25.0" SD_2="37.0" SE="11.054233507185042" STUDY_ID="STD-Pettersson-1994" TOTAL_1="15" TOTAL_2="17" WEIGHT="79.87460714775794"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.10" MODIFIED="2010-12-29 21:47:45 +1100" MODIFIED_BY="Narelle S Willis" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in creatinine clearance: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:47:45 +1100" MODIFIED_BY="Narelle S Willis" ORDER="13" STUDY_ID="STD-Donadio-1994">
<TR>
<TD>
<P>Annual median change: - 0.3 mL/min/1.73 m²</P>
</TD>
<TD>
<P>Annual median change: - 7.1 mL/min/1.73 m²</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2010-12-29 21:20:23 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="17" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6299540637922824" CI_START="-0.8299540637922825" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.8" MODIFIED="2008-09-25 15:10:16 +1000" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="0.9" SD_2="1.2" SE="0.37243238628365977" STUDY_ID="STD-Pettersson-1994" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.10394930205468612" CI_END="0.5688662817382927" CI_START="-0.9619469996249012" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19654035894330424" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2011-02-01 18:45:42 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.7471408548559557" P_Q="1.0" P_Z="0.6147691076287406" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.5032776103097546">
<NAME>Change in proteinuria</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0584533392131057" CI_START="-1.858453339213106" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" MODIFIED="2011-02-01 18:45:32 +1100" MODIFIED_BY="Narelle S Willis" ORDER="28" SD_1="2.26" SD_2="1.99" SE="0.9992292484255506" STUDY_ID="STD-Bennett-1989" TOTAL_1="8" TOTAL_2="11" WEIGHT="15.274183159055934">
<FOOTNOTE>Group A (SCr &gt; 0.12 mmol/L). Change over 2 years</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.5815422946098069" CI_START="-1.081542294609807" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.27" MODIFIED="2011-02-01 18:45:42 +1100" MODIFIED_BY="Narelle S Willis" ORDER="30" SD_1="0.9" SD_2="0.9" SE="0.42426406871192857" STUDY_ID="STD-Bennett-1989" TOTAL_1="9" TOTAL_2="9" WEIGHT="84.72581684094406">
<FOOTNOTE>Group B (SCr &lt; 0.12 mmol/L but active disease). Change over 2 years</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.13" MODIFIED="2010-12-29 21:48:14 +1100" MODIFIED_BY="Narelle S Willis" NO="13" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in proteinuria: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:48:14 +1100" MODIFIED_BY="Narelle S Willis" ORDER="17" STUDY_ID="STD-Donadio-1994">
<TR>
<TD>
<P>Median annual change in 24 hour protein: - 0.23 g (-15%)</P>
</TD>
<TD>
<P>Median annual change in 24 hour protein: - 0.10 g (- 7%)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="51.40286999357465" CI_END="8.463105062643754" CI_START="-3.296496729310421" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5833041666666667" ESTIMABLE="YES" I2="98.05458333333334" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2011-02-01 18:47:29 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="7.52065076881081E-13" P_Q="1.0" P_Z="0.389174869202616" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="17.649825000000003" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.861114724351145">
<NAME>Change in haematuria (cells/mL x 10<SUP>5</SUP>)</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.915295016298473" CI_START="4.284704983701528" EFFECT_SIZE="5.6000000000000005" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-7.4" MODIFIED="2011-02-01 18:47:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="32" SD_1="1.7" SD_2="0.99" SE="0.6710812171414128" STUDY_ID="STD-Bennett-1989" TOTAL_1="8" TOTAL_2="11" WEIGHT="49.72173611111111">
<FOOTNOTE>Group A (SCr &gt; 0.12 mmol/L). Change over 2 years</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.5799819922700272" CI_START="-1.379981992270027" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.6" MODIFIED="2011-02-01 18:47:29 +1100" MODIFIED_BY="Narelle S Willis" ORDER="31" SD_1="0.9" SD_2="1.2" SE="0.5" STUDY_ID="STD-Bennett-1989" TOTAL_1="9" TOTAL_2="9" WEIGHT="50.278263888888894">
<FOOTNOTE>Group B (SCr &lt; 0.12 mmol/L but active disease). Change over 2 years</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.15" MODIFIED="2010-12-29 21:27:47 +1100" MODIFIED_BY="Narelle S Willis" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse effects</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:27:47 +1100" MODIFIED_BY="Narelle S Willis" ORDER="20" STUDY_ID="STD-Donadio-1994">
<TR>
<TD>
<P>Fishy aftertaste (number not specified): no discontinuation because of adverse effects</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-29 21:27:38 +1100" MODIFIED_BY="Narelle S Willis" ORDER="21" STUDY_ID="STD-Pettersson-1994">
<TR>
<TD>
<P>Belching occasionally (number not specified)</P>
</TD>
<TD>
<P>Belching occasionally (number not specified)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-12-29 21:40:19 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Fish oil versus symptomatic treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-29 21:32:31 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Symptomatic treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours symptomatic</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2109439298055535" CI_START="0.02293894629971693" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.08312403452224397" LOG_CI_START="-1.6394265352895312" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2008-09-25 12:27:55 +1000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.0118347314702751" STUDY_ID="STD-Alexopoulos-2004" TOTAL_1="14" TOTAL_2="14" VAR="1.023809523809524" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-29 18:30:11 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Symptomatic treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours symptomatic</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2109439298055535" CI_START="0.02293894629971693" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.08312403452224397" LOG_CI_START="-1.6394265352895312" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2008-09-25 13:40:25 +1000" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="1.0118347314702751" STUDY_ID="STD-Alexopoulos-2004" TOTAL_1="14" TOTAL_2="14" VAR="1.023809523809524" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-29 18:31:11 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% decrease in creatinine clearance</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Symptomatic treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours symptomatic</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0141530548901907" CI_START="0.020123356299031066" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.006103503200599009" LOG_CI_START="-1.6962995832291128" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2008-09-25 13:34:36 +1000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.0" STUDY_ID="STD-Alexopoulos-2004" TOTAL_1="14" TOTAL_2="14" VAR="1.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-12-29 21:33:43 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Symptomatic treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours symptomatic</GRAPH_LABEL_2>
<CONT_DATA CI_END="-110.89501928997615" CI_START="-525.5849807100237" EFFECT_SIZE="-318.23999999999995" ESTIMABLE="YES" MEAN_1="203.32" MEAN_2="521.56" MODIFIED="2008-09-25 14:02:04 +1000" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="194.48" SD_2="344.76" SE="105.79019938403692" STUDY_ID="STD-Alexopoulos-2004" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.05" MODIFIED="2010-12-29 21:35:27 +1100" MODIFIED_BY="Narelle S Willis" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in serum creatinine: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Symptomatic treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:35:27 +1100" MODIFIED_BY="Narelle S Willis" ORDER="26" STUDY_ID="STD-Alexopoulos-2004">
<TR>
<TD>
<P>n = 14; mean annual change = 0.2 mg/dL/y (17.68 µmol/L/y); SD missing</P>
</TD>
<TD>
<P>n = 14; mean annual change = 1 mg/dL/y (88.4 µmol/L/y); SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-12-29 21:36:16 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Symptomatic treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours symptomatic</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.126669844180828" CI_START="-10.126669844180828" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="34.0" MODIFIED="2008-09-25 14:56:00 +1000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="13.0" SD_2="30.0" SE="8.738257426806724" STUDY_ID="STD-Alexopoulos-2004" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.07" MODIFIED="2010-12-29 21:38:00 +1100" MODIFIED_BY="Narelle S Willis" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in creatinine clearance: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Symptomatic treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:38:00 +1100" MODIFIED_BY="Narelle S Willis" ORDER="28" STUDY_ID="STD-Alexopoulos-2004">
<TR>
<TD>
<P>n = 14; mean annual change = -1.4 mL/min/1.73 m²/y; SD missing</P>
</TD>
<TD>
<P>n = 14; mean annual change = -3 mL/min/1.73 m²/y; SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2010-12-29 21:38:48 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Symptomatic treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours symptomatic</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.27773371069737796" CI_START="-0.4777337106973779" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.9" MODIFIED="2008-11-04 14:49:38 +1100" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="0.4" SD_2="0.6" SE="0.19272482233188631" STUDY_ID="STD-Alexopoulos-2004" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.09" MODIFIED="2010-12-29 21:40:19 +1100" MODIFIED_BY="Narelle S Willis" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in proteinuria: Other data</NAME>
<TR>
<TH>
<P>Fish oil</P>
</TH>
<TH>
<P>Symptomatic treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:40:19 +1100" MODIFIED_BY="Narelle S Willis" ORDER="30" STUDY_ID="STD-Alexopoulos-2004">
<TR>
<TD>
<P>n = 14; mean annual change = -0.7 g/24 h/y; SD missing</P>
</TD>
<TD>
<P>n = 14; mean annual change = -0.19 g/24 h/y; SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-12-30 15:16:31 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Fish oil: high versus low dose</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-29 21:42:53 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8456528882125418" CI_START="0.3662928100043678" EFFECT_SIZE="0.8222222222222222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.26615002664186554" LOG_CI_START="-0.43617160605856303" LOG_EFFECT_SIZE="-0.0850107897083487" MODIFIED="2008-09-25 12:37:40 +1000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.4125472035963827" STUDY_ID="STD-Donadio-2001" TOTAL_1="36" TOTAL_2="37" VAR="0.17019519519519521" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.02" MODIFIED="2010-12-29 21:43:57 +1100" MODIFIED_BY="Narelle S Willis" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Change in serum creatinine: Other data</NAME>
<TR>
<TH>
<P>Fish oil (high dose)</P>
</TH>
<TH>
<P>Fish oil (low dose)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:43:57 +1100" MODIFIED_BY="Narelle S Willis" ORDER="32" STUDY_ID="STD-Donadio-2001">
<TR>
<TD>
<P>n = 36; annual median change = 0.1 mg/dL (8.84 µmol/L)</P>
</TD>
<TD>
<P>n = 37; annual median change = 0.08 mg/dL (7.07 µmol/L)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.03" MODIFIED="2010-12-30 15:16:31 +1100" MODIFIED_BY="Narelle S Willis" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Proteinuria: Other data</NAME>
<TR>
<TH>
<P>Fish oil (high dose)</P>
</TH>
<TH>
<P>Fish oil (low dose)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:45:09 +1100" MODIFIED_BY="Narelle S Willis" ORDER="33" STUDY_ID="STD-Donadio-2001">
<TR>
<TD>
<P>n = 26; mean = 1.7 g/24 h; SD missing</P>
</TD>
<TD>
<P>n = 28; mean = 1.16 g/24 h; SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-003.04" MODIFIED="2010-12-29 21:45:58 +1100" MODIFIED_BY="Narelle S Willis" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Fish oil (high dose)</P>
</TH>
<TH>
<P>Fish oil (low dose)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-29 21:45:58 +1100" MODIFIED_BY="Narelle S Willis" ORDER="34" STUDY_ID="STD-Donadio-2001">
<TR>
<TD>
<P>GIT intolerance (1): " no serious adverse effects"</P>
</TD>
<TD>
<P>GIT intolerance (1)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-12-30 12:08:41 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Fish oil+ACEi+ARB versus ACEi+ARB</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-12-29 21:51:40 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Fish oil + ACEi+ ARB</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi + ARB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil+ACEi+ARB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi+ARB</GRAPH_LABEL_2>
<CONT_DATA CI_END="51.39226017528844" CI_START="1.0077398247115674" EFFECT_SIZE="26.200000000000003" ESTIMABLE="YES" MEAN_1="93.9" MEAN_2="67.7" MODIFIED="2010-06-19 16:50:39 +1000" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="35.4" SD_2="35.0" SE="12.8534301517792" STUDY_ID="STD-Costanzi-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-12-29 21:52:37 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Fish oil + ACEi+ ARB</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi + ARB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil+ACEi+ARB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi+ARB</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.27556311529852207" CI_START="-1.696436884701478" EFFECT_SIZE="-0.986" ESTIMABLE="YES" MEAN_1="0.367" MEAN_2="1.353" MODIFIED="2010-06-19 16:55:24 +1000" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="0.52" SD_2="1.304" SE="0.3624744588703228" STUDY_ID="STD-Costanzi-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.03" MODIFIED="2010-12-29 21:56:38 +1100" MODIFIED_BY="Narelle S Willis" NO="3" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Haematuria: Other data</NAME>
<TR>
<TH>
<P>Class of erythrocyturia</P>
</TH>
<TH>
<P>Fish oil + ACEi + ARB</P>
<P>Number (%)</P>
</TH>
<TH>
<P>ACEi + ARB</P>
<P>Number (%)</P>
</TH>
<TH>
<P>Notes: P value 0.031</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-06-20 18:40:17 +1000" MODIFIED_BY="[Empty name]" ORDER="37" STUDY_ID="STD-Costanzi-2006">
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>7 (46.7)</P>
</TD>
<TD>
<P>10 (66.7)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>4 (26.7)</P>
</TD>
<TD>
<P>4 (26.7)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>4 (26.7)</P>
</TD>
<TD>
<P>1 (6.7)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-02-07 10:23:09 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Antihypertensive agents versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-07 10:23:09 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="54" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>ESKD or doubling serum creatinine</NAME>
<GROUP_LABEL_1>Antihypertensive agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensives</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.205496834273393" CI_START="0.02939757032418633" EFFECT_SIZE="0.25462962962962965" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34350643873714964" LOG_CI_START="-1.5316885620505236" LOG_EFFECT_SIZE="-0.594091061656687" MODIFIED="2011-02-07 10:23:09 +1100" MODIFIED_BY="Narelle S Willis" ORDER="47" O_E="0.0" SE="1.1014988258276373" STUDY_ID="STD-HKVIN-Study-2006" TOTAL_1="54" TOTAL_2="55" VAR="1.2132996632996633" WEIGHT="0.0">
<FOOTNOTE>ARB versus placebo</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.045031451690632246" CI_END="14.242168070365713" CI_START="1.1071746577536143" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9709655701071767" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.1535761065286905" LOG_CI_START="0.04421613661076593" LOG_EFFECT_SIZE="0.5988961215697282" METHOD="MH" MODIFIED="2011-02-01 18:55:33 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.8319463507634937" P_Q="0.0" P_Z="0.03432764112927671" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="2.1162018832250333">
<NAME>Remission of proteinuria</NAME>
<GROUP_LABEL_1>Antihypertensive agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antihypertensives</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="102.48565332081476" CI_START="0.2734790749019623" DF="0" EFFECT_SIZE="5.2941176470588225" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="2.0106630739801497" LOG_CI_START="-0.563075897858048" LOG_EFFECT_SIZE="0.7237935880610509" MODIFIED="2011-02-01 18:55:26 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.27029983597349405" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="17" WEIGHT="18.578728322738097" Z="1.1023723698192212">
<NAME>Complete remission</NAME>
<DICH_DATA CI_END="102.48565332081476" CI_START="0.2734790749019623" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0106630739801497" LOG_CI_START="-0.563075897858048" LOG_EFFECT_SIZE="0.723793588061051" MODIFIED="2011-02-01 18:55:26 +1100" MODIFIED_BY="Narelle S Willis" ORDER="63" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-IgACE-Study-2001" TOTAL_1="16" TOTAL_2="17" VAR="2.28562091503268" WEIGHT="18.578728322738097">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.314810257271528" CI_START="0.9029887625237728" DF="0" EFFECT_SIZE="3.71875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="1.1851116204876502" LOG_CI_START="-0.044317654342400516" LOG_EFFECT_SIZE="0.5703969830726248" MODIFIED="2011-02-01 18:55:33 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.06896316356704828" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="17" WEIGHT="81.4212716772619" Z="1.818661010601342">
<NAME>Partial remission</NAME>
<DICH_DATA CI_END="15.314810257271528" CI_START="0.9029887625237728" EFFECT_SIZE="3.71875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1851116204876502" LOG_CI_START="-0.044317654342400516" LOG_EFFECT_SIZE="0.5703969830726248" MODIFIED="2011-02-01 18:55:33 +1100" MODIFIED_BY="Narelle S Willis" ORDER="62" O_E="0.0" SE="0.7221728418082323" STUDY_ID="STD-IgACE-Study-2001" TOTAL_1="16" TOTAL_2="17" VAR="0.5215336134453781" WEIGHT="81.4212716772619">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.03" MODIFIED="2010-12-30 15:17:34 +1100" MODIFIED_BY="Narelle S Willis" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Proteinuria: Other data</NAME>
<TR>
<TH>
<P>Antihypertensive</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 11:46:39 +1100" MODIFIED_BY="Narelle S Willis" ORDER="41" STUDY_ID="STD-Maschio-1994">
<TR>
<TD>
<P>ACEi: Mean basal values: 1.74 ± 0.84 g/24 h. Unchanged during placebo sequence (1.79 ± 1.20) and fell to 1.37 ± 0.98 g/24 h afer 4 months of fosinopril treatment.</P>
<P>Conclusion: "fosinopril can signficantly reduce proteinuria even in normotensive patients with IgA nephropathy."</P>
</TD>
<TD>
<P>Crossover RCT (data not useable in meta-analysis)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.24219118940647" CI_START="-20.24219118940647" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2011-02-01 18:58:20 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="8" UNITS="" WEIGHT="99.99999999999997" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Antihypertensive agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensives</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="23.74033689878886" CI_START="-23.74033689878886" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" MODIFIED="2011-02-01 18:58:16 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="6" WEIGHT="72.70115148432285" Z="0.0">
<NAME>ACEi or ARB versus placebo/no treatment</NAME>
<CONT_DATA CI_END="34.86780059952961" CI_START="-34.86780059952961" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="70.72" MODIFIED="2011-02-01 18:58:12 +1100" MODIFIED_BY="Narelle S Willis" ORDER="67" SD_1="25.62" SD_2="26.52" SE="17.790021079245523" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="3" WEIGHT="33.70279646192697">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="32.4141306448981" CI_START="-32.4141306448981" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="70.72" MODIFIED="2011-02-01 18:58:16 +1100" MODIFIED_BY="Narelle S Willis" ORDER="192" SD_1="17.68" SD_2="26.52" SE="16.53812564954082" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="3" WEIGHT="38.998355022395884">
<FOOTNOTE>ARB versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="38.742296293484905" CI_START="-38.742296293484905" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" MODIFIED="2011-02-01 18:58:20 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="2" WEIGHT="27.29884851567712" Z="0.0">
<NAME>CCB versus placebo/no treatment</NAME>
<CONT_DATA CI_END="38.742296293484905" CI_START="-38.742296293484905" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="70.72" MODIFIED="2011-02-01 18:58:20 +1100" MODIFIED_BY="Narelle S Willis" ORDER="125" SD_1="17.68" SD_2="26.52" SE="19.76684092109814" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="2" WEIGHT="27.29884851567712">
<FOOTNOTE>CCB versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.5137360328690717" CI_END="12.549784769712161" CI_START="-1.5431835662954487" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="5.503300601708356" ESTIMABLE="YES" I2="0.0" I2_Q="7.461036077629896" ID="CMP-005.05" MODIFIED="2011-02-01 18:59:03 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.47579287469418785" P_Q="0.2985580207670051" P_Z="0.12583591631095994" Q="1.0806258873169239" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="97" UNITS="" WEIGHT="100.0" Z="1.530730889089846">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Antihypertensive agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antihypertensives</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.4331101455521478" CI_END="14.544875454010228" CI_START="-0.5987322146103846" DF="3" EFFECT_SIZE="6.973071619699922" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" MODIFIED="2011-02-01 18:58:58 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.4875011587202688" P_Z="0.07107750689182563" STUDIES="3" TAU2="0.0" TOTAL_1="102" TOTAL_2="95" WEIGHT="86.60565547250333" Z="1.804981948198492">
<NAME>ACEi or ARB versus placebo/no treatment</NAME>
<CONT_DATA CI_END="21.92152985846776" CI_START="-3.9815298584677628" EFFECT_SIZE="8.969999999999999" ESTIMABLE="YES" MEAN_1="72.36" MEAN_2="63.39" MODIFIED="2011-02-01 18:58:42 +1100" MODIFIED_BY="Narelle S Willis" ORDER="188" SD_1="34.2" SD_2="34.79" SE="6.60804482155171" STUDY_ID="STD-HKVIN-Study-2006" TOTAL_1="54" TOTAL_2="55" WEIGHT="29.600757072910408">
<FOOTNOTE>ARB versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="29.38666726123332" CI_START="0.013332738766683505" EFFECT_SIZE="14.700000000000003" ESTIMABLE="YES" MEAN_1="124.0" MEAN_2="109.3" MODIFIED="2011-02-01 18:58:48 +1100" MODIFIED_BY="Narelle S Willis" ORDER="79" SD_1="31.0" SD_2="29.8" SE="7.49333527405599" STUDY_ID="STD-IgACE-Study-2001" TOTAL_1="32" TOTAL_2="34" WEIGHT="23.019635873252778">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="17.530450811531633" CI_START="-17.530450811531633" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="110.0" MODIFIED="2011-02-01 18:58:58 +1100" MODIFIED_BY="Narelle S Willis" ORDER="189" SD_1="16.0" SD_2="12.0" SE="8.94427190999916" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="3" WEIGHT="16.156928086292854">
<FOOTNOTE>ARB versus placeo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="16.688491978016593" CI_START="-16.688491978016593" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="110.0" MODIFIED="2011-02-01 18:58:54 +1100" MODIFIED_BY="Narelle S Willis" ORDER="83" SD_1="14.0" SD_2="12.0" SE="8.514693182963201" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="3" WEIGHT="17.828334440047286">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.25359125454218" CI_START="-23.25359125454218" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" MODIFIED="2011-02-01 18:59:03 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.6838689762899888" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="2" WEIGHT="13.394344527496667" Z="0.4071892788474301">
<NAME>CCB versus placebo/no treatment</NAME>
<CONT_DATA CI_END="15.25359125454218" CI_START="-23.25359125454218" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="110.0" MODIFIED="2011-02-01 18:59:03 +1100" MODIFIED_BY="Narelle S Willis" ORDER="86" SD_1="14.0" SD_2="12.0" SE="9.82344135219425" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="2" WEIGHT="13.394344527496667">
<FOOTNOTE>CCB versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1548024610042091" CI_END="-0.36917701531785885" CI_START="-1.0034980596052778" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6863375374615683" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2011-02-01 19:03:29 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.8854825616150932" P_Q="0.43977378998289984" P_Z="2.221541503730042E-5" Q="0.5968729502548611" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="97" UNITS="g/24 h" WEIGHT="100.0" Z="4.241375457356128">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Antihypertensive agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensives</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.557929510749348" CI_END="-0.39344003455481674" CI_START="-1.0601459441274013" DF="3" EFFECT_SIZE="-0.726792989341109" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.01" MODIFIED="2011-02-01 19:03:29 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.9059921933768897" P_Z="1.9267648924792828E-5" STUDIES="3" TAU2="0.0" TOTAL_1="102" TOTAL_2="95" WEIGHT="90.5210598838569" Z="4.27321271004781">
<NAME>ACEi or ARB versus placebo/no treatment</NAME>
<CONT_DATA CI_END="-0.1868786548599194" CI_START="-1.2931213451400807" EFFECT_SIZE="-0.74" ESTIMABLE="YES" MEAN_1="1.23" MEAN_2="1.97" MODIFIED="2011-02-01 19:03:11 +1100" MODIFIED_BY="Narelle S Willis" ORDER="190" SD_1="1.25" SD_2="1.67" SE="0.28220995360273515" STUDY_ID="STD-HKVIN-Study-2006" TOTAL_1="54" TOTAL_2="55" WEIGHT="32.878910015092934">
<FOOTNOTE>ARB versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.29593794470650936" CI_START="-1.4240620552934908" EFFECT_SIZE="-0.8600000000000001" ESTIMABLE="YES" MEAN_1="0.94" MEAN_2="1.8" MODIFIED="2011-02-01 19:03:16 +1100" MODIFIED_BY="Narelle S Willis" ORDER="97" SD_1="0.98" SD_2="1.34" SE="0.2877920511513172" STUDY_ID="STD-IgACE-Study-2001" TOTAL_1="32" TOTAL_2="34" WEIGHT="31.61582196211824">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.36457149050463056" CI_START="-1.3645714905046304" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.7" MODIFIED="2011-02-01 19:03:23 +1100" MODIFIED_BY="Narelle S Willis" ORDER="104" SD_1="0.5" SD_2="0.7" SE="0.44111600892886815" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="3" WEIGHT="13.457253312639985">
<FOOTNOTE>ACEi versus placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.29459707185857875" CI_START="-1.4945970718585784" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.7" MODIFIED="2011-02-01 19:03:29 +1100" MODIFIED_BY="Narelle S Willis" ORDER="191" SD_1="0.6" SD_2="0.7" SE="0.4564354645876384" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="3" WEIGHT="12.569074594005746">
<FOOTNOTE>ARB versus placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7301470764976972" CI_START="-1.3301470764976973" DF="0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.02" MODIFIED="2010-12-29 22:09:57 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5681475689945736" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="2" WEIGHT="9.478940116143095" Z="0.570781792985393">
<NAME>CCB versus placebo/no treatment</NAME>
<CONT_DATA CI_END="0.7301470764976972" CI_START="-1.3301470764976973" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.7" MODIFIED="2008-11-12 10:48:35 +1100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="0.5" SD_2="0.7" SE="0.5255949010407159" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="2" WEIGHT="9.478940116143095"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.07" MODIFIED="2010-12-30 11:47:39 +1100" MODIFIED_BY="Narelle S Willis" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Antihypertensive</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 11:47:39 +1100" MODIFIED_BY="Narelle S Willis" ORDER="55" STUDY_ID="STD-HKVIN-Study-2006">
<TR>
<TD>
<P>ARB: Major adverse events: pregnancy, TB (2)</P>
<P>Minor adverse event: dizzy, headache, palpitation, ankle oedema (5)</P>
</TD>
<TD>
<P>Major adverse events: allergy, heart failure, pregnancy, nephotic syndrome (4)</P>
<P>Minor adverse events: dizzy, headache, palpitation, ankle oedema (9)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 11:47:39 +1100" MODIFIED_BY="Narelle S Willis" ORDER="56" STUDY_ID="STD-IgACE-Study-2001">
<TR>
<TD>
<P>ACEi: Cough, temporary (1)</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-02-17 08:11:41 +1100" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Antihypertensive agents versus other treatment</NAME>
<DICH_OUTCOME CHI2="2.668262295864657" CI_END="2.878496468299283" CI_START="1.0363271456664005" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7271548942707515" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.45916570094450554" LOG_CI_START="0.015496874260524587" LOG_EFFECT_SIZE="0.2373312876025151" METHOD="MH" MODIFIED="2011-02-07 12:00:04 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.44564781549863575" P_Q="0.0" P_Z="0.03600394736343717" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="155" WEIGHT="400.0" Z="2.096882846523605">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1848314266153848" CI_START="1.0591528283791383" DF="0" EFFECT_SIZE="1.8366336633663367" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.5030864500377057" LOG_CI_START="0.024958630299138675" LOG_EFFECT_SIZE="0.26402254016842214" MODIFIED="2011-02-07 11:29:55 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.030419315144779278" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="106" WEIGHT="100.0" Z="2.1645871604786957">
<NAME>ACEi versus ARB</NAME>
<DICH_DATA CI_END="3.1848314266153848" CI_START="1.0591528283791383" EFFECT_SIZE="1.8366336633663367" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" LOG_CI_END="0.5030864500377057" LOG_CI_START="0.024958630299138675" LOG_EFFECT_SIZE="0.26402254016842214" MODIFIED="2010-12-30 11:32:06 +1100" MODIFIED_BY="Narelle S Willis" ORDER="204" O_E="0.0" SE="0.28085464808531274" STUDY_ID="STD-Woo-2008" TOTAL_1="101" TOTAL_2="106" VAR="0.07887933335112488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.58711188336108" CI_START="0.2588337047513139" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="1.9849191801281645" LOG_CI_START="-0.5869791714561268" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-02-07 11:29:55 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.2867281151029345" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.0653267334057028">
<NAME>ACEi versus CCB</NAME>
<DICH_DATA CI_END="96.58711188336108" CI_START="0.2588337047513139" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9849191801281645" LOG_CI_START="-0.5869791714561268" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-02-07 10:04:15 +1100" MODIFIED_BY="Narelle S Willis" ORDER="237" O_E="0.0" SE="1.5107458228227775" STUDY_ID="STD-Bannister-1995" TOTAL_1="16" TOTAL_2="16" VAR="2.282352941176471" WEIGHT="100.0">
<FOOTNOTE>ACEi versus CCB</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.158848816388927" CI_START="0.2178956636880808" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.911628885719666" LOG_CI_START="-0.6617514125030661" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-02-07 11:29:54 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.7555930712400751" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="16" WEIGHT="100.0" Z="0.31127302700156045">
<NAME>ACEi versus BB</NAME>
<DICH_DATA CI_END="8.158848816388927" CI_START="0.2178956636880808" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.911628885719666" LOG_CI_START="-0.6617514125030661" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-02-07 10:04:29 +1100" MODIFIED_BY="Narelle S Willis" ORDER="163" O_E="0.0" SE="0.924211375534118" STUDY_ID="STD-Cheng-1998" TOTAL_1="12" TOTAL_2="16" VAR="0.8541666666666666" WEIGHT="100.0">
<FOOTNOTE>ACEi versus BB</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.879887508096271" CI_START="0.010309577253601012" DF="0" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="0.5888191340165585" LOG_CI_START="-1.9867591426885958" LOG_EFFECT_SIZE="-0.6989700043360186" MODIFIED="2011-02-07 11:29:53 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.2874172339006109" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="1.0638046198502171">
<NAME>ACEi versus anticoagulants</NAME>
<DICH_DATA CI_END="3.87988750809627" CI_START="0.010309577253601012" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5888191340165584" LOG_CI_START="-1.9867591426885958" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-02-07 10:04:41 +1100" MODIFIED_BY="Narelle S Willis" ORDER="164" O_E="0.0" SE="1.5129074290546958" STUDY_ID="STD-Hashizume-1998" TOTAL_1="17" TOTAL_2="17" VAR="2.288888888888889" WEIGHT="100.0">
<FOOTNOTE>ACEi versus antiplatelet drug (NS)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-07 11:59:39 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6984187309213505" CI_START="0.07460141354733589" EFFECT_SIZE="0.22826086956521738" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.1558841217843028" LOG_CI_START="-1.1272529434389693" LOG_EFFECT_SIZE="-0.641568532611636" MODIFIED="2010-12-29 22:18:19 +1100" MODIFIED_BY="Narelle S Willis" ORDER="60" O_E="0.0" SE="0.5705868541931665" STUDY_ID="STD-Praga-2003" TOTAL_1="23" TOTAL_2="21" VAR="0.3255693581780538" WEIGHT="0.0">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-07 12:00:57 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Doubling of serum creatinine</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8744540526052806" CI_START="0.03865468331643874" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4585553709539996" LOG_CI_START="-1.4127978803933248" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-12-29 22:19:59 +1100" MODIFIED_BY="Narelle S Willis" ORDER="61" O_E="0.0" SE="1.0992421631894098" STUDY_ID="STD-Bannister-1995" TOTAL_1="16" TOTAL_2="16" VAR="1.2083333333333333" WEIGHT="0.0">
<FOOTNOTE>ACEi versus CCB</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.869124252479661" CI_END="5.973862601276834" CI_START="-7.149891003514321" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5880142011187435" ESTIMABLE="YES" I2="0.0" I2_Q="5.584358510551361" ID="CMP-006.04" MODIFIED="2011-02-07 13:51:31 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.8661397711592473" P_Q="0.3846323066998455" P_Z="0.860581730585724" Q="6.354879239654932" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="229" TOTAL_2="235" UNITS="" WEIGHT="700.0" Z="0.17563369311811602">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.578969171877671E-4" CI_END="20.416040146423043" CI_START="-20.13958543582269" DF="1" EFFECT_SIZE="0.13822735530017807" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.01" MODIFIED="2010-12-29 22:24:52 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.9753094882058737" P_Z="0.9893402229411618" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.013360446753171194">
<NAME>ACEi versus ARB</NAME>
<CONT_DATA CI_END="52.04411258776459" CI_START="-50.2841125877646" EFFECT_SIZE="0.8799999999999955" ESTIMABLE="YES" MEAN_1="80.44" MEAN_2="79.56" MODIFIED="2010-12-29 22:24:45 +1100" MODIFIED_BY="Narelle S Willis" ORDER="69" SD_1="46.31" SD_2="91.936" SE="26.10461875388557" STUDY_ID="STD-Horita-2004" TOTAL_1="14" TOTAL_2="16" WEIGHT="15.707654011383953"/>
<CONT_DATA CI_END="22.086507072870454" CI_START="-22.086507072870454" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="70.72" MODIFIED="2010-12-29 22:24:52 +1100" MODIFIED_BY="Narelle S Willis" ORDER="73" SD_1="26.52" SD_2="17.68" SE="11.268833125040054" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="84.29234598861605"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.5146924244755127E-4" CI_END="44.29945196343958" CI_START="-45.376012895119075" DF="1" EFFECT_SIZE="-0.5382804658397465" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.02" MODIFIED="2010-12-29 22:25:25 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.985042525160555" P_Z="0.9812278913596246" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.023529520104331094">
<NAME>ACEi+ARB versus ARB or ACEi</NAME>
<CONT_DATA CI_END="71.9531935378915" CI_START="-71.9531935378915" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="79.56" MEAN_2="79.56" MODIFIED="2010-12-29 22:25:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="197" SD_1="70.12" SD_2="91.936" SE="36.71148761173629" STUDY_ID="STD-Horita-2004" TOTAL_1="6" TOTAL_2="16" WEIGHT="38.83176524548302">
<FOOTNOTE>ACEi+ARB versus ARB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="56.44983175546532" CI_START="-58.20983175546531" EFFECT_SIZE="-0.8799999999999955" ESTIMABLE="YES" MEAN_1="79.56" MEAN_2="80.44" MODIFIED="2010-12-29 22:25:13 +1100" MODIFIED_BY="Narelle S Willis" ORDER="198" SD_1="70.12" SD_2="46.31" SE="29.250451644864757" STUDY_ID="STD-Horita-2004" TOTAL_1="7" TOTAL_2="14" WEIGHT="61.168234754516966">
<FOOTNOTE>ARB+ACEi versus ACEi</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5129356466650946" CI_END="-6.799602575308398" CI_START="-71.94593689270464" DF="2" EFFECT_SIZE="-39.37276973400652" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.03" MODIFIED="2011-02-07 11:41:59 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.7737799033920356" P_Z="0.01783125338534317" STUDIES="3" TAU2="0.0" TOTAL_1="88" TOTAL_2="80" WEIGHT="100.0" Z="2.3691036942852124">
<NAME>ACEi or ARB or ACEi+ARB versus symptomatic treatment</NAME>
<CONT_DATA CI_END="12.192662073662305" CI_START="-135.95266207366234" EFFECT_SIZE="-61.88000000000001" ESTIMABLE="YES" MEAN_1="106.08" MEAN_2="167.96" MODIFIED="2010-12-29 22:26:13 +1100" MODIFIED_BY="Narelle S Willis" ORDER="75" SD_1="44.2" SD_2="167.96" SE="37.792868980214955" STUDY_ID="STD-Praga-2003" TOTAL_1="23" TOTAL_2="21" WEIGHT="19.33766668408434">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="6.347466180767995" CI_START="-81.027466180768" EFFECT_SIZE="-37.34" ESTIMABLE="YES" MEAN_1="117.06" MEAN_2="154.4" MODIFIED="2010-12-29 22:26:23 +1100" MODIFIED_BY="Narelle S Willis" ORDER="76" SD_1="97.58" SD_2="104.58" SE="22.289933144368547" STUDY_ID="STD-Shi-2002" TOTAL_1="44" TOTAL_2="39" WEIGHT="55.591227306047095">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="38.533885562764226" CI_START="-91.57388556276419" EFFECT_SIZE="-26.519999999999982" ESTIMABLE="YES" MEAN_1="176.8" MEAN_2="203.32" MODIFIED="2011-02-07 10:06:41 +1100" MODIFIED_BY="Narelle S Willis" ORDER="77" SD_1="114.92" SD_2="97.24" SE="33.19136783935876" STUDY_ID="STD-Woo-2000" TOTAL_1="21" TOTAL_2="20" WEIGHT="25.071106009868565">
<FOOTNOTE>ACEi or ARB or ACEi+ARB versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.211593645248456" CI_START="-17.211593645248456" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.04" MODIFIED="2011-02-07 11:41:59 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="28" TOTAL_2="24" WEIGHT="100.00000000000001" Z="0.0">
<NAME>ACEi or ARB versus CCB</NAME>
<CONT_DATA CI_END="24.50277961450231" CI_START="-24.50277961450231" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="70.72" MODIFIED="2010-12-29 22:25:50 +1100" MODIFIED_BY="Narelle S Willis" ORDER="74" SD_1="17.68" SD_2="17.68" SE="12.50164789137816" STUDY_ID="STD-Nakamura-2000" TOTAL_1="4" TOTAL_2="4" WEIGHT="49.34139916089375">
<FOOTNOTE>ARB versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="31.23503784790269" CI_START="-31.23503784790269" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="70.72" MODIFIED="2010-12-29 22:25:58 +1100" MODIFIED_BY="Narelle S Willis" ORDER="72" SD_1="26.52" SD_2="17.68" SE="15.936536637550832" STUDY_ID="STD-Nakamura-2000" TOTAL_1="4" TOTAL_2="4" WEIGHT="30.363937945165386">
<FOOTNOTE>ACEi versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="38.20587612180409" CI_START="-38.20587612180409" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="132.6" MEAN_2="132.6" MODIFIED="2011-02-07 10:06:17 +1100" MODIFIED_BY="Narelle S Willis" ORDER="73" SD_1="53.04" SD_2="61.88" SE="19.493152130940754" STUDY_ID="STD-Park--2003" TOTAL_1="20" TOTAL_2="16" WEIGHT="20.294662893940874">
<FOOTNOTE>ARB versus CCB</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.138054173615807" CI_START="-21.97805417361581" DF="0" EFFECT_SIZE="-4.420000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.05" MODIFIED="2010-12-29 22:27:09 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.621734133070948" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0" Z="0.4933941270488189">
<NAME>ACEi+BB versus CCB+BB</NAME>
<CONT_DATA CI_END="13.138054173615807" CI_START="-21.97805417361581" EFFECT_SIZE="-4.420000000000002" ESTIMABLE="YES" MEAN_1="104.312" MEAN_2="108.732" MODIFIED="2010-12-29 22:27:09 +1100" MODIFIED_BY="Narelle S Willis" ORDER="193" SD_1="22.984" SD_2="37.128" SE="8.958355516790869" STUDY_ID="STD-Kanno-2005" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.418983012085256" CI_START="-20.418983012085256" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.06" MODIFIED="2011-02-07 13:51:31 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.0">
<NAME>ACEi or ARB versus anticoagulant</NAME>
<CONT_DATA CI_END="20.418983012085256" CI_START="-20.418983012085256" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="79.56" MEAN_2="79.56" MODIFIED="2010-06-19 17:31:01 +1000" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="26.52" SD_2="35.36" SE="10.4180399094818" STUDY_ID="STD-Shimizu-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.486768288410484" CI_START="-6.186768288410473" DF="0" EFFECT_SIZE="3.6500000000000057" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.07" MODIFIED="2011-02-07 13:51:31 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.4670679203354663" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="0.7272580113531577">
<NAME>ACEi versus herbal medicine</NAME>
<CONT_DATA CI_END="13.486768288410484" CI_START="-6.186768288410473" EFFECT_SIZE="3.6500000000000057" ESTIMABLE="YES" MEAN_1="69.48" MEAN_2="65.83" MODIFIED="2010-12-29 22:27:22 +1100" MODIFIED_BY="Narelle S Willis" ORDER="200" SD_1="23.49" SD_2="17.96" SE="5.018851553396721" STUDY_ID="STD-Chen-2006" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0">
<FOOTNOTE>ACEi versus Shenle</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="20.2189397525285" CI_END="4.999552196356466" CI_START="-1.179180255366951" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9101859704947575" ESTIMABLE="YES" I2="35.703849167589155" I2_Q="59.08821398816202" ID="CMP-006.05" MODIFIED="2011-02-07 13:42:45 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.08988395381524739" P_Q="0.023022425067810826" P_Z="0.22556397207557866" Q="14.665700486074787" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="28.376373971675545" TOTALS="SUB" TOTAL_1="244" TOTAL_2="241" UNITS="" WEIGHT="700.0" Z="1.211865292823657">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8798707043635963" CI_END="15.039135263622155" CI_START="-6.6402832029275185" DF="2" EFFECT_SIZE="4.199426030347318" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.01" MODIFIED="2010-12-30 08:19:18 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.644078081538812" P_Z="0.44766581031897157" STUDIES="3" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="99.99999999999999" Z="0.7593122285932506">
<NAME>ACEi versus ARB</NAME>
<CONT_DATA CI_END="64.4006107761773" CI_START="-77.60061077617729" EFFECT_SIZE="-6.599999999999994" ESTIMABLE="YES" MEAN_1="80.4" MEAN_2="87.0" MODIFIED="2010-12-30 08:18:54 +1100" MODIFIED_BY="Narelle S Willis" ORDER="87" SD_1="99.15" SD_2="98.8" SE="36.22546706787525" STUDY_ID="STD-Horita-2004" TOTAL_1="14" TOTAL_2="16" WEIGHT="2.3308326664752035"/>
<CONT_DATA CI_END="14.732359735263666" CI_START="-14.732359735263666" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="110.0" MODIFIED="2010-12-30 08:19:08 +1100" MODIFIED_BY="Narelle S Willis" ORDER="88" SD_1="14.0" SD_2="16.0" SE="7.516648189186454" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="54.13655747017797"/>
<CONT_DATA CI_END="26.428967874510572" CI_START="-6.4289678745105725" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="55.0" MODIFIED="2010-12-30 08:19:18 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Perico ACE vs ARB for 28/7 then for 3 additional days NSAID added to both arms. Here 28/7 data only used&lt;/p&gt;" NOTES_MODIFIED="2010-12-30 08:19:18 +1100" NOTES_MODIFIED_BY="Narelle S Willis" ORDER="89" SD_1="25.0" SD_2="11.0" SE="8.382280492958122" STUDY_ID="STD-Perico-1998" TOTAL_1="11" TOTAL_2="9" WEIGHT="43.53260986334681"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0109154324132456" CI_END="67.47623297490061" CI_START="-56.28781611114955" DF="1" EFFECT_SIZE="5.594208431875531" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.02" MODIFIED="2010-12-30 08:19:50 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.9167908629618734" P_Z="0.8593645940067933" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="30" WEIGHT="100.0" Z="0.17718306938815517">
<NAME>ACEi+ARB versus ARB or ACEi</NAME>
<CONT_DATA CI_END="90.9909781496726" CI_START="-86.5909781496726" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="89.2" MEAN_2="87.0" MODIFIED="2010-12-30 08:19:41 +1100" MODIFIED_BY="Narelle S Willis" ORDER="199" SD_1="93.023" SD_2="98.8" SE="45.30235190546586" STUDY_ID="STD-Horita-2004" TOTAL_1="6" TOTAL_2="16" WEIGHT="48.5725995170374">
<FOOTNOTE>ACEi+ARB versus ACEi</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="95.09134285651201" CI_START="-77.49134285651202" EFFECT_SIZE="8.799999999999997" ESTIMABLE="YES" MEAN_1="89.2" MEAN_2="80.4" MODIFIED="2010-12-30 08:19:50 +1100" MODIFIED_BY="Narelle S Willis" ORDER="200" SD_1="93.023" SD_2="99.15" SE="44.02700434149153" STUDY_ID="STD-Horita-2004" TOTAL_1="7" TOTAL_2="14" WEIGHT="51.4274004829626">
<FOOTNOTE>ACEi+ARB versus ARB</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2563433972549738" CI_END="36.117822795202514" CI_START="10.402689488198948" DF="1" EFFECT_SIZE="23.260256141700733" ESTIMABLE="YES" I2="20.403927605706127" ID="CMP-006.05.03" MODIFIED="2011-02-07 11:42:05 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.26234446414044654" P_Z="3.915497355000239E-4" STUDIES="2" TAU2="18.046253770866773" TOTAL_1="67" TOTAL_2="60" WEIGHT="100.00000000000001" Z="3.545714794835904">
<NAME>ACEi or ARB or ACEi+ARB versus symptomatic treatment</NAME>
<CONT_DATA CI_END="49.058527806901424" CI_START="12.941472193098576" EFFECT_SIZE="31.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="64.0" MODIFIED="2010-12-30 08:20:48 +1100" MODIFIED_BY="Narelle S Willis" ORDER="95" SD_1="30.0" SD_2="31.0" SE="9.213703899329165" STUDY_ID="STD-Praga-2003" TOTAL_1="23" TOTAL_2="21" WEIGHT="41.8064371556446">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="32.35460142012706" CI_START="3.045398579872943" EFFECT_SIZE="17.700000000000003" ESTIMABLE="YES" MEAN_1="88.02" MEAN_2="70.32" MODIFIED="2010-12-30 08:20:51 +1100" MODIFIED_BY="Narelle S Willis" ORDER="96" SD_1="30.46" SD_2="36.85" SE="7.47697485041597" STUDY_ID="STD-Shi-2002" TOTAL_1="44" TOTAL_2="39" WEIGHT="58.19356284435541">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.35364680383832675" CI_END="11.320049052938554" CI_START="-7.862522076997838" DF="2" EFFECT_SIZE="1.728763487970358" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.04" MODIFIED="2011-02-07 11:42:05 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.8379277843809237" P_Z="0.723885978147613" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="24" WEIGHT="100.0" Z="0.3532700753468787">
<NAME>ACEi or ARB versus CCB</NAME>
<CONT_DATA CI_END="21.63967586086049" CI_START="-13.639675860860489" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="106.0" MODIFIED="2010-12-30 08:20:05 +1100" MODIFIED_BY="Narelle S Willis" ORDER="91" SD_1="16.0" SD_2="14.0" SE="9.0" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="4" WEIGHT="29.564629597175973">
<FOOTNOTE>ARB versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="20.803190867243586" CI_START="-12.803190867243586" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="106.0" MODIFIED="2010-12-30 08:19:59 +1100" MODIFIED_BY="Narelle S Willis" ORDER="93" SD_1="14.0" SD_2="14.0" SE="8.573214099741124" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="4" WEIGHT="32.58142853566332">
<FOOTNOTE>ACEi versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="13.589108013102038" CI_START="-17.589108013102038" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="64.0" MODIFIED="2008-09-28 13:23:04 +1000" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="22.0" SD_2="25.0" SE="7.953772689736613" STUDY_ID="STD-Park--2003" TOTAL_1="20" TOTAL_2="16" WEIGHT="37.8539418671607"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.689905416360692" CI_START="-3.689905416360692" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.05" MODIFIED="2011-02-07 13:42:45 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0" Z="0.0">
<NAME>ACEi+BB versus CCB+BB</NAME>
<CONT_DATA CI_END="3.689905416360692" CI_START="-3.689905416360692" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="85.5" MEAN_2="85.5" ORDER="194" SD_1="5.5" SD_2="7.4" SE="1.8826393982063931" STUDY_ID="STD-Kanno-2005" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.05246292858357" CI_END="20.27099307629226" CI_START="-13.438290669703417" DF="1" EFFECT_SIZE="3.4163512032944228" ESTIMABLE="YES" I2="67.23956937737394" ID="CMP-006.05.06" MODIFIED="2011-02-07 13:42:45 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.08061503952533" P_Z="0.6911647925770694" STUDIES="2" TAU2="100.6206535947712" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.3972748497091727">
<NAME>ACEi or ARB versus anticoagulant</NAME>
<CONT_DATA CI_END="28.82317060019539" CI_START="-2.8231706001953913" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="72.0" MEAN_2="59.0" MODIFIED="2008-09-28 13:23:07 +1000" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="18.0" SD_2="28.0" SE="8.073194571434241" STUDY_ID="STD-Hashizume-1998" TOTAL_1="17" TOTAL_2="17" WEIGHT="44.603186146210525"/>
<CONT_DATA CI_END="6.937316762082178" CI_START="-15.537316762082172" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="71.8" MEAN_2="76.1" MODIFIED="2010-06-19 17:36:26 +1000" MODIFIED_BY="[Empty name]" ORDER="202" SD_1="17.1" SD_2="17.3" SE="5.733430231739305" STUDY_ID="STD-Shimizu-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="55.39681385378948"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.677634316352016" CI_START="-25.77763431635204" DF="0" EFFECT_SIZE="-4.050000000000011" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.07" MODIFIED="2011-02-07 10:09:59 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.7148617386989397" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="0.36533448703217924">
<NAME>ACEi versus herbal medicine</NAME>
<CONT_DATA CI_END="17.677634316352016" CI_START="-25.77763431635204" EFFECT_SIZE="-4.050000000000011" ESTIMABLE="YES" MEAN_1="128.6" MEAN_2="132.65" MODIFIED="2011-02-07 10:09:59 +1100" MODIFIED_BY="Narelle S Willis" ORDER="201" SD_1="55.33" SD_2="34.39" SE="11.085731415340707" STUDY_ID="STD-Chen-2006" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0">
<FOOTNOTE>ACEi versus Shenle</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-006.06" MODIFIED="2010-12-30 08:27:49 +1100" MODIFIED_BY="Narelle S Willis" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Creatinine clearance: Other data</NAME>
<TR>
<TH>
<P>ACEi</P>
</TH>
<TH>
<P>ARB</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 08:27:16 +1100" MODIFIED_BY="Narelle S Willis" ORDER="90" STUDY_ID="STD-Roccatello-2000">
<TR>
<TD>
<P>GFR remained stable while effective renal plasma flow increased with each treatment (p &lt; 0.05)</P>
</TD>
<TD/>
<TD>
<P>Crossover 3-arm RCT (data not useable in meta-analyses)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 08:27:38 +1100" MODIFIED_BY="Narelle S Willis" ORDER="91" STUDY_ID="STD-Tesar-1999">
<TR>
<TD>
<P>"Therapy with losartan and enalapril had no influence on serum creatinine or creatinine clearance"</P>
</TD>
<TD/>
<TD>
<P>Insufficient data, not included in meta-analyses</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 08:27:49 +1100" MODIFIED_BY="Narelle S Willis" ORDER="92" STUDY_ID="STD-Woo-2008">
<TR>
<TD/>
<TD>
<P>High dose ARB had significantly higher eGFR ....compared to other three treatment groups</P>
</TD>
<TD>
<P>4-arm study</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="36.96104908598894" CI_END="-0.2982158810936669" CI_START="-0.538985827999416" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.41860085454654145" ESTIMABLE="YES" I2="56.711185435304046" I2_Q="79.96086300490046" ID="CMP-006.07" MODIFIED="2011-02-07 13:42:51 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0021237091825863086" P_Q="4.032962349198588E-5" P_Z="9.41603085288304E-12" Q="29.94140916081998" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07952467756764973" TOTALS="SUB" TOTAL_1="248" TOTAL_2="262" UNITS="g/24 h" WEIGHT="700.0" Z="6.815157866277044">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antihypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6770755169405986" CI_END="0.09215056558827656" CI_START="-0.423562855915473" DF="3" EFFECT_SIZE="-0.16570614516359822" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.01" MODIFIED="2010-12-30 08:30:52 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.4441371994873857" P_Z="0.20783924696389255" STUDIES="4" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="1.259529277289741">
<NAME>ACEi versus ARB</NAME>
<CONT_DATA CI_END="0.525604956406079" CI_START="-0.805604956406079" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.44" MODIFIED="2010-12-30 08:30:43 +1100" MODIFIED_BY="Narelle S Willis" ORDER="106" SD_1="0.86" SD_2="1.0" SE="0.3396006057541291" STUDY_ID="STD-Horita-2004" TOTAL_1="14" TOTAL_2="16" WEIGHT="15.008033222197104"/>
<CONT_DATA CI_END="0.6412127447482431" CI_START="-0.44121274474824335" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.1" MODIFIED="2010-12-30 08:30:46 +1100" MODIFIED_BY="Narelle S Willis" ORDER="107" SD_1="0.5" SD_2="0.6" SE="0.2761340254296815" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="22.699738117620086"/>
<CONT_DATA CI_END="0.14647595608741953" CI_START="-0.5464759560874195" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.5" MODIFIED="2010-12-30 08:30:49 +1100" MODIFIED_BY="Narelle S Willis" ORDER="184" SD_1="0.3" SD_2="0.4" SE="0.1767766952966369" STUDY_ID="STD-Nakamura-2007" TOTAL_1="8" TOTAL_2="8" WEIGHT="55.38736100699301"/>
<CONT_DATA CI_END="0.161297650576947" CI_START="-1.8012976505769471" EFFECT_SIZE="-0.8200000000000001" ESTIMABLE="YES" MEAN_1="0.72" MEAN_2="1.54" MODIFIED="2010-12-30 08:30:52 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Perico ACE vs ARB for 28/7 then for 3 additional days NSAID added to both arms. Here 28/7 data only used&lt;/p&gt;" NOTES_MODIFIED="2010-12-30 08:30:52 +1100" NOTES_MODIFIED_BY="Narelle S Willis" ORDER="108" SD_1="0.39" SD_2="1.46" SE="0.5006712665729053" STUDY_ID="STD-Perico-1998" TOTAL_1="11" TOTAL_2="9" WEIGHT="6.904867653189799"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.7408409650931738" CI_END="-0.25135111454450787" CI_START="-0.720667904211095" DF="3" EFFECT_SIZE="-0.4860095093778014" ESTIMABLE="YES" I2="19.804128857820118" ID="CMP-006.07.02" MODIFIED="2010-12-30 08:31:30 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.29084297520836555" P_Z="4.9208986821797204E-5" STUDIES="2" TAU2="0.011909226099551301" TOTAL_1="21" TOTAL_2="46" WEIGHT="100.00000000000001" Z="4.059352469368048">
<NAME>ACEi+ARB versus ARB or ACEi</NAME>
<CONT_DATA CI_END="0.48325046855578346" CI_START="-0.9032504685557834" EFFECT_SIZE="-0.21" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.44" MODIFIED="2010-12-30 08:31:00 +1100" MODIFIED_BY="Narelle S Willis" ORDER="203" SD_1="0.6129" SD_2="1.0" SE="0.3537057180764823" STUDY_ID="STD-Horita-2004" TOTAL_1="6" TOTAL_2="16" WEIGHT="10.461685932604096">
<FOOTNOTE>ACEi+ARB versus ARB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.5695982764929506" CI_START="-0.7095982764929505" EFFECT_SIZE="-0.06999999999999998" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.3" MODIFIED="2010-12-30 08:31:11 +1100" MODIFIED_BY="Narelle S Willis" ORDER="201" SD_1="0.6129" SD_2="0.86" SE="0.3263316476925189" STUDY_ID="STD-Horita-2004" TOTAL_1="7" TOTAL_2="14" WEIGHT="12.10649833274273">
<FOOTNOTE>ACEi+ARB versus ACEi</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.21428860726294063" CI_START="-0.7857113927370594" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.3" MODIFIED="2010-12-30 08:31:30 +1100" MODIFIED_BY="Narelle S Willis" ORDER="202" SD_1="0.2" SD_2="0.3" SE="0.14577379737113252" STUDY_ID="STD-Nakamura-2007" TOTAL_1="4" TOTAL_2="8" WEIGHT="43.22864502807968">
<FOOTNOTE>ACEi+ARB versus ACEi</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.36052427977714835" CI_START="-1.0394757202228515" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.5" MODIFIED="2010-12-30 08:31:19 +1100" MODIFIED_BY="Narelle S Willis" ORDER="204" SD_1="0.2" SD_2="0.4" SE="0.17320508075688776" STUDY_ID="STD-Nakamura-2007" TOTAL_1="4" TOTAL_2="8" WEIGHT="34.2031707065735">
<FOOTNOTE>ACEi+ARB versus ARB</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04951958757607749" CI_END="-0.8054167761151207" CI_START="-1.5228564170847907" DF="2" EFFECT_SIZE="-1.1641365965999557" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.03" MODIFIED="2011-02-07 11:42:18 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.9755442310197174" P_Z="2.0099448177531452E-10" STUDIES="3" TAU2="0.0" TOTAL_1="88" TOTAL_2="80" WEIGHT="100.0" Z="6.360579126453386">
<NAME>ACEi or ARB or ACEi+ARB versus symptomatic treatment</NAME>
<CONT_DATA CI_END="-0.2283910470998004" CI_START="-1.9716089529001999" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="2.0" MODIFIED="2010-12-30 08:32:11 +1100" MODIFIED_BY="Narelle S Willis" ORDER="114" SD_1="1.0" SD_2="1.8" SE="0.44470661694568875" STUDY_ID="STD-Praga-2003" TOTAL_1="23" TOTAL_2="21" WEIGHT="16.938204896110378">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.7650638555793929" CI_START="-1.614936144420607" EFFECT_SIZE="-1.19" ESTIMABLE="YES" MEAN_1="0.59" MEAN_2="1.78" MODIFIED="2010-12-30 08:32:17 +1100" MODIFIED_BY="Narelle S Willis" ORDER="115" SD_1="0.11" SD_2="1.35" SE="0.2168081392170719" STUDY_ID="STD-Shi-2002" TOTAL_1="44" TOTAL_2="39" WEIGHT="71.26288511106212">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.055677994172241174" CI_START="-2.1443220058277586" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.9" MODIFIED="2010-12-30 08:34:57 +1100" MODIFIED_BY="Narelle S Willis" ORDER="116" SD_1="1.6" SD_2="1.8" SE="0.5328271407358693" STUDY_ID="STD-Woo-2000" TOTAL_1="21" TOTAL_2="20" WEIGHT="11.798909992827497">
<FOOTNOTE>ACEi or ARB or ACEi+ARB versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.552203855559108" CI_END="0.14465025511466834" CI_START="-0.790612805555785" DF="2" EFFECT_SIZE="-0.3229812752205583" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.04" MODIFIED="2011-02-07 11:42:18 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.7587356096552071" P_Z="0.17583288315241277" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="100.0" Z="1.3536975718025641">
<NAME>ACEi or ARB versus CCB</NAME>
<CONT_DATA CI_END="0.4298434917279004" CI_START="-1.8298434917279003" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.8" MODIFIED="2010-12-30 08:31:37 +1100" MODIFIED_BY="Narelle S Willis" ORDER="110" SD_1="1.1" SD_2="1.7" SE="0.5764613536983136" STUDY_ID="STD-JLIGHT-Study-2003" TOTAL_1="11" TOTAL_2="13" WEIGHT="17.130537721746492">
<FOOTNOTE>ARB versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.4653904037521338" CI_START="-1.0653904037521333" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.4" MODIFIED="2010-12-30 08:31:42 +1100" MODIFIED_BY="Narelle S Willis" ORDER="112" SD_1="0.6" SD_2="0.5" SE="0.3905124837953327" STUDY_ID="STD-Nakamura-2000" TOTAL_1="4" TOTAL_2="4" WEIGHT="37.328586611825905">
<FOOTNOTE>ARB versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.492951912174839" CI_START="-0.8929519121748389" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2010-12-30 08:31:49 +1100" MODIFIED_BY="Narelle S Willis" ORDER="111" SD_1="0.5" SD_2="0.5" SE="0.3535533905932738" STUDY_ID="STD-Nakamura-2000" TOTAL_1="4" TOTAL_2="4" WEIGHT="45.5408756664276">
<FOOTNOTE>ACEi versus CCB</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2512948510552539" CI_START="-0.8287051489447461" DF="0" EFFECT_SIZE="-0.54" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.05" MODIFIED="2011-02-07 13:42:51 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="2.464156988049925E-4" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="99.99999999999999" Z="3.665956618786136">
<NAME>ACEi+BB versus CCB+BB</NAME>
<CONT_DATA CI_END="-0.2512948510552539" CI_START="-0.8287051489447461" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="0.79" MEAN_2="1.33" MODIFIED="2010-12-30 08:33:48 +1100" MODIFIED_BY="Narelle S Willis" ORDER="195" SD_1="0.36" SD_2="0.62" SE="0.14730125207504602" STUDY_ID="STD-Kanno-2005" TOTAL_1="26" TOTAL_2="23" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15436152973987105" CI_START="-0.9543615297398713" DF="0" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.06" MODIFIED="2011-02-07 13:42:51 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.15729920705263292" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="1.4142135623730956">
<NAME>ACEi or ARB versus anticoagulant</NAME>
<CONT_DATA CI_END="0.15436152973987105" CI_START="-0.9543615297398713" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" MODIFIED="2010-12-30 08:31:58 +1100" MODIFIED_BY="Narelle S Willis" ORDER="113" SD_1="0.6" SD_2="1.0" SE="0.282842712474619" STUDY_ID="STD-Hashizume-1998" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0">
<FOOTNOTE>ACEi versus anticoagulant</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.43910733348165176" CI_START="-0.2591073334816518" DF="0" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.07" MODIFIED="2010-12-30 15:19:29 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.6133625819237495" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="34" WEIGHT="100.0" Z="0.505279441853592">
<NAME>ACEi versus herbal medicine</NAME>
<CONT_DATA CI_END="0.43910733348165176" CI_START="-0.2591073334816518" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="0.78" MODIFIED="2009-06-09 13:39:40 +1000" MODIFIED_BY="[Empty name]" ORDER="202" SD_1="0.78" SD_2="0.71" SE="0.17811925945342152" STUDY_ID="STD-Chen-2006" TOTAL_1="36" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.7947480975632306" CI_END="16.60946823465383" CI_START="-0.583990943440984" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="8.012738645606422" ESTIMABLE="YES" I2="0.0" I2_Q="17.637789841045812" ID="CMP-006.08" MODIFIED="2011-02-07 12:04:04 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.5927396573628456" P_Q="0.2969626742229894" P_Z="0.06772680949764055" Q="2.428298118931144" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="46" UNITS="" WEIGHT="300.0" Z="1.8268201878687984">
<NAME>Change in proteinuria</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antihypertensive</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.36644997863208695" CI_END="13.30369721704602" CI_START="-11.773957736335676" DF="1" EFFECT_SIZE="0.7648697403551719" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.01" MODIFIED="2011-02-07 10:11:24 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.5449459846533685" P_Z="0.9048332916220224" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="0.11955800067808853">
<NAME>ACEi versus ARB</NAME>
<CONT_DATA CI_END="13.49680671869904" CI_START="-17.696806718699044" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="36.8" MEAN_2="38.9" MODIFIED="2011-02-07 10:11:13 +1100" MODIFIED_BY="Narelle S Willis" ORDER="118" SD_1="15.2" SD_2="16.6" SE="7.957700672933106" STUDY_ID="STD-Nakamura-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="64.63123777339293">
<FOOTNOTE>ACEi versus ARB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="27.083708165280274" CI_START="-15.083708165280274" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="55.0" MODIFIED="2011-02-07 10:11:24 +1100" MODIFIED_BY="Narelle S Willis" ORDER="119" SD_1="28.0" SD_2="20.0" SE="10.757191627798202" STUDY_ID="STD-Perico-1998" TOTAL_1="11" TOTAL_2="9" WEIGHT="35.368762226607075">
<FOOTNOTE>ACEi versus ARB</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="50.53500891367315" CI_START="-24.535008913673153" DF="0" EFFECT_SIZE="13.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.02" MODIFIED="2011-02-07 11:42:26 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.4972516365316859" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.6788204541957386">
<NAME>ACEi or ARB or ACEi+ARB versus symptomatic treatment</NAME>
<CONT_DATA CI_END="50.53500891367315" CI_START="-24.535008913673153" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="23.0" MODIFIED="2011-02-07 10:11:41 +1100" MODIFIED_BY="Narelle S Willis" ORDER="122" SD_1="40.0" SD_2="79.0" SE="19.150866653542877" STUDY_ID="STD-Praga-2003" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0">
<FOOTNOTE>ACEi versus symptomatic treatment</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.040947513773187" CI_START="2.159052486226809" DF="1" EFFECT_SIZE="14.599999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.03" MODIFIED="2011-02-07 11:42:26 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.02144232401603431" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="2.300104083117867">
<NAME>ACEi or ARB versus CCB</NAME>
<CONT_DATA CI_END="32.831879545309164" CI_START="-3.631879545309168" EFFECT_SIZE="14.599999999999998" ESTIMABLE="YES" MEAN_1="36.8" MEAN_2="22.2" MODIFIED="2011-02-07 10:11:35 +1100" MODIFIED_BY="Narelle S Willis" ORDER="120" SD_1="16.6" SD_2="8.4" SE="9.302150289046077" STUDY_ID="STD-Nakamura-2000" TOTAL_1="4" TOTAL_2="4" WEIGHT="46.56332983387883">
<FOOTNOTE>ARB versus CCB</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="31.61898924966865" CI_START="-2.4189892496686554" EFFECT_SIZE="14.599999999999998" ESTIMABLE="YES" MEAN_1="36.8" MEAN_2="22.2" MODIFIED="2011-02-07 10:11:30 +1100" MODIFIED_BY="Narelle S Willis" ORDER="121" SD_1="15.2" SD_2="8.4" SE="8.683317338436964" STUDY_ID="STD-Nakamura-2000" TOTAL_1="4" TOTAL_2="4" WEIGHT="53.43667016612116">
<FOOTNOTE>ACEi versus CCB</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-006.09" MODIFIED="2010-12-30 12:00:37 +1100" MODIFIED_BY="Narelle S Willis" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO">
<NAME>Proteinuria: Other data</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 11:51:10 +1100" MODIFIED_BY="Narelle S Willis" ORDER="115" STUDY_ID="STD-Liu-2007">
<TR>
<TD>
<P>ACEi+ARB: "24 hour proteinuria decreased especially in the combined [ACEi+ARB] group"</P>
</TD>
<TD>
<P>ACEi or ARB</P>
</TD>
<TD>
<P>Chinese paper not translated, abstract and data tables only in English</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 11:53:01 +1100" MODIFIED_BY="Narelle S Willis" ORDER="116" STUDY_ID="STD-Nakao-2001">
<TR>
<TD>
<P>"the combination therapy was the most potent in the reduction of proteinuria 1) -69% on the combination, 2) -43% on ACEi, 3) -39% on ARB, and 4) +4% on placebo"</P>
</TD>
<TD/>
<TD>
<P>4-arm study</P>
<P>ACEi+ARB versus ACEi+placebo versus ARB+placebo versus other antihypertensives+placebo</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:00:32 +1100" MODIFIED_BY="Narelle S Willis" ORDER="117" STUDY_ID="STD-Panichi-2000">
<TR>
<TD>
<P>ACEi: Proteinuria was reduced from 1.9 ± 1.0 to 1.1 ± 0.8 g/24 h (P &lt; 0.001)</P>
<P>Conclusion: "in hypertensive patients with IgA nephropathy EN and LOS have different antiproteinuric mechanisms not related to the decrease of blood pressure"</P>
</TD>
<TD>
<P>ARB: Proteinuria was reduced from 1.9 ± 0.9 to 1.2 ± 0.8 g/24 h (P &lt; 0.01)</P>
</TD>
<TD>
<P>Crossover RCT (data not useable in meta-analysis)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:00:33 +1100" MODIFIED_BY="Narelle S Willis" ORDER="118" STUDY_ID="STD-Roccatello-2000">
<TR>
<TD>
<P>Unlike losartan, enalapril significantly reduced albuminuria (P = 0.01)</P>
</TD>
<TD/>
<TD>
<P>Crossover RCT (data not useable in meta-analysis)</P>
<P>ACEi versus ARB versus<BR/>nitric oxide donor isosorbide 5 mononitrate</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 11:56:43 +1100" MODIFIED_BY="Narelle S Willis" ORDER="119" STUDY_ID="STD-Russo-2001">
<TR>
<TD>
<P>When enalapril (E) and losartan (LOS) were coadministered, proteinuria decreased by a greater extent compared with E and LOS alone; an additional reduction in proteinuria was observed when combined therapy doses were doubled...combination therapy as an additive dose-dependent antiproteinuric effect that is likely induced by the drug related reduction in systemic blood pressure.</P>
</TD>
<TD/>
<TD>
<P>Crossover RCT (data not useable in meta-analysis)</P>
<P>ACEi versus ARB versus ACEi+ARB</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:00:36 +1100" MODIFIED_BY="Narelle S Willis" ORDER="120" STUDY_ID="STD-Song-2003">
<TR>
<TD>
<P>"The addition of candesartan (combination) reduced 24-hour urinary protein excretion rate in IgA nephropathy patients with a mean change of -12.3 ± 4.5%, which is significantly greater compared to a mean change of -0.1 ± 3.3% after the addition of placebo (mean difference 12.4 ± 5.0 95% CI 1.2 to 23.5; P &lt; 0.05)...definite beneficial effects of dual blockade of RAS on proteinuria...found in IgA nephropathy patients which was independent of blood pressure reducing effect"</P>
</TD>
<TD/>
<TD>
<P>Crossover RCT IgA and diabetic nephropathy patients (data not useable as IgA nephropathy and diabetic nephropathy groups combined)</P>
<P>ACEi versus ACEi+ARB versus ACEi+placebo</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:00:37 +1100" MODIFIED_BY="Narelle S Willis" ORDER="121" STUDY_ID="STD-Tesar-1999">
<TR>
<TD>
<P>"..it was possible to demonstrate the antiproteinuric effect of both drugs only in patients with proteinuria higher than 1 g/24 h in the losartan group (from 3.07 ± 2.61 to 1.98 ± 1.25 g/24 h, P &lt; 0.05)"</P>
</TD>
<TD/>
<TD>
<P>Insufficient data, not included in meta-analysis</P>
<P>ACEi versus ARB</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:00:03 +1100" MODIFIED_BY="Narelle S Willis" ORDER="122" STUDY_ID="STD-Woo-2008">
<TR>
<TD>
<P>Patients on high dose ARB had significantly lower proteinuria (compared with other groups) at the end of the study</P>
</TD>
<TD/>
<TD>
<P>4-arm study</P>
<P>High dose ARB versus normal dose ARB versus high dose ACEi versus normal dose ACEi</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.10" MODIFIED="2011-02-07 12:04:50 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>Antihypertensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antiypertensive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9898405699231176" CI_START="-40.58984056992311" EFFECT_SIZE="-19.799999999999997" ESTIMABLE="YES" MEAN_1="18.6" MEAN_2="38.4" MODIFIED="2010-06-19 17:44:03 +1000" MODIFIED_BY="[Empty name]" ORDER="203" SD_1="27.4" SD_2="35.7" SE="10.607256426092889" STUDY_ID="STD-Shimizu-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0">
<FOOTNOTE>Sediment RBC/HPF</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-006.11" MODIFIED="2010-12-30 12:23:13 +1100" MODIFIED_BY="Narelle S Willis" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 11:34:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="124" STUDY_ID="STD-Chen-2006">
<TR>
<TD>
<P>ACEi: the authors noted "no severe adverse event was found"</P>
</TD>
<TD>
<P>Shenle capsule</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:07:04 +1100" MODIFIED_BY="Narelle S Willis" ORDER="125" STUDY_ID="STD-Horita-2004">
<TR>
<TD/>
<TD/>
<TD>
<P>Dry cough (1), postural (1; dropped out because of S/E) unclear which group</P>
<P>ACEi+ARB versus ACEi versus ARB</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 11:37:03 +1100" MODIFIED_BY="Narelle S Willis" ORDER="126" STUDY_ID="STD-JLIGHT-Study-2003">
<TR>
<TD>
<P>ARB: Increased ALT, AST (n in each group not specified but incidence 'almost the same' across groups), hyperkalaemia (3), dizzyness (2), TIA (1)</P>
</TD>
<TD>
<P>CCB: Increased ALT, AST (n in each group not specified but incidence 'almost the same' across groups), increased uric acid (2), hyperkalaemia (2), dizzyness (2), TIA (1)</P>
</TD>
<TD>
<P>No fatal adverse events in either group</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:05:35 +1100" MODIFIED_BY="Narelle S Willis" ORDER="127" STUDY_ID="STD-Nakamura-2007">
<TR>
<TD/>
<TD/>
<TD>
<P>The authors noted " we did not notice any adverse effects of the monotherapy and the combination therapy"</P>
<P>ACEi versus ARB versus ACEi+ARB</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:07:37 +1100" MODIFIED_BY="Narelle S Willis" ORDER="128" STUDY_ID="STD-Praga-2003">
<TR>
<TD>
<P>ACEi: no withdrawals because of enalapril side effects, mild increase in K<SUP>+</SUP> only (number not specified)</P>
</TD>
<TD>
<P>Symptomatic treatment: not specified</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:07:50 +1100" MODIFIED_BY="Narelle S Willis" ORDER="129" STUDY_ID="STD-Shi-2002">
<TR>
<TD>
<P>ACEi: minor dry cough (9, all except 1 remained on treatment); headache and dizzyness (5, 1 withdrew from study); tolerable GIT side effects (3)</P>
</TD>
<TD>
<P>Symptomatic treatment: not specified</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:07:53 +1100" MODIFIED_BY="Narelle S Willis" ORDER="130" STUDY_ID="STD-Woo-2000">
<TR>
<TD>
<P>ACEi or ARB or ACEi+ARB: cough, dizzy and hypotension (number not specified)</P>
</TD>
<TD>
<P>Symptomatic treatment: not specified</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-02-07 14:09:59 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Antihypertensive agents+other treatment versus other treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 12:11:00 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.227017483783065" CI_START="0.041940994859782615" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6260340441608866" LOG_CI_START="-1.3773612720826574" LOG_EFFECT_SIZE="-0.3756636139608854" MODIFIED="2010-12-30 12:10:45 +1100" MODIFIED_BY="Narelle S Willis" ORDER="238" O_E="0.0" SE="1.176804325728212" STUDY_ID="STD-Cheng-1998" TOTAL_1="19" TOTAL_2="16" VAR="1.3848684210526316" WEIGHT="0.0">
<FOOTNOTE>ACEi+anticoagulant versus BB</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="32.12229382313673" CI_END="14.572548209783736" CI_START="-48.44391355085942" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.935682670537844" ESTIMABLE="YES" I2="93.77379457702531" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2011-02-07 14:09:30 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0586109588928139E-7" P_Q="0.7943065298179508" P_Z="0.2921205330919838" Q="0.06797621407672239" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="723.0017925361863" TOTALS="YES" TOTAL_1="118" TOTAL_2="113" UNITS="" WEIGHT="100.00000000000001" Z="1.0534811749327426">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4182502922674036" CI_START="-20.09825029226741" DF="0" EFFECT_SIZE="-8.840000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" MODIFIED="2011-02-07 14:09:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.12381222381669084" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="34.18471890538798" Z="1.5389675281277317">
<NAME>ACEi or ARB+other treatment versus other treatment</NAME>
<CONT_DATA CI_END="2.4182502922674036" CI_START="-20.09825029226741" EFFECT_SIZE="-8.840000000000003" ESTIMABLE="YES" MEAN_1="70.72" MEAN_2="79.56" MODIFIED="2010-12-30 12:13:54 +1100" MODIFIED_BY="Narelle S Willis" ORDER="196" SD_1="17.68" SD_2="17.68" SE="5.744110800540749" STUDY_ID="STD-Horita-2007" TOTAL_1="20" TOTAL_2="18" WEIGHT="34.18471890538798">
<FOOTNOTE>ACEi+steroid+antiplatelet versus steroid+antiplatelet</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="32.05431760906001" CI_END="40.56784783951556" CI_START="-83.94117710524435" DF="1" EFFECT_SIZE="-21.686664632864392" ESTIMABLE="YES" I2="96.880295465353" ID="CMP-007.02.02" MODIFIED="2011-02-07 14:09:30 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.4992631358623498E-8" P_Z="0.4947565779370764" STUDIES="2" TAU2="1955.0738625407926" TOTAL_1="98" TOTAL_2="95" WEIGHT="65.81528109461203" Z="0.6827630630642352">
<NAME>ACEi or ARB+herbal medicine versus herbal medicine</NAME>
<CONT_DATA CI_END="22.253363395194327" CI_START="-2.7933633951943477" EFFECT_SIZE="9.72999999999999" ESTIMABLE="YES" MEAN_1="89.66" MEAN_2="79.93" MODIFIED="2010-12-30 12:14:20 +1100" MODIFIED_BY="Narelle S Willis" ORDER="191" SD_1="38.2" SD_2="34.88" SE="6.389588530185773" STUDY_ID="STD-Chen-2007" TOTAL_1="66" TOTAL_2="65" WEIGHT="33.83420070769673">
<FOOTNOTE>ACEi+Shenhua versus Shenhua</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-35.72085052598288" CI_START="-71.87914947401714" EFFECT_SIZE="-53.80000000000001" ESTIMABLE="YES" MEAN_1="128.6" MEAN_2="182.4" MODIFIED="2010-12-30 12:14:28 +1100" MODIFIED_BY="Narelle S Willis" ORDER="196" SD_1="36.4" SD_2="36.2" SE="9.22422535139582" STUDY_ID="STD-Guan-2005" TOTAL_1="32" TOTAL_2="30" WEIGHT="31.981080386915295">
<FOOTNOTE>ARB+Huobahuagen versus Huobahuagen</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2010-12-30 12:15:32 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in serum creatinine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09858568741272997" CI_START="-0.1585856874127299" EFFECT_SIZE="-0.02999999999999997" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.29" MODIFIED="2010-12-30 12:15:32 +1100" MODIFIED_BY="Narelle S Willis" ORDER="166" SD_1="0.23" SD_2="0.21" SE="0.0656061480858819" STUDY_ID="STD-Bang-1994" TOTAL_1="24" TOTAL_2="21" WEIGHT="0.0">
<FOOTNOTE>ACEi+anticoagulant versus anticoagulant (mL/min/mo)</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6919722862095083" CI_END="22.221154032428466" CI_START="-12.631208104193377" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.794972964117545" ESTIMABLE="YES" I2="40.897377093552755" I2_Q="40.897377093552755" ID="CMP-007.04" MODIFIED="2011-02-07 14:09:45 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.19334126640751848" P_Q="0.19334126640751848" P_Z="0.5896784908203849" Q="1.6919722862095083" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="68.18157145299128" TOTALS="YES" TOTAL_1="85" TOTAL_2="84" UNITS="" WEIGHT="100.0" Z="0.5393020008040456">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="38.89236442341091" CI_START="-6.892364423410914" DF="0" EFFECT_SIZE="16.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" MODIFIED="2011-02-07 14:09:38 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.17072938854881894" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="38.63621557567108" Z="1.3698639062626097">
<NAME>ACEi or ARB+other treatment versus other treatment</NAME>
<CONT_DATA CI_END="38.89236442341091" CI_START="-6.892364423410914" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="100.0" MEAN_2="84.0" MODIFIED="2010-12-30 12:16:18 +1100" MODIFIED_BY="Narelle S Willis" ORDER="194" SD_1="38.0" SD_2="34.0" SE="11.679992389647444" STUDY_ID="STD-Horita-2007" TOTAL_1="20" TOTAL_2="18" WEIGHT="38.63621557567108">
<FOOTNOTE>ARB+steroid+anticoagulant versus steroid+anticoagulant</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.002851897822426" CI_START="-17.522851897822406" DF="0" EFFECT_SIZE="-2.259999999999991" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" MODIFIED="2011-02-07 14:09:45 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.771651258551707" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="61.36378442432891" Z="0.2902156579067948">
<NAME>ACEi or ARB+herbal medicine versus herbal medicine</NAME>
<CONT_DATA CI_END="13.002851897822424" CI_START="-17.522851897822406" EFFECT_SIZE="-2.259999999999991" ESTIMABLE="YES" MEAN_1="114.56" MEAN_2="116.82" MODIFIED="2010-12-30 12:17:18 +1100" MODIFIED_BY="Narelle S Willis" ORDER="193" SD_1="39.64" SD_2="49.06" SE="7.787312429316989" STUDY_ID="STD-Chen-2007" TOTAL_1="65" TOTAL_2="66" WEIGHT="61.36378442432891">
<FOOTNOTE>ACEi+Shenhua versus Shenhua</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.864876743092076" CI_END="0.08051741566023227" CI_START="-0.5077621465385688" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.21362236543916827" ESTIMABLE="YES" I2="95.22272569372844" I2_Q="96.2849711753811" ID="CMP-007.05" MODIFIED="2011-02-07 14:09:59 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="8.112656102454707E-10" P_Q="2.1231237801178082E-7" P_Z="0.1546068586206512" Q="26.917691549878747" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.05732445057023076" TOTALS="YES" TOTAL_1="118" TOTAL_2="113" UNITS="g/24 h" WEIGHT="99.99999999999999" Z="1.4234461621888965">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1363221137315192" CI_START="-0.2636778862684808" DF="0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2011-02-07 14:09:52 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="7.46664012245538E-10" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="38.578666467841245" Z="6.155870112510924">
<NAME>ACEi or ARB+other treatment versus other treatment</NAME>
<CONT_DATA CI_END="-0.1363221137315192" CI_START="-0.2636778862684808" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.5" MODIFIED="2010-12-30 12:19:47 +1100" MODIFIED_BY="Narelle S Willis" ORDER="188" SD_1="0.1" SD_2="0.1" SE="0.03248931448269655" STUDY_ID="STD-Horita-2007" TOTAL_1="20" TOTAL_2="18" WEIGHT="38.578666467841245">
<FOOTNOTE>ARB+steroid+anticoagulant versus steroid+anticoagulant</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.947185193213329" CI_END="0.609455204094383" CI_START="-0.9165299680056855" DF="1" EFFECT_SIZE="-0.15353738195565123" ESTIMABLE="YES" I2="93.30977714483632" ID="CMP-007.05.02" MODIFIED="2011-02-07 14:09:59 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.1056379789176063E-4" P_Z="0.6932823943617819" STUDIES="2" TAU2="0.2838483420745919" TOTAL_1="98" TOTAL_2="95" WEIGHT="61.42133353215874" Z="0.39440453867518005">
<NAME>ACEi or ARB+herbal medicine versus herbal medicine</NAME>
<CONT_DATA CI_END="0.6456241758582864" CI_START="-0.12562417585828634" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="1.05" MODIFIED="2010-12-30 12:20:19 +1100" MODIFIED_BY="Narelle S Willis" ORDER="199" SD_1="1.18" SD_2="1.07" SE="0.19675064383837693" STUDY_ID="STD-Chen-2007" TOTAL_1="66" TOTAL_2="65" WEIGHT="23.452038700479445">
<FOOTNOTE>ACEi+Shenhua versus Shenhua</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.4325122482844996" CI_START="-0.6074877517155004" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="0.98" MODIFIED="2010-12-30 12:20:27 +1100" MODIFIED_BY="Narelle S Willis" ORDER="197" SD_1="0.22" SD_2="0.12" SE="0.04463742824133129" STUDY_ID="STD-Guan-2005" TOTAL_1="32" TOTAL_2="30" WEIGHT="37.9692948316793">
<FOOTNOTE>ARB+Huobahuagen versus Huobahuagen</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-007.06" MODIFIED="2010-12-30 12:23:37 +1100" MODIFIED_BY="Narelle S Willis" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Proteinuria: Other data</NAME>
<TR>
<TH>
<P>Antihypertensive+other agent</P>
</TH>
<TH>
<P>Other agent</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 12:22:04 +1100" MODIFIED_BY="Narelle S Willis" ORDER="141" STUDY_ID="STD-Bang-1994">
<TR>
<TD>
<P>ACEI+anticoagulant: n = 24; % change = 76.5</P>
<P/>
</TD>
<TD>
<P>Anticoagulant: n = 21; % change = 34</P>
<P/>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.07" MODIFIED="2010-12-30 12:24:14 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="54.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.922216935868313" CI_START="-11.077783064131687" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="16.5" MODIFIED="2010-12-30 12:24:14 +1100" MODIFIED_BY="Narelle S Willis" ORDER="179" SD_1="6.5" SD_2="9.5" SE="2.0805397937394354" STUDY_ID="STD-Guan-2005" TOTAL_1="32" TOTAL_2="30" WEIGHT="0.0">
<FOOTNOTE>ARB+Huobahuagen versus Huobahuagen (RBC/HPF)</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-007.08" MODIFIED="2010-12-30 12:26:44 +1100" MODIFIED_BY="Narelle S Willis" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse effects</NAME>
<TR>
<TH>
<P>Antihypertensives+other agent</P>
</TH>
<TH>
<P>Other agent</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 12:25:44 +1100" MODIFIED_BY="Narelle S Willis" ORDER="143" STUDY_ID="STD-Chen-2007">
<TR>
<TD>
<P>ACEi+Shenhua</P>
</TD>
<TD>
<P>Shenhua</P>
</TD>
<TD>
<P>The authors noted "no severe adverse event occured during treatment, and the occurrence in the two groups was similar"</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:26:44 +1100" MODIFIED_BY="Narelle S Willis" ORDER="144" STUDY_ID="STD-Horita-2007">
<TR>
<TD>
<P>ARB+steroid+anticoagulant): Postural hypotension (number not specified)</P>
<P/>
</TD>
<TD>
<P>Steroid+anticoagulant: not specified</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-02-07 10:14:04 +1100" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Anticoagulant versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 12:27:59 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" MODIFIED="2008-09-26 12:27:15 +1000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Lee-1997" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2011-02-07 10:14:04 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.60070116660907" CI_START="-158.04070116660913" EFFECT_SIZE="-70.72000000000003" ESTIMABLE="YES" MEAN_1="221.0" MEAN_2="291.72" MODIFIED="2011-02-07 10:14:04 +1100" MODIFIED_BY="Narelle S Willis" ORDER="37" SD_1="106.08" SD_2="97.24" SE="44.55219680330028" STUDY_ID="STD-Lee-1997" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0">
<FOOTNOTE>Warfarin+dipyridamole versus no treatment</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2010-12-30 12:28:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anticoagulant</GRAPH_LABEL_2>
<CONT_DATA CI_END="42.191190059530484" CI_START="-0.19119005953048074" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="52.0" MEAN_2="31.0" MODIFIED="2008-09-26 12:51:22 +1000" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="27.0" SD_2="22.0" SE="10.812030336620408" STUDY_ID="STD-Lee-1997" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-008.04" MODIFIED="2010-12-30 12:29:35 +1100" MODIFIED_BY="Narelle S Willis" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Renal function: Other data</NAME>
<TR>
<TH>
<P>Anticoagulant</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 12:29:35 +1100" MODIFIED_BY="Narelle S Willis" ORDER="148" STUDY_ID="STD-Camara-1991">
<TR>
<TD>
<P>No change in renal function; UP/UCr significantly diminished</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2010-12-30 12:30:41 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7420068935949159" CI_START="-1.1420068935949157" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.5" MODIFIED="2008-09-26 12:59:14 +1000" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="1.1" SD_2="1.1" SE="0.48062459362791665" STUDY_ID="STD-Lee-1997" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-008.06" MODIFIED="2010-12-30 12:31:25 +1100" MODIFIED_BY="Narelle S Willis" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Proteinuria: Other data</NAME>
<TR>
<TH>
<P>Anticoagulant</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 12:31:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="150" STUDY_ID="STD-Camara-1991">
<TR>
<TD>
<P>Dropped by 65-70%; UP/UCr significantly diminished</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.07" MODIFIED="2010-12-30 12:32:10 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.755949038204534" CI_START="-53.755949038204534" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="25.0" MODIFIED="2008-09-26 13:08:02 +1000" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="32.0" SD_2="66.0" SE="22.32487401980132" STUDY_ID="STD-Lee-1997" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-008.08" MODIFIED="2010-12-30 12:32:45 +1100" MODIFIED_BY="Narelle S Willis" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Anticoagulant</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 12:32:45 +1100" MODIFIED_BY="Narelle S Willis" ORDER="152" STUDY_ID="STD-Camara-1991">
<TR>
<TD>
<P>Transient headache: 100%</P>
</TD>
<TD>
<P>Mot specified</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-02-07 10:14:21 +1100" MODIFIED_BY="Narelle S Willis" NO="9">
<NAME>Anticoagulant versus other treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2011-02-07 10:14:21 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.241398345839473" CI_START="-14.241398345839473" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="198.0" MEAN_2="199.0" MODIFIED="2011-02-07 10:14:21 +1100" MODIFIED_BY="Narelle S Willis" ORDER="199" SD_1="21.578" SD_2="20.04" SE="6.7559396245471515" STUDY_ID="STD-Chan-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant versus vitamin B12</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2010-12-30 12:35:49 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anticoagulant</GRAPH_LABEL_2>
<CONT_DATA CI_END="29.60070533226395" CI_START="-17.60070533226395" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="78.0" MEAN_2="72.0" MODIFIED="2010-12-30 12:35:19 +1100" MODIFIED_BY="Narelle S Willis" ORDER="200" SD_1="39.23" SD_2="34.87" SE="12.041397453434502" STUDY_ID="STD-Chan-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant versus vitamin B12</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2010-12-30 12:36:38 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="19" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.108063539590918" CI_START="-1.6080635395909184" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="2.46" MEAN_2="2.21" MODIFIED="2010-12-30 12:36:12 +1100" MODIFIED_BY="Narelle S Willis" ORDER="201" SD_1="3.399" SD_2="2.35" SE="0.948009021720341" STUDY_ID="STD-Chan-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant versus vitamin B12</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-12-30 12:50:15 +1100" MODIFIED_BY="Narelle S Willis" NO="10">
<NAME>Anticoagulant+other treatment versus other treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 12:49:48 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Anticoagulant+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1155319753513364" CI_START="0.03200833516674306" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4935322128680652" LOG_CI_START="-1.494736914006436" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2010-12-30 12:49:48 +1100" MODIFIED_BY="Narelle S Willis" ORDER="156" O_E="0.0" SE="1.167919127216991" STUDY_ID="STD-Cheng-1998" TOTAL_1="19" TOTAL_2="12" VAR="1.3640350877192984" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant+ACEi versus ACEi</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2010-12-30 12:50:01 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Anticoagulant+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6442082307776289" CI_START="-54.34420823077762" EFFECT_SIZE="-26.849999999999994" ESTIMABLE="YES" MEAN_1="141.11" MEAN_2="167.96" MODIFIED="2010-12-30 12:50:01 +1100" MODIFIED_BY="Narelle S Willis" ORDER="160" SD_1="26.52" SD_2="35.56" SE="14.027915026831323" STUDY_ID="STD-Frasca-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant+steroid versus steroid</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.03" MODIFIED="2010-12-30 12:50:15 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in creatinine clearance</NAME>
<GROUP_LABEL_1>Anticoagulant+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anticoagulant+other</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.61788502380707" CI_START="-10.61788502380707" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="64.0" MEAN_2="57.0" MODIFIED="2010-12-30 12:50:15 +1100" MODIFIED_BY="Narelle S Willis" ORDER="163" SD_1="18.0" SD_2="22.0" SE="8.988882021697693" STUDY_ID="STD-Frasca-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant+steroid versus steroid</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-010.04" MODIFIED="2010-12-30 12:48:21 +1100" MODIFIED_BY="Narelle S Willis" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Renal function: Other data</NAME>
<TR>
<TH>
<P>Anticoagulant + other</P>
</TH>
<TH>
<P>Other</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 12:47:32 +1100" MODIFIED_BY="Narelle S Willis" ORDER="159" STUDY_ID="STD-Cheng-1998">
<TR>
<TD/>
<TD>
<P>ACEi</P>
</TD>
<TD>
<P>% of patients who had doubling of serum creatinine over time was similar in the 3 groups.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2010-12-30 12:47:52 +1100" MODIFIED_BY="Narelle S Willis" ORDER="160" STUDY_ID="STD-Frasca-1997">
<TR>
<TD>
<P>SCr lower than baseline</P>
</TD>
<TD>
<P>Steroid: not specified</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.05" MODIFIED="2010-12-30 12:49:25 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Anticoagulant+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticoagulant+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.10800720309198913" CI_START="-0.8919927969080108" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.9" MODIFIED="2010-12-30 12:48:47 +1100" MODIFIED_BY="Narelle S Willis" ORDER="166" SD_1="0.2" SD_2="0.6" SE="0.2" STUDY_ID="STD-Frasca-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0">
<FOOTNOTE>Anticoagulant+steroid versus steroid</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-02-07 10:19:18 +1100" MODIFIED_BY="Narelle S Willis" NO="11">
<NAME>Tonsillectomy+other treatment versus other treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 12:52:36 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Remission of proteinuria</NAME>
<GROUP_LABEL_1>Tonsillectomy+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tonsillectomy+other</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.703367009711497" CI_START="0.8901592313517952" EFFECT_SIZE="2.046153846153846" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.6724088686192737" LOG_CI_START="-0.05053229997081331" LOG_EFFECT_SIZE="0.3109382843242302" MODIFIED="2010-12-30 12:52:12 +1100" MODIFIED_BY="Narelle S Willis" ORDER="171" O_E="0.0" SE="0.4246592210463168" STUDY_ID="STD-Hotta-1993" TOTAL_1="26" TOTAL_2="19" VAR="0.18033545401966458" WEIGHT="0.0">
<FOOTNOTE>Tonsillectomy+steroid+cytotoxic+anticoagulant versus steroid+cytotoxic+anticoagulant</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6694213688118559" CI_END="2.2532141250131024" CI_START="1.0494379845411912" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5377283538042388" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.35280246508950674" LOG_CI_START="0.020956779490762432" LOG_EFFECT_SIZE="0.18687962229013463" METHOD="MH" MODIFIED="2011-02-07 10:17:34 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.4132537424573586" P_Q="0.0" P_Z="0.027278030905677313" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="35" WEIGHT="100.0" Z="2.2075159932981725">
<NAME>Remission of haematuria</NAME>
<GROUP_LABEL_1>Tonsillectomy+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tonsillectomy+other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.469003645880503E-31" CI_END="3.2231842286316517" CI_START="1.0355126149308023" DF="0" EFFECT_SIZE="1.8269230769230769" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" I2="100.0" ID="CMP-011.02.01" LOG_CI_END="0.5082851293384365" LOG_CI_START="0.015155393969660607" LOG_EFFECT_SIZE="0.2617202616540486" MODIFIED="2011-02-07 10:17:34 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.037485612248667644" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="19" WEIGHT="45.28454092109122" Z="2.080435431388973">
<NAME>Microscopic haematuria</NAME>
<DICH_DATA CI_END="3.2231842286316517" CI_START="1.0355126149308023" EFFECT_SIZE="1.8269230769230769" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.5082851293384365" LOG_CI_START="0.015155393969660607" LOG_EFFECT_SIZE="0.2617202616540486" MODIFIED="2011-02-07 10:17:34 +1100" MODIFIED_BY="Narelle S Willis" ORDER="174" O_E="0.0" SE="0.2896668475871775" STUDY_ID="STD-Hotta-1993" TOTAL_1="26" TOTAL_2="19" VAR="0.08390688259109311" WEIGHT="45.28454092109122">
<FOOTNOTE>Tonsillectomy+steroid+cytotoxic+anticoagulant versus steroid+cytotoxic+anticoagulant: absence of haematuria (microscopic &lt; 3 RBC/HPF)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2348585393474605" CI_START="0.7954766471692912" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="0.3492500386423989" LOG_CI_START="-0.09937256542579911" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-02-07 10:17:08 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.27497524296832965" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="54.71545907890878" Z="1.0916767091342494">
<NAME>Macroscopic haematuria</NAME>
<DICH_DATA CI_END="2.2348585393474605" CI_START="0.7954766471692912" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.3492500386423989" LOG_CI_START="-0.09937256542579911" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-02-07 10:17:08 +1100" MODIFIED_BY="Narelle S Willis" ORDER="173" O_E="0.0" SE="0.2635231383473649" STUDY_ID="STD-Kawasaki-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.06944444444444442" WEIGHT="54.71545907890878">
<FOOTNOTE>Tonsillectomy+steroid pulse+PWD versus PWD+cytotoxic</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.03" MODIFIED="2011-02-07 10:17:55 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Tonsillectomy+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tonsillectomy+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.653904037521336" CI_START="-9.653904037521336" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="44.0" MODIFIED="2011-02-07 10:17:55 +1100" MODIFIED_BY="Narelle S Willis" ORDER="175" SD_1="10.0" SD_2="12.0" SE="3.905124837953327" STUDY_ID="STD-Kawasaki-2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0">
<FOOTNOTE>Tonsillectomy+steroid pulse+PWD versus PWD+cytotoxic</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.16236868258103" CI_END="21.346492790005506" CI_START="-13.802897985687018" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.771797402159244" ESTIMABLE="YES" I2="75.97521804868296" I2_Q="0.0" ID="CMP-011.04" MODIFIED="2011-02-07 10:18:44 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.04133169012930693" P_Q="1.0" P_Z="0.6740193446054181" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="123.07985323886636" TOTALS="YES" TOTAL_1="42" TOTAL_2="35" UNITS="mL/min" WEIGHT="100.0" Z="0.4206381335249875">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Tonsillectomy+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tonsillectomy+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.805265839773273" CI_START="2.1947341602267265" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="92.1" MEAN_2="80.1" MODIFIED="2011-02-07 10:18:30 +1100" MODIFIED_BY="Narelle S Willis" ORDER="176" SD_1="14.9" SD_2="17.7" SE="5.002778580175941" STUDY_ID="STD-Hotta-1993" TOTAL_1="26" TOTAL_2="19" WEIGHT="54.28776334532913">
<FOOTNOTE>Tonsillectomy+steroid+cytotoxic+anticoagulant versus steroid+cytotoxic+anticoagulant</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="8.243491284369453" CI_START="-20.243491284369455" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="113.0" MEAN_2="119.0" MODIFIED="2011-02-07 10:18:44 +1100" MODIFIED_BY="Narelle S Willis" ORDER="177" SD_1="19.0" SD_2="22.0" SE="7.267220926874317" STUDY_ID="STD-Kawasaki-2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="45.71223665467087">
<FOOTNOTE>Tonsillectomy+steroid pulse+PWD versus PWD+cytotoxic</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.050917788963507286" CI_END="0.16701827453146734" CI_START="-0.8104616559743946" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3217216907214636" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.05" MODIFIED="2011-02-07 10:19:18 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.8214738806565445" P_Q="1.0" P_Z="0.19698788551941424" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="1.2901808153402723">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Tonsillectomy+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tonsillectomy+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.23555370729432884" CI_START="-0.9578130837667365" EFFECT_SIZE="-0.3611296882362038" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.6" MODIFIED="2010-12-30 14:38:58 +1100" MODIFIED_BY="Narelle S Willis" ORDER="178" SD_1="0.5" SD_2="0.6" SE="0.3044358979231736" STUDY_ID="STD-Hotta-1993" TOTAL_1="26" TOTAL_2="19" WEIGHT="67.09154642460786">
<FOOTNOTE>Tonsillectomy+steroid+cytotoxic+anticoagulant versus steroid+cytotoxic+anticoagulant (g/24 h)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.610590324599853" CI_START="-1.0933489452895082" EFFECT_SIZE="-0.2413793103448276" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="10.0" MODIFIED="2011-02-07 10:19:18 +1100" MODIFIED_BY="Narelle S Willis" ORDER="179" SD_1="8.0" SD_2="8.0" SE="0.4346863726399609" STUDY_ID="STD-Kawasaki-2006" TOTAL_1="16" TOTAL_2="8" WEIGHT="32.90845357539215">
<FOOTNOTE>Tonsillectomy+steroid pulse+PWD versus PWD+cytotoxic (mg/m²/h)</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-011.06" MODIFIED="2010-12-30 14:42:40 +1100" MODIFIED_BY="Narelle S Willis" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Tonsillectomy + other treatment</P>
</TH>
<TH>
<P>Other treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 14:42:40 +1100" MODIFIED_BY="Narelle S Willis" ORDER="170" STUDY_ID="STD-Kawasaki-2006">
<TR>
<TD>
<P>Tonsillectomy+steroid pulse+PWD (prednisone+warfarin+dipyridamole)</P>
<P>Glaucoma (1, 8.3%); growth retardation (1, 8.3%); hypertension (1, 8.3%)</P>
</TD>
<TD>
<P>PWD + cytotoxic</P>
<P>Glaucoma (2, 12.5%); growth retardation (1, 8.3%); hypertension (2, 12.5%); hyperuricaemia (3, 18.8%)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2010-12-30 14:48:16 +1100" MODIFIED_BY="Narelle S Willis" NO="12">
<NAME>Statins versus placebo/no treatment</NAME>
<OTHER_OUTCOME COLS="2" ID="CMP-012.01" MODIFIED="2010-12-30 14:44:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Serum creatinine: Other data</NAME>
<TR>
<TH>
<P>Statins</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 14:44:51 +1100" MODIFIED_BY="Narelle S Willis" ORDER="171" STUDY_ID="STD-Buemi-2000">
<TR>
<TD>
<P>n = 13; 132.6 µmol/L; interquartile range = 79.56 -176.8; SD missing</P>
</TD>
<TD>
<P>n = 8; 123.76 µmol/L; Interquartile range = 106.08 -185.64; SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-012.02" MODIFIED="2010-12-30 14:46:58 +1100" MODIFIED_BY="Narelle S Willis" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>GFR: Other data</NAME>
<TR>
<TH>
<P>Statins</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 14:46:58 +1100" MODIFIED_BY="Narelle S Willis" ORDER="172" STUDY_ID="STD-Buemi-2000">
<TR>
<TD>
<P>n = 13; 85 mL/min/1.73 m²; interquartile range = 70-147; SD missing</P>
</TD>
<TD>
<P>n = 8; 77 mL/min/1.73 m²; interquartile range = 47-92; SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-012.03" MODIFIED="2010-12-30 14:48:16 +1100" MODIFIED_BY="Narelle S Willis" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Proteinuria: Other data</NAME>
<TR>
<TH>
<P>Statin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 14:48:16 +1100" MODIFIED_BY="Narelle S Willis" ORDER="173" STUDY_ID="STD-Buemi-2000">
<TR>
<TD>
<P>n = 13; 0.49 g/24 h; interquartile range = 0.41- 0.80; SD missing</P>
</TD>
<TD>
<P>n = 8; 1.1 g/24 h; interquartile range = 0.84-1.86; SD missing</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-02-07 10:19:55 +1100" MODIFIED_BY="Narelle S Willis" NO="13">
<NAME>Statins+other treatment versus other treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2010-12-30 14:49:56 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Statins+ other treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1554588863495674" CI_START="-15.35545888634957" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" MEAN_1="41.5" MEAN_2="48.6" MODIFIED="2010-12-30 14:49:56 +1100" MODIFIED_BY="Narelle S Willis" ORDER="129" SD_1="12.4" SD_2="10.6" SE="4.212046216903767" STUDY_ID="STD-Kano-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0">
<FOOTNOTE>Statin+anticoagulant versus anticoagulant</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.02" MODIFIED="2010-12-30 14:50:59 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Statins+ other treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours statins+other</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.37148370688542" CI_START="11.828516293114566" EFFECT_SIZE="22.599999999999994" ESTIMABLE="YES" MEAN_1="133.1" MEAN_2="110.5" MODIFIED="2010-12-30 14:50:59 +1100" MODIFIED_BY="Narelle S Willis" ORDER="131" SD_1="14.9" SD_2="15.2" SE="5.4957559382976" STUDY_ID="STD-Kano-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0">
<FOOTNOTE>Statin+anticoagulant versus anticoagulant.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.03" MODIFIED="2011-02-07 10:19:55 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Statins+ other treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.06492543409678869" CI_START="-0.6649254340967887" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.8" MODIFIED="2011-02-07 10:19:55 +1100" MODIFIED_BY="Narelle S Willis" ORDER="133" SD_1="0.4" SD_2="0.6" SE="0.18618986725025255" STUDY_ID="STD-Kano-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0">
<FOOTNOTE>Statin+anticoagulant versus anticoagulant.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.04" MODIFIED="2010-12-30 14:52:28 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>Statins+ other treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.993887317287562" CI_START="-35.99388731728756" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="36.0" MODIFIED="2010-12-30 14:52:28 +1100" MODIFIED_BY="Narelle S Willis" ORDER="134" SD_1="22.0" SD_2="42.0" SE="12.242004193213898" STUDY_ID="STD-Kano-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0">
<FOOTNOTE>Statin+anticoagulant versus anticoagulant (RBC/HPF)</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2010-12-30 14:58:03 +1100" MODIFIED_BY="Narelle S Willis" NO="14">
<NAME>Phenytoin versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 14:54:19 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Remission of haematuria</NAME>
<GROUP_LABEL_1>Phenytoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phentyoin</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.57422473412601" CI_START="0.5788662094209757" EFFECT_SIZE="4.473684210526316" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5387524506044594" LOG_CI_START="-0.23742180108153177" LOG_EFFECT_SIZE="0.6506653247614638" MODIFIED="2010-12-30 14:54:19 +1100" MODIFIED_BY="Narelle S Willis" ORDER="132" O_E="0.0" SE="1.0433335476446959" STUDY_ID="STD-Houssin-1984" TOTAL_1="19" TOTAL_2="17" VAR="1.0885448916408669" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.09614262145767648" CI_END="41.56217771289407" CI_START="-80.73343109499015" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-19.585626691048045" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" MODIFIED="2010-12-30 14:55:09 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7565087074350015" P_Q="1.0" P_Z="0.5301507060608995" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="41" UNITS="" WEIGHT="100.0" Z="0.6277759815465395">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Phenytoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phenytoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="59.8478205360701" CI_START="-119.8478205360701" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="160.0" MODIFIED="2010-12-30 14:55:06 +1100" MODIFIED_BY="Narelle S Willis" ORDER="133" SD_1="100.0" SD_2="200.0" SE="45.841567112854236" STUDY_ID="STD-Clarkson-1980" TOTAL_1="23" TOTAL_2="24" WEIGHT="46.31766335591777"/>
<CONT_DATA CI_END="72.85745983388966" CI_START="-94.05745983388965" EFFECT_SIZE="-10.599999999999994" ESTIMABLE="YES" MEAN_1="132.9" MEAN_2="143.5" MODIFIED="2010-12-30 14:55:09 +1100" MODIFIED_BY="Narelle S Willis" ORDER="134" SD_1="154.0" SD_2="98.0" SE="42.58111908799929" STUDY_ID="STD-Houssin-1984" TOTAL_1="19" TOTAL_2="17" WEIGHT="53.68233664408223"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.03" MODIFIED="2010-12-30 14:55:49 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="24" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Phenytoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phenytoin</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.049995652426034" CI_START="-28.049995652426034" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="85.0" MODIFIED="2010-12-30 14:55:24 +1100" MODIFIED_BY="Narelle S Willis" ORDER="135" SD_1="36.7" SD_2="40.4" SE="11.250204506997877" STUDY_ID="STD-Clarkson-1980" TOTAL_1="23" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3021765778470144" CI_END="0.1472896009868278" CI_START="-0.9890172281514087" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.42086381358229047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.04" MODIFIED="2010-12-30 14:56:40 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.5825212021863232" P_Q="1.0" P_Z="0.14654117270622788" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="41" UNITS="g/24 h" WEIGHT="99.99999999999999" Z="1.4518577128380854">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Phenytoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phenytoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.13435920519209088" CI_START="-1.1343592051920908" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="1.03" MODIFIED="2010-12-30 14:56:37 +1100" MODIFIED_BY="Narelle S Willis" ORDER="137" SD_1="0.71" SD_2="1.41" SE="0.32365860301303256" STUDY_ID="STD-Clarkson-1980" TOTAL_1="23" TOTAL_2="24" WEIGHT="80.21595339557261"/>
<CONT_DATA CI_END="1.1773445457585168" CI_START="-1.377344545758517" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.6" MODIFIED="2010-12-30 14:56:40 +1100" MODIFIED_BY="Narelle S Willis" ORDER="136" SD_1="2.2" SD_2="1.7" SE="0.6517183763753046" STUDY_ID="STD-Houssin-1984" TOTAL_1="19" TOTAL_2="17" WEIGHT="19.784046604427378"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-014.05" MODIFIED="2010-12-30 14:58:03 +1100" MODIFIED_BY="Narelle S Willis" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Phenytoin</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 14:58:03 +1100" MODIFIED_BY="Narelle S Willis" ORDER="184" STUDY_ID="STD-Houssin-1984">
<TR>
<TD>
<P>Gastric (5); skin rash (1); gingival hyperplasia (1); increased liver enzyme (8)</P>
</TD>
<TD>
<P>Gastric (0); skin rash (0); gingival hyperplasia (0): increased liver enzyme (3)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2010-12-30 15:03:29 +1100" MODIFIED_BY="Narelle S Willis" NO="15">
<NAME>Herbal medicine versus placebo/no treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.01" MODIFIED="2010-12-30 15:00:21 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Herbal medicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal medicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6861528940422135" CI_START="-0.24615289404221347" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="0.99" MODIFIED="2010-12-30 15:00:02 +1100" MODIFIED_BY="Narelle S Willis" ORDER="211" SD_1="0.78" SD_2="0.49" SE="0.23783747952470963" STUDY_ID="STD-Qian-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0">
<FOOTNOTE>TWG versus no treament</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.16887611833083" CI_END="0.043764900607082824" CI_START="-0.6612515520182193" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30874332570556823" ESTIMABLE="YES" I2="53.89317114296038" I2_Q="53.89317114296038" ID="CMP-015.02" MODIFIED="2010-12-30 15:01:25 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.14082919655514425" P_Q="0.14082919655514425" P_Z="0.08604700372632063" Q="2.16887611833083" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.038910869565217394" TOTALS="YES" TOTAL_1="61" TOTAL_2="63" UNITS="" WEIGHT="100.00000000000001" Z="1.7166288718417808">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Herbal medicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal medicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09384710595778661" CI_START="-1.0261528940422135" DF="0" EFFECT_SIZE="-0.56" ESTIMABLE="YES" I2="0.0" ID="CMP-015.02.01" MODIFIED="2010-12-30 15:01:21 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.01854519839173825" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="33.87982255409692" Z="2.3545490017767365">
<NAME>TWG</NAME>
<CONT_DATA CI_END="-0.09384710595778661" CI_START="-1.0261528940422135" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="0.99" MODIFIED="2010-12-30 15:01:21 +1100" MODIFIED_BY="Narelle S Willis" ORDER="210" SD_1="0.78" SD_2="0.49" SE="0.23783747952470963" STUDY_ID="STD-Qian-1987" TOTAL_1="15" TOTAL_2="15" WEIGHT="33.87982255409692"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.694798272305689E-32" CI_END="0.016109986639984336" CI_START="-0.3761099866399843" DF="0" EFFECT_SIZE="-0.17999999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-015.02.02" MODIFIED="2010-12-30 15:01:25 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.07202541517305679" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="48" WEIGHT="66.1201774459031" Z="1.7989574282357308">
<NAME>Sairei-to</NAME>
<CONT_DATA CI_END="0.01610998663998431" CI_START="-0.3761099866399843" EFFECT_SIZE="-0.18" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.43" MODIFIED="2010-12-30 15:01:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="209" SD_1="0.4" SD_2="0.56" SE="0.10005795422103408" STUDY_ID="STD-Yoshikawa-1997" TOTAL_1="46" TOTAL_2="48" WEIGHT="66.1201774459031"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.03" MODIFIED="2010-12-30 15:03:29 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="46" TOTAL_2="48" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>Herbal medicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal medicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.33492921657026026" CI_START="-1.2650707834297399" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.8" MODIFIED="2010-12-30 15:02:50 +1100" MODIFIED_BY="Narelle S Willis" ORDER="139" SD_1="1.1" SD_2="1.2" SE="0.23728537212834458" STUDY_ID="STD-Yoshikawa-1997" TOTAL_1="46" TOTAL_2="48" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2011-02-07 10:21:27 +1100" MODIFIED_BY="Narelle S Willis" NO="16">
<NAME>Herbal medicine versus other treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2010-12-30 15:05:15 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Herbal medicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal medicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.026473433550025" CI_START="-2.6464734335500295" EFFECT_SIZE="-0.3100000000000023" ESTIMABLE="YES" MEAN_1="82.96" MEAN_2="83.27" MODIFIED="2008-10-01 13:03:30 +1000" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.15" SD_2="6.31" SE="1.192100187544175" STUDY_ID="STD-Bo-2000" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.02" MODIFIED="2010-12-30 15:11:00 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="35" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Herbal medicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal medicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5732926734336312" CI_START="-1.2267073265663686" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.49" MEAN_2="1.39" MODIFIED="2010-12-30 15:11:00 +1100" MODIFIED_BY="Narelle S Willis" ORDER="141" SD_1="0.38" SD_2="0.91" SE="0.16669047449003882" STUDY_ID="STD-Bo-2000" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0">
<FOOTNOTE>Shenning mixture versus steroid+vitamin E+dipyridamole</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.03" MODIFIED="2011-02-07 10:21:27 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>Herbal medicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal medicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-13.94673076154869" CI_START="-22.393269238451314" EFFECT_SIZE="-18.17" ESTIMABLE="YES" MEAN_1="8.26" MEAN_2="26.43" MODIFIED="2011-02-07 10:21:27 +1100" MODIFIED_BY="Narelle S Willis" ORDER="142" SD_1="8.08" SD_2="9.86" SE="2.154768797673795" STUDY_ID="STD-Bo-2000" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0">
<FOOTNOTE>Shenning mixture versus steroid+vitamin E+dipyridamole (RBC x 10<SUP>4</SUP>/mL)</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-016.04" MODIFIED="2010-12-30 15:13:59 +1100" MODIFIED_BY="Narelle S Willis" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Herbal medicine</P>
</TH>
<TH>
<P>Other treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 15:13:59 +1100" MODIFIED_BY="Narelle S Willis" ORDER="192" STUDY_ID="STD-Bo-2000">
<TR>
<TD>
<P>Shenning mixture: GIT reaction "burning sensation in the abdomen", irregular menstruation (number not specified)</P>
</TD>
<TD>
<P>Steroid+vitamin E+dypyridamole: no signficant side effects</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2010-12-30 15:27:14 +1100" MODIFIED_BY="Narelle S Willis" NO="17">
<NAME>Herbal medicine+other treatment versus other treatment</NAME>
<OTHER_OUTCOME COLS="2" ID="CMP-017.01" MODIFIED="2010-12-30 15:24:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Other data</NAME>
<TR>
<TH>
<P>Herbal medicine + other treatment</P>
</TH>
<TH>
<P>Other treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 15:24:13 +1100" MODIFIED_BY="Narelle S Willis" ORDER="193" STUDY_ID="STD-Wu-2003">
<TR>
<TD>
<P>Dan Shao Tang (DST) + western medicine: "the general effective rate in the treatment group was 70%, which was markedly higher than that in control group (37.50%, p&lt;0.01). Treatment group is obviously better than control group on decreasing hematuria, proteinuria, blood IgA and improving renal function (p&lt;0.05)"</P>
</TD>
<TD>
<P>Western medicine</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-017.02" MODIFIED="2010-12-30 15:26:03 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="47" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Herbal medicine+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours othr treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.134159972357661" CI_START="-11.894159972357652" EFFECT_SIZE="-0.8799999999999955" ESTIMABLE="YES" MEAN_1="90.06" MEAN_2="90.94" MODIFIED="2010-12-30 15:26:03 +1100" MODIFIED_BY="Narelle S Willis" ORDER="203" SD_1="21.21" SD_2="20.98" SE="5.61957263461775" STUDY_ID="STD-Li-2006" TOTAL_1="47" TOTAL_2="20" WEIGHT="0.0">
<FOOTNOTE>Astragalus+ACEi+anticoagulant versus ACEi+anticoagulant</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-017.03" MODIFIED="2010-12-30 15:27:14 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="47" TOTAL_2="20" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Herbal medicine+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours herbal+other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.06296569666608659" CI_START="-0.6229656966660866" EFFECT_SIZE="-0.28" ESTIMABLE="YES" MEAN_1="1.19" MEAN_2="1.47" MODIFIED="2010-12-30 15:26:29 +1100" MODIFIED_BY="Narelle S Willis" ORDER="204" SD_1="0.47" SD_2="0.72" SE="0.1749857137025763" STUDY_ID="STD-Li-2006" TOTAL_1="47" TOTAL_2="20" WEIGHT="0.0">
<FOOTNOTE>Astragalus+ACEi+anticoagulant versus ACEi+anticoagulant</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2010-12-30 15:31:51 +1100" MODIFIED_BY="Narelle S Willis" NO="18">
<NAME>Urokinase+ACEi versus ACEi</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 15:28:36 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Urokinase+ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase+ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7426812219450363" CI_START="0.007860081215580388" EFFECT_SIZE="0.14682539682539683" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43817533308923146" LOG_CI_START="-2.10457296651833" LOG_EFFECT_SIZE="-0.8331988167145491" MODIFIED="2008-10-01 13:30:36 +1000" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="1.4936229379965618" STUDY_ID="STD-Chen--2004" TOTAL_1="35" TOTAL_2="36" VAR="2.2309094809094807" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 15:29:00 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 50% decrease in proteinuria</NAME>
<GROUP_LABEL_1>Urokinase+ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours urokinase+ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.448588812569027" CI_START="1.054855821445722" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.38891586090034447" LOG_CI_START="0.02319310396590447" LOG_EFFECT_SIZE="0.20605448243312446" MODIFIED="2008-10-01 13:31:12 +1000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.21482735778013393" STUDY_ID="STD-Chen--2004" TOTAL_1="35" TOTAL_2="36" VAR="0.046150793650793664" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-018.03" MODIFIED="2010-12-30 15:29:30 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Urokinase+ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase+ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<CONT_DATA CI_END="-31.293841480233496" CI_START="-47.686158519766494" EFFECT_SIZE="-39.489999999999995" ESTIMABLE="YES" MEAN_1="105.95" MEAN_2="145.44" MODIFIED="2008-10-01 13:32:41 +1000" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="22.51" SD_2="10.41" SE="4.181790371872521" STUDY_ID="STD-Chen--2004" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-018.04" MODIFIED="2010-12-30 15:29:52 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Urokinase+ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours urokinase+ACEi</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.14308876784359" CI_START="4.256911232156387" EFFECT_SIZE="10.199999999999989" ESTIMABLE="YES" MEAN_1="81.85" MEAN_2="71.65" MODIFIED="2008-10-01 13:33:49 +1000" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="11.19" SD_2="14.22" SE="3.0322438650515657" STUDY_ID="STD-Chen--2004" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-018.05" MODIFIED="2010-12-30 15:30:16 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Urokinase+ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase+ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5954792175472072" CI_START="-0.7445207824527929" EFFECT_SIZE="-0.67" ESTIMABLE="YES" MEAN_1="0.62" MEAN_2="1.29" ORDER="189" SD_1="0.15" SD_2="0.17" SE="0.03802150602796949" STUDY_ID="STD-Chen--2004" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-018.06" MODIFIED="2010-12-30 15:31:51 +1100" MODIFIED_BY="Narelle S Willis" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Urokinase+ACEi</P>
</TH>
<TH>
<P>ACEi</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 15:31:51 +1100" MODIFIED_BY="Narelle S Willis" ORDER="201" STUDY_ID="STD-Chen--2004">
<TR>
<TD>
<P>Bleeding (3, mild nose bleed)</P>
</TD>
<TD>
<P>Hyperkalaemia (3, 'due to ACEi but not significant)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2010-12-30 15:35:52 +1100" MODIFIED_BY="Narelle S Willis" NO="19">
<NAME>Vitamin E versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-30 15:33:14 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-01 13:35:20 +1000" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.0" STUDY_ID="STD-Chan-2003" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-019.02" MODIFIED="2010-12-30 15:33:49 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin E</GRAPH_LABEL_2>
<CONT_DATA CI_END="37.080194430083495" CI_START="-7.080194430083491" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="127.0" MEAN_2="112.0" MODIFIED="2008-10-01 13:36:33 +1000" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="50.0" SD_2="31.0" SE="11.265612329741387" STUDY_ID="STD-Chan-2003" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-019.03" MODIFIED="2010-12-30 15:34:28 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.15730058536538993" CI_START="-0.8973005853653899" EFFECT_SIZE="-0.37" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.61" MODIFIED="2008-10-01 13:38:08 +1000" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="0.38" SD_2="1.37" SE="0.26903585449766915" STUDY_ID="STD-Chan-2003" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0">
<FOOTNOTE>UPr/UCr</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-019.04" MODIFIED="2010-12-30 15:35:00 +1100" MODIFIED_BY="Narelle S Willis" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Haematuria: Other data</NAME>
<TR>
<TH>
<P>Vitamin E</P>
</TH>
<TH>
<P>Placebo/no treatment</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 15:34:47 +1100" MODIFIED_BY="Narelle S Willis" ORDER="205" STUDY_ID="STD-Chan-2003">
<TR>
<TD>
<P>'no difference'</P>
</TD>
<TD>
<P>'no difference'</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-019.05" MODIFIED="2010-12-30 15:35:52 +1100" MODIFIED_BY="Narelle S Willis" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Vitamin E</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2010-12-30 15:35:52 +1100" MODIFIED_BY="Narelle S Willis" ORDER="206" STUDY_ID="STD-Chan-2003">
<TR>
<TD/>
<TD/>
<TD>
<P>No compaints or untoward complications from either group</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2010-12-30 15:37:50 +1100" MODIFIED_BY="Narelle S Willis" NO="20">
<NAME>Sodium cromoglycate versus placebo/no treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-020.01" MODIFIED="2010-12-30 15:37:15 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Sodium cromoglycate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sodium cromoglycate</GRAPH_LABEL_2>
<CONT_DATA CI_END="26.988891947587362" CI_START="-10.18889194758735" EFFECT_SIZE="8.400000000000006" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="78.6" MODIFIED="2008-10-01 13:41:01 +1000" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="28.8" SD_2="22.8" SE="9.484302820977407" STUDY_ID="STD-Sato-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-020.02" MODIFIED="2010-12-30 15:37:50 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Sodium cromoglycate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sodium cromoglycate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.033220998677319535" CI_START="-2.093220998677319" EFFECT_SIZE="-1.0299999999999998" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="2.84" MODIFIED="2008-10-01 13:42:20 +1000" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="1.1" SD_2="1.79" SE="0.5424696612100379" STUDY_ID="STD-Sato-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-02-08 19:34:11 +1100" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="flow chart 019.PNG" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-01-17 22:11:19 +1100" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart showing number of reports of studies identified by searches, reports excluded and number of studies included</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-02-08 19:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAAEZCAMAAAB4lwZ2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///80TKWtAAALHUlEQVR42u2di5KkKBBF3YmO4Of4XH6OiJ6ZnS4fvBUU0KLOjd2pKgRFrpkkes2eJjA0/psEgzAw9C/GYGxAMAQDCAYQDCAYQDCAYODga5QFPVTaEMMRnOuKPsNjfeOimYMBBAMIBhAMIBjUIlgGX+KQXfsoYweUUsJeKcFSPXXQVMCvUgqGT7roxTYWG/n372JCci2cSzYT2iqm6v80kGbPdstopeWXdbSwFshD5E6WVPN4qvmrsv3jXKjm8tf/dsVU/W2DmvyWMlbJ3aVyDrOUK6grt+CfcZMRj6h2XGWsXO1sVzsNg6Oq3UNJSC61YHkcScnw289FoY7r75Qlj7vnjOG3nGDlDKlKjKr0Ny++U2VFR7GylMOQqnfAPrSLfpnE7KOlY0FyinwEm1P1XYpkYj0mj/xE1qUDcoKsfxy/vO7sec0v6+MV+qxjbCpG69umLq2KU7rS+sscbfJr4aIzkfVmQ+lYltSvxJPmebCF741UfesDf4mnfYYFvwGQ7Dh4iAW3OCPwiXMSBAMIBhAMngeE72NH0WML3z/WPSF8Zw4GEAwgGEAwgGBwD8Gr9kMmN1+R28iDbQjfWxOcoZJv+KwX4XtfFy0DYXtSru6p20NB/Gab89awvkSJl4+vSvY0+cL2qFx9iqvbnTKji5+F8WF9hfC9gwUblbzvlQ/lszEhvUptTWrwUd01tmB5Kj7K2GOmgB5+GxOcFKWflqurneaw2dlFWyr5iKXJYtuXx80llN8WZFmi9wO5eiB+D8rW5rEDeEEdOMYwslmeB1uwhO/cqsRFvwf+ZJZB8HsC4XvtGx0AggEEAwgGBFkTwvdkzPlpGd/fxW39vtT6Ly6aORhAMIBgAMEAgsEtBEu5alnDRIS7svWkYOMw4bx0jg57GbiyDn6lmFXrt2BTiiS1u8Oj5tZe0HR0c9Ey0LA7BdIyOrm+8hII2lehvN/cU7xjut0sOLApN+G7X+AI4uPp3a0vsQpWpnmMtwPBbqpJ419loiDijlXEJ6ujCpa+FvSZg69dJEUVNn0l/HZ20Wf9+j7HYQWiq7vXwTLLSuVR9UQFmR9pg6pz8OZB3SnXFCTE7kra66e5OF5hcjLNY8ZZ6CJ8j3BxSE8hf5rnwRb+dswXTVb3D7DgDkCy44CM70TRAIIBBAMIBk2B8H3sKHpY4fsHeabIPRGE78zBAIIBBAMIBhAMehN8SfK+r9DJFYSgns3EuXXwFcm7yth3xjWGNKuPiz4jed9k7JMlZPfSxJts8ZbaHeF7LwsOrKlE8j7Z8nY3z7tJEy+dZp4+HuF7awv+mYNjkvdUQdQNK+k5WV/9rlLuG+F7vzm4gv1PC9shodE3IlBVdnfR12Cs0qcsmfsdbm9aB2eucIwxquTiKPn3GxC+97DgS5L3qMtdq2zqd2mnjrd2gIsuQ2PZ7HkWLgrfP/x5cBfZ7HnJO2L5t7HgbkCy4wDhO1E0gGAAwQCCQVMgfB87ih5N+P6xDsm924HwnTkYQDCAYADBAIJBJYIrpnBvr2xFPZsHZx1cPYV7Q36RZl1y0eV69k2bvsnXIxnbpWt70ik4/kD4ftGCAyMp0LM7JqVMVUuyPjklvpQ94wPh+0WCL6Vwj0C5X9X+5qCG2q+Gh74wBzedPr1vvq4yVmj1EVVlLRfdCsoJlKZNym4+pqDQbQ63ddfBhXp2eVzPyeYeatwlwvcec/DmErP07ManGrH6vo+19O1Wzb0PXHQ5zslmnze4mufBFi4J31Glf4AFPw9IdhwgfCeKBhAMIBhAMGgKhO9jR9FDZnz/RK+E8J05GEAwgGAAwQCCQVeCLwviMzQexUA9m4esdfADBfEI32sS7IyrnLU4k1x5twqWIX+patZs0HJR2GxlRn5jdJR5H1I5zUF9gjeSSwTx8eztCN+fE2RdTPDuit5j3xC+P2UOvjBpJr8hfH+Yiz4fFCW+IXx/6Do4VxAv920Y4fvtFnxREB9kbzf1EL63Rl3Z7H2DrnkebKFJxncE8R9gwfcByY4DhO9E0QCCAQQDCAZNgfB97Ch6SOH7oM7qd35VhO/MwQCCAQQDCAYQDDoSvKNhT8jgZfLHbmF0k636QPiehbrr4NbPg83+Eb63c9FL9naTfd0UyMktm7ws7dJkgzeJ3P2U8W5e+PWdGZNPHtNtbcEv+bny9ehe5vdl8+Ro3VVMzx5t6FlooJbHeBsGWVkvKKmM5ipWrNxNan0FJmiHh24/B8uLDXcCMPeXk4MYVWU3gtW1hkYD7//wftlyd6Krvuvgi0Z8bMPKY75XxI4FvzTs9jgvcZQ/9k695TVjPz385CvpPV09Lvos3kA2m8Wk5nmwBUv4/vyzxlJHt+AsINlxgPCdKBpAMIBgAMGgKRC+jx1Ff5LwfXxft90KQfjOHAwgGEAwgGAAwaA5wUdS1Qsp3VeRrGkvq3QJFKyDG6rM5Ul1BsL3iha8SXFcobujb7dF7FEFu/vh1HfF8fZGO1vp9lcjMN3qFvyCcrXpkyNfj6V0dxTsXup2Ny288pXue/Y518V4WwZZVgp3tV8rVpDNzUvzLiP5om3vDmpZ8KEjTwRaBxncM3etErM3qEbw0YAm3kg5zOCe6TFAOxdttMt7drtvxPLMKupnblb2K2j2LmC9ngWvjjXiYJe/mWT9TQ1PDp9K3e7vy08Tn0wxvx4RF52Fi7LZ/qOcOKLmebD9PPidhO/gTgt+DJDsOED4ThQNIBhAMIBgAMEAggEEQzCA4MdCP2IXD+wGFowFAwgGjwVPk4bEeE+TKlynusKlrh/SDVw0czCAYECQBe4OPr/GOZU50NI//xYEKluz12dpaxPTiNM92KIiUdKNeavpferIwxCs53N7/VfC7zokYvlV1NoJ4U/2YNuBngq6ob2TTh750+dgUWFtokXFK7T2Ib8GJO3MgOsrXGt/GX5mH6KkGyL73EcjWOif/3RJ6Lh66H+fJ1pPW+PzPfD3dLYbsWbDWbCYtmmp3FOfay1q9OB6N+LNBpyDSwPYy961xhzhNznZjbDZx9/o2Oa+Swu0eks9bnQcRTp6XUeWLkBPtA7W0qf3sZhe/i5i6+BIM82drMEdFPeiBwcEQzCAYADBAIJBA3w1XWWDuyAiBLMiHmj5i4tmDgYQDCAYQDDotEzaWTDdHl/To6oE+3b953H9/L6/R/+5P//iogEEg/sI1vGZZy7UGVNVUEdrU6qPZrj8Lt15xzXaIx2epO42RvkEi9ehYpHErgAwvU0Lka4m3vTGuN4bHnHHGJW7aP26qtYPr3y94PR66WqnqrZrau8iTe04Z1jXprE+6o5GLbweBJaol95obcy76Rh9FfRdrK/PmPedzBUae7VGC3eL/VuYdtp7d2sW95csO9Y3r6K7qvTuUNkl556z3TPtnHXzMfpVcnWKQ9fy8+rE63+vgkj68pgDKyYk7gXFDSvUuN8U/ncR2dRmjMpfXdHbiYj8cxYZQUHxjg+nwjsmcnHKX7Qbo3KCxfaReypL1YN3bbT1/vNVhoWzx3dAszH6ddJA9M4F7F3EOjvu1GVWFwnsdc6y7g4nfTAczcao3IIX92C8xEJn2m34Vd2aQm8b5y06/wL1jmnvaumjuInhYHisLuquY2S9uqKTfy7rT0a2iAZhqP3Tvxd9/8MG/160yB2eauOlxfGmGklYRAOG9Tj6MGd4dMWgPm+MarwA3oCMkfR/otF55e0rTvCfx43S9+N69Pc9Lq+v97AfenQWPC4cHBAMwQCCAQQDCAaNl0m8Pzo2wbw9iosGEAwgGEAwgGAAwQCCAXhv/A9akLWggETeqAAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-02-08 19:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-02-17 08:11:28 +1100" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2011-02-08 16:56:25 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2009-04-07 16:15:24 +1000" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-08 16:56:25 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms used</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>Glomerulonephritis, IGA/</LI>
<LI>iga glomeruloneph$.tw.</LI>
<LI>iga neph$.tw.</LI>
<LI>IgAGN.tw.</LI>
<LI>IgA-N.tw.</LI>
<LI>berger$ disease.tw.</LI>
<LI>("immunoglobulin a" and neph$).tw.</LI>
<LI>Glomerulonephritis/im [Immunology]</LI>
<LI>or/1-8</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>Immunoglobulin a Nephropathy/</LI>
<LI>iga neph$.tw.</LI>
<LI>iga glomeruloneph$.tw.</LI>
<LI>berger$ disease.tw.</LI>
<LI>IgAGN.tw.</LI>
<LI>igA-N.tw.</LI>
<LI>("immunoglobulin a" and neph$).tw.</LI>
<LI>or/1-7</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor Glomerulonephritis, IGA explode all trees in MeSH products</LI>
<LI>iga next glomeruloneph* in Clinical Trials</LI>
<LI>iga next nephropath* in Clinical Trials</LI>
<LI>IgAGN in Clinical Trials</LI>
<LI>("iga-N" or "igan") in Clinical Trials</LI>
<LI>berger* next disease* in Clinical Trials</LI>
<LI>("immunoglobulin a" next nephropath*) in Clinical Trials</LI>
<LI>(1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7)</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-01-12 16:57:09 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2011-01-12 16:56:36 +1100" MODIFIED_BY="Narelle S Willis">Quality checklist</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-12 16:57:01 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Allocation Concealment</HEADING>
<UL>
<LI>Adequate (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study</LI>
<LI>Unclear (B): Randomisation stated but no information on method used is available</LI>
<LI>Inadequate (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<UL>
<LI>Blinding of investigators Yes/No/not stated</LI>
<LI>Blinding of participants Yes/No/not stated</LI>
<LI>Blinding of outcome assessor Yes/No/not stated</LI>
<LI>Blinding of data analysis Yes/No/not stated</LI>
</UL>
<P>The above were considered not blinded if the treatment group could be identified in &gt;20% of participants because of the side effects of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat analysis</HEADING>
<UL>
<LI>Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>No: Not reported and lack of intention-to-treat analysis confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation)</LI>
<LI>Not stated</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness to follow-up</HEADING>
<P>Per-cent of participants excluded.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-02-09 16:15:15 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<TITLE MODIFIED="2009-06-19 15:40:47 +1000" MODIFIED_BY="[Empty name]">Key characteristics of included studies</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-09 16:15:15 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Fish oil</HEADING>
<TABLE COLS="3" ROWS="8">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study, year, country</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Intervention/s (dose), duration</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participant characteristics</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Alexopoulos-2004" TYPE="STUDY">Alexopoulos 2004</LINK>
</P>
<P>Greece</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: MaxEPA (6 g/d; 0.85 g/d EPA and 0.58 DHA g/d)</P>
<P>Control: Symptomatic treatment (e.g. ACEi ± BB, CCB, diuretics)</P>
<P>Duration: 4 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 34</P>
<P>Mean age: 41 years</P>
<P>Sex (M/F): 79/21 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bennett-1989" TYPE="STUDY">Bennett 1989</LINK>
</P>
<P>Australia</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: MaxEPA (10 g/d; 1.8 g/d EPA and 1.2 g/d DHA)</P>
<P>Control: No treatment</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 27</P>
<P>Mean age: Group A (52 years); group B (28 years)</P>
<P>Sex (M/F): 57/43 (%)</P>
<P>Group A: SCr &gt; 0.12 mmol/L</P>
<P>Group B: SCr &lt; 0.12 mmol/L with proteinuria, urine RBC &gt; 200,000/mL or &gt; 10% crescents</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Costanzi-2006" TYPE="STUDY">Costanzi 2006</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: EPA (85%)+ DHA (3 x 1 g/d) + ARB (irbesartan, 300 mg/d) + ACEi (ramipril, 10 mg/d)</P>
<P>Control: ARB (irbesartan, 300 mg/d) + ACEi (ramipril, 10 mg/d)</P>
<P>Duration: 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 30</P>
<P>Mean age: 39.5 years</P>
<P>Sex (M/F): 47/53 (%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Donadio-1994" TYPE="STUDY">Donadio 1994</LINK>
</P>
<P>USA</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: MaxEPA (12 g/d; 1.87 g/d EPA and 1.36 g/d DHA)</P>
<P>Control: Placebo</P>
<P>Duration: 2 years<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 106</P>
<P>Mean age: 37 years</P>
<P>Sex (M/F): 74/26 (%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Donadio-2001" TYPE="STUDY">Donadio 2001</LINK>
</P>
<P>USA</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: Low dose Omacor (8 x 1 g capsules; EPA 1.88 g/d + DHA 1.47 g/d)</P>
<P>Control: High dose Omacor (4 x 1g capsules; EPA 3.76 g/d + DHA 2.94 g/d)</P>
<P>Duration: 2 years<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 73</P>
<P>Mean age: 46 years</P>
<P>Sex (M/F): 84/16 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-NA-IgAN-Study-2006" TYPE="STUDY">NA IgAN Study 2006</LINK>
</P>
<P>USA</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: O3FA (4 g/d; 1.88 g/d EPA + 1.48 g/d DHA)</P>
<P>Control: placebo</P>
<P>Treatment 2: Steroid (prednisone, 60 mg/m² alternate days for 3 months then 40 mg/m² for 9 months then 30 mg/m² for 12 months)</P>
<P>Duration 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 98</P>
<P>Mean age: 20 years</P>
<P>Sex (M/F): 66/34 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pettersson-1994" TYPE="STUDY">Pettersson 1994</LINK>
</P>
<P>Sweden</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: K85 (6 g/d) with EPA (55%) and DHA (30%; 5.1g of w-3-PUFA)</P>
<P>Control: Corn oil (6 g/d)</P>
<P>Duration: 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 34</P>
<P>Mean age: 39 years</P>
<P>Sex (M/F): 78/22 (%)<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"> Antihypertensive agents</HEADING>
<TABLE COLS="3" ROWS="31">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study, year, country</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Intervention/s (drug; dose), duration</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participant characteristics</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bang-1994" TYPE="STUDY">Bang 1994</LINK>
</P>
<P>Korea</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ACEi (captopril; NS) + antiplatelet (dipyridamole; NS)</P>
<P>Control: Antiplatelet (dipyridamole; NS)</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 45</P>
<P>Age: NS</P>
<P>Sex: NS<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bannister-1995" TYPE="STUDY">Bannister 1995</LINK>
</P>
<P>Australia</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (enalapril; NS)</P>
<P>Treatment 2: CCB (nifedipine; NS)</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 52</P>
<P>Mean age: 53 years</P>
<P>Sex (M/F): 74/26 (%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (fosinopril; NS)</P>
<P>Treatment 2: Herbal medicine (Shenle capsule; NS)</P>
<P>Duration: 12 weeks </P>
</TD>
<TD VALIGN="TOP">
<P>Number: 70</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (fosinopril; NS) + Herbal medicine (compound Shenhua tablet; NS)</P>
<P>Treatment 2: Herbal medicine (compound Shenhua tablet; NS)</P>
<P>Duration: 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 131</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>
</P>
<P>Hong Kong</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: BB (nadolol; 80 mg)</P>
<P>Treatment 2: ACEi (captopril 75 mg)</P>
<P>Treatment 3: ACEi (captopril; 75 mg) + anticoagulant (ticlopidine; 250 mg twice daily)</P>
<P>Dose titrated to target dose (above) to normalise BP in hypertensives and reduce 5-10 mm Hg in normotensives</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 47</P>
<P>Mean age: 32 years</P>
<P>Sex (M/F): 74/26 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Guan-2005" TYPE="STUDY">Guan 2005</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (irbesartan; 150 to 300 mg/d)</P>
<P>Treatment 2: Herbal medicine (Huobahuagen tablets; 5, 3 times/d) + ARB (irbesartan; 50 to 300 mg/d)</P>
<P>Duration: 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 62</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hashizume-1998" TYPE="STUDY">Hashizume 1998</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (cilazapril; 1 mg/d)</P>
<P>Treatment 2: antiplatelet (NS; NS)</P>
<P>Duration: 5 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 47</P>
<P>Mean age: 42 years</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HKVIN-Study-2006" TYPE="STUDY">HKVIN Study 2006</LINK>
</P>
<P>Hong Kong</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ARB (valsartan; 80-160 mg/d to achieve target BP)</P>
<P>Control: placebo</P>
<P>Duration: 104 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 109</P>
<P>Mean age: 41 years</P>
<P>Sex (M/F): 28/72 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Horita-2004" TYPE="STUDY">Horita 2004</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (temocapril; 1 mg)</P>
<P>Treatment 2: ARB (losartan; 12.5 mg)</P>
<P>Treatment 3: ACEi (temocapril; 1 mg) + ARB (losartan; 12.5 mg)</P>
<P>Duration: 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 46</P>
<P>Mean age: 43 years</P>
<P>Sex (M/F): 56/44 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Horita-2007" TYPE="STUDY">Horita 2007</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (losartan; 50 mg/d) + steroid (prednisolone; 30 mg/d tapered to 5 mg/d over 2 years) + antiplatelet (dipyridamole; 300 mg/d)</P>
<P>Treatment 2: steroid (prednisolone; 30 mg/d tapered to 5 mg/d over 2 years) + antiplatelet (dipyridamole; 300 mg/d)</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 40</P>
<P>Mean age: 34 years</P>
<P>Sex (M/F): 53/47 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-IgACE-Study-2001" TYPE="STUDY">IgACE Study 2001</LINK>
</P>
<P>Italy, France,<BR/>Germany, Sweden, Portugal</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ACEi (benazepril; 0.2 mg/kg/d)</P>
<P>Control: placebo</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 66</P>
<P>Mean age: 20.5 years (range 9-35)</P>
<P>Sex (M/F): 73/27 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-JLIGHT-Study-2003" TYPE="STUDY">JLIGHT Study 2003</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (losartan; 25-100 mg/d)</P>
<P>Treatment 2: CCB (amlodipine; 2.5-5 mg/d)</P>
<P>Duration: 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 24</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kanno-2005" TYPE="STUDY">Kanno 2005</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (temocapril or trandolapril; 1-2 mg/d) ± BB (arotinolol; 10-20 mg/d if need for BP control)</P>
<P>Treatment 2: CCB (amlodipine; 2.5-5 mg/d) ± BB (arotinolol; 10-20 mg/d if need for BP control)</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 49</P>
<P>Mean age: 35 years<BR/>Sex (M/F): 31/60 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (valsartan; 160 mg/d)</P>
<P>Treatment 2: ACEi (benazepril; 20 mg/d)</P>
<P>Treatment 3: ARB (valsartan; 160 mg/d) + ACEi (benazepril; 20 mg/d)</P>
<P>Duration: 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 61</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Maschio-1994" TYPE="STUDY">Maschio 1994</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ACEi (fosinopril; 20 mg/d)</P>
<P>Control: placebo</P>
<P>Duration: 2 x 4 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 44</P>
<P>Mean age: 33 years</P>
<P>Sex (M/F): 67/33 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nakamura-2000" TYPE="STUDY">Nakamura 2000</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: CCB (verapamil; 120 mg/d)</P>
<P>Treatment 2: ACEi (trandolapril; 2 mg/d)</P>
<P>Treatment 3: ARB (candesartan; 8 mg/d)</P>
<P>Control: placebo</P>
<P>Duration: 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 32</P>
<P>Mean age: 33 years</P>
<P>Sex (M/F): 44/56 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nakamura-2007" TYPE="STUDY">Nakamura 2007</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (temocapril; 2 mg)</P>
<P>Treatment 2: ARB (olmesartan; 10 mg)</P>
<P>Treatment 3: ACEi (temocapril; 2 mg) + ARB (olmesartan; 10 mg)</P>
<P>Duration: 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 23</P>
<P>Mean age: 32 years</P>
<P>Sex (M/F): 54/36 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nakao-2001" TYPE="STUDY">Nakao 2001</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (trandolapril; NS) + ARB (losartan; NS)</P>
<P>Treatment 2: ACEi (trandolapril; NS) + placebo</P>
<P>Treatment 3: ARB (losartan; NS) + placebo</P>
<P>Treatment 4: Other antihypertensives (NS; NS) + placebo</P>
<P>Duration: 1 year</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 40</P>
<P>Mean age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Panichi-2000" TYPE="STUDY">Panichi 2000</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (enalapril; 10 mg/d)</P>
<P>Treatment 2: ARB (losartan; 50 mg/d)</P>
<P>Duration: 2 x 4 weeks with 4-week washout</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 10</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Park--2003" TYPE="STUDY">Park 2003</LINK>
</P>
<P>Korea</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (losartan; 50 mg/d)</P>
<P>Treatment 2: CCB (amlodipine; 5 mg/d)</P>
<P>Duration: 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 36</P>
<P>Mean age: 39 years</P>
<P>Sex (M/F): 50/50 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Perico-1998" TYPE="STUDY">Perico 1998</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (enalapril; 20 mg/d)</P>
<P>Treatment 2: ARB (irbesartan; 100 mg/d)</P>
<P>Duration: 4weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 20</P>
<P>Age range: 20-65 years</P>
<P>Sex (M/F): 80/20 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Praga-2003" TYPE="STUDY">Praga 2003</LINK>
</P>
<P>Spain</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ACEi (enalapril; 5-40 mg/d aim BP &lt; 140/90)</P>
<P>Control: symptomatic treatment (included other antihypertensive agents other than ACEi or ARB if necessary for BP &lt; 140/90)</P>
<P>Duration: 78 days</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 44</P>
<P>Mean age: 28 years</P>
<P>Sex (M/F): 61/39 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Roccatello-2000" TYPE="STUDY">Roccatello 2000</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (losartan; 50 mg/d)</P>
<P>Treatment 2: ACEi (enalapril; 10 mg/d)</P>
<P>Treatment 3: nitric oxide (NO donor isosorbide 5 mononitrate; NS)</P>
<P>Duration: 3 x 7 day sequences with 7 day wash out periods</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 8</P>
<P>Mean age: 49 years</P>
<P>Sex (M/F): 88/12 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Russo-2001" TYPE="STUDY">Russo 2001</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (enalapril; 10-20 mg/d)</P>
<P>Treatment 2: ARB (losartan; 50-100 mg/d)</P>
<P>Treatment 3: ACEi (enalapril; 10-20 mg/d) + ARB (losartan; 50-100 mg/d)</P>
<P>Duration: 6 x 4 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 10</P>
<P>Mean age: 25 years</P>
<P>Sex (M/F): 40/60 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shi-2002" TYPE="STUDY">Shi 2002</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ACEi (benazepril; 10-20 mg/d)</P>
<P>Control: symptomatic treatment (non-ACEi antihypertensive agents e.g. CCB or BB or AB)</P>
<P>Duration: 18 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 131</P>
<P>Mean age: 29 years</P>
<P>Sex (M/F): 66/34 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shimizu-2008" TYPE="STUDY">Shimizu 2008</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (losartan; 6.25-25 mg/d)</P>
<P>Treatment 2: antiplatelet (NS; NS)</P>
<P>Duration: NS</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 36</P>
<P>Mean age: 36 years</P>
<P>Sex (M/F): 47/53 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>
</P>
<P>Korea</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: ARB (candesartan; 4-8 mg/d) + ACEi (ramipril; 5 mg/d)</P>
<P>Control: placebo + ACEi (ramipril; 5 mg/d)</P>
<P>Duration: 2 x 16 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 14</P>
<P>Mean age: 31 years</P>
<P>Sex (M/F): 43/57 (%)<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tesar-1999" TYPE="STUDY">Tesar 1999</LINK>
</P>
<P>Czech Republic</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (enalapril; 10 mg/d)</P>
<P>Treatment 2: ARB (losartan; 50 mg/d)</P>
<P>Duration: 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 23</P>
<P>Mean age: 35 years</P>
<P>Sex: NS<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Woo-2000" TYPE="STUDY">Woo 2000</LINK>
</P>
<P>Singapore</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ACEi (enalapril; 5-10 mg/d)</P>
<P>Treatment 2: ARB (losartan; 50-100 mg/d)</P>
<P>Treatment 3: ACEi (enalapril; 5-10 mg/d) + ARB (losartan; 50-100 mg/d)</P>
<P>Control: symptomatic treatment (antihypertensive agents i.e. atenolol, hydralazine or methyldopa)</P>
<P>Duration: 13 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 41</P>
<P>Mean age: 39 years</P>
<P>Sex (M/F): 78:22 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Woo-2008" TYPE="STUDY">Woo 2008</LINK>
</P>
<P>Singapore</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: ARB (losartan-high dose; 200 mg/d)</P>
<P>Treatment 2: ARB (losartan-normal dose; 100 mg/d)</P>
<P>Treatment 3: ACEi (enalapril-normal dose; 20 mg/d)</P>
<P>Treatment 4: ACEi (enalapril-low dose; 10 mg/d)</P>
<P>Duration: 6 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 226</P>
<P>Mean age: 34 years</P>
<P>Sex (M/F): 53/47 (%)</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"> Antiplatelet/anticoagulant agents</HEADING>
<TABLE COLS="3" ROWS="6">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study, year, country</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Intervention/s (drug; dose), duration</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>Participant</P>
<P>
<B>characteristics</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK>
</P>
<P>Spain</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: antiplatelet (dipyridamole; 300 mg/d)</P>
<P>Control: placebo</P>
<P>Duration: 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 12</P>
<P>Mean age: 35 years</P>
<P>Sex (M/F): 58/42 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chan-1987" TYPE="STUDY">Chan 1987</LINK>
</P>
<P>Hong Kong</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment : antiplatelet (aspirin SR; 650 mg/d + dipyridamole; 75-225 mg/d)</P>
<P>Control: Vitamin B complex (NS)</P>
<P>Duration: 33.2 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 52</P>
<P>Mean age: 29 years</P>
<P>Sex (M/F): 63:37 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>
</P>
<P>Hong Kong</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: antiplatelet (ticlopidine; 250 mg twice/d) + ACEi (captopril; 75 mg)</P>
<P>Treatment 2: ACEi (captopril; 75 mg)</P>
<P>Treatment 3: BB (nadolol; 80 mg)</P>
<P>Titrated to normalise BP in hypertensives and reduce 5-10 mm Hg in normotensives</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 47</P>
<P>Mean age: 32 years</P>
<P>Sex (M/F): 74/26 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Frasca-1997" TYPE="STUDY">Frasca 1997</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: antiplatelet (defibrotide; 10 mg/kg/d) + steroid (prednisone; 0.5 mg/kg/alternate days 6 months)</P>
<P>Treatment 2: Steroid (prednisone; 0.5mg/kg/alternate days 6 months)</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 20</P>
<P>Mean age: 30 years</P>
<P>Sex (M/F): 90/10 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lee-1997" TYPE="STUDY">Lee 1997</LINK>
</P>
<P>Singapore</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: antiplatelet (dipyridamole; 75 mg twice/d) + anticoagulant (warfarin; INR 1.3-1.5)</P>
<P>Control: no treatment</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 21</P>
<P>Mean age: 36 years</P>
<P>Sex (M/F): 76/24 (%)<BR/>
</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other interventions</HEADING>
<TABLE COLS="3" ROWS="21">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study, year, country</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Intervention/s (drug; dose), duration</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participant characteristics</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Tonsillectomy</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hotta-1993" TYPE="STUDY">Hotta 1993</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: tonsillectomy + steroid (methylprednisolone; pulse initially 1-3 courses 1000 mg/d for 3 days; 30 mg/d for 4 weeks then tapered over 1 to 2 years) + cytotoxic (cyclophosphamide; 50 mg/d for 4 months) + antiplatelet (dipyridamole; 150-300 mg/d for 3 years) + anticoagulant (warfarin during the steroid therapy; thrombotest 20-40%)</P>
<P>Treatment 2: steroid (methylprednisolone; pulse initially 1-3 courses 1000 mg/d for 3 days; 30 mg/d for 4 weeks then tapered over 1 to 2 years) + cytotoxic (cyclophosphamide; 50 mg/d for 4 months) + antiplatelet (dipyridamole; 150-300 mg/d for 3 years) + anticoagulant (warfarin during the steroid therapy; thrombotest 20-40%)</P>
<P>Duration: 3 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 45</P>
<P>Mean age: 29 years</P>
<P>Sex (M/F): 38/62 (%)<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kawasaki-2006" TYPE="STUDY">Kawasaki 2006</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: tonsillectomy + steroid pulse (methylprednisolone; 10 days after surgery 20-25 mg/kg/d for 3 days) + steroid (prednisolone; 2 mg/kg/d [max 60 mg] reduced over 12 months to 0.5 mg/kg alternate days for 21 months) + anticoagulant (warfarin; 1-2 mg/d) + antiplatelet (dipyridamole; 5 mg/kg/d [max 300 mg])</P>
<P>Treatment 2: steroid (prednisolone; 2 mg/kg/d [max 60 mg] reduced over 12 months to 0.5 mg/kg alternate days for 21 months) + anticoagulant (warfarin; 1-2 mg/d) + antiplatelet (dipyridamole; 5 mg/kg/d [max 300 mg]) + cytotoxic (mizoribine; 5 mg/kg/d)</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 34</P>
<P>Mean age: 13 years</P>
<P>Sex (M/F): 53/47 (%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Statins </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Buemi-2000" TYPE="STUDY">Buemi 2000</LINK>
</P>
<P>Italy</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment : statin (fluvastatin; 40 mg/d)</P>
<P>Control: placebo</P>
<P>Duration: 6 months<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 21</P>
<P>Mean age: 36 years</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kano-2003" TYPE="STUDY">Kano 2003</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: statin (fluvastatin; 20 mg) + antiplatelet (dipyridamole; 5 mg/kg)</P>
<P>Treatment 2: antiplatelet (dipyridamole; 5 mg/kg)</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 30</P>
<P>Mean age: 13 years</P>
<P>Sex (M/F): 47/53 (%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Phenytoin </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Adamkova-1989" TYPE="STUDY">Adamkova 1989</LINK>
</P>
<P>Czech Republic</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: phenytoin (diphenylhydantoin; 2-3 mg/kg)</P>
<P>Control: no treatment</P>
<P>Duration: 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 17</P>
<P>Age: NS</P>
<P>Sex (M/F): 89/11 (%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Clarkson-1980" TYPE="STUDY">Clarkson 1980</LINK>
</P>
<P>Australia</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: phenytoin (5-6 mg/kg/d in 3 divided doses; (blood level 40-80 µmol/L or 10-20 µg/mL)</P>
<P>Control: no treatment</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 47</P>
<P>Age: 32 years</P>
<P>Sex (M/F): 74/26 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Houssin-1984" TYPE="STUDY">Houssin 1984</LINK>
</P>
<P>France</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: phenytoin (200-300 mg/d)</P>
<P>Control: no treatment</P>
<P>Duration: NS</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 36</P>
<P>Mean age: 34 years</P>
<P>Sex (M/F): 83/17 (%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Herbal medicine</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bo-2000" TYPE="STUDY">Bo 2000</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: Shenning Mixture (30 mL 3 times/d)</P>
<P>Treatment 2: steroid (prednisolone; 30 mg initially then tapered over 7 weeks)+ vitamin E (0.1 g/d) + antiplatelet (dipyridamole; 150 mg)</P>
<P>Duration: 6 months<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 70</P>
<P>Mean age: 30 years</P>
<P>Sex (M/F): 53/47 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: Astragalus IV injection (NS) + antiplatelet (dipyridamole; NS) + ACEi (benazepril; NS)</P>
<P>Control: antiplatelet (dipyridamole; NS) + ACEi (benazepril; NS)</P>
<P>Duration: NS</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 67</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Qian-1987" TYPE="STUDY">Qian 1987</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: Tripterygium Wilfordii Glycoside (20-60 mg/d)</P>
<P>Control: no treatment</P>
<P>Duration: 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 30</P>
<P>Mean age: NS</P>
<P>Sex (M/F): 60/40 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: Dan Shao Tang (NS)</P>
<P>Treatment 2: Western medicine (NS; NS)</P>
<P>Duration: 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 90</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yoshikawa-1997" TYPE="STUDY">Yoshikawa 1997</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: Sairei-to (TJ 114; NS)</P>
<P>Control: no treatment</P>
<P>Duration: 2 years<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 101</P>
<P>Age: NS</P>
<P>Sex: NS</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Miscellaneous </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen--2004" TYPE="STUDY">Chen 2004</LINK>
</P>
<P>China</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment 1: urokinase (100,000 IU/250 mL 5% glucose IV/d for 10 days/ month) + ACEi (benazepril; 10 mg/d)</P>
<P>Treatment 2: ACEi (benazepril; 10 mg/d)</P>
<P>Duration: 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 71</P>
<P>Mean age: 30 years</P>
<P>Sex (M/F): 68/32 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chan-2003" TYPE="STUDY">Chan 2003</LINK>
</P>
<P>USA</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: vitamin E (&lt; 30 kg, 400 IU/d; &#8805; 30 kg 800 IU/d)</P>
<P>Control: placebo</P>
<P>Duration: 2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 55</P>
<P>Mean age: 11 years</P>
<P>Sex (M/F): 67/33 (%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sato-1990" TYPE="STUDY">Sato 1990</LINK>
</P>
<P>Japan</P>
</TD>
<TD VALIGN="TOP">
<P>Treatment: sodium cromoglycate (1200 mg/d)</P>
<P>Control: no treatment</P>
<P>Duration: 16 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Number: 30</P>
<P>Mean age: 39 years</P>
<P>Sex (M/F): 37:63 (%)<BR/>
</P>
</TD>
</TR>
</TABLE>
<P>
<I>AB - alpha blockers; ACEi - angiotensin converting enzyme inhibitors; ARB - angiotensin receptor blockers; BB - beta blockers; CCB - calcium channel blockers; DHA - Docosahexanoic acid; EPA - Eicosapentaenoic acid; MaxEPA (Seven Seas Health Care Ltd, UK); NS - not stated; O3FA - omega 3 fatty acid; PFA - Polyunsaturated fatty acid; w-3-PUFA - omega 3 polyunsaturated fatty acids<BR/>
</I>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-02-01 17:21:58 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<TITLE MODIFIED="2011-02-01 17:21:58 +1100" MODIFIED_BY="Narelle S Willis">Studies not included in meta-analyses</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-01 17:18:55 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="4" ROWS="17">
<TR>
<TH VALIGN="TOP">
<P>Study ID</P>
</TH>
<TH VALIGN="TOP">
<P>N</P>
</TH>
<TH VALIGN="TOP">
<P>Intervention</P>
</TH>
<TH VALIGN="TOP">
<P>Reason not included</P>
</TH>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Antihypertensive agents</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>
</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi and ARB</P>
</TD>
<TD>
<P>Data not useable - not able to distinguish groups (abstract only in English, paper in Chinese, groups not clearly labelled)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Maschio-1994" TYPE="STUDY">Maschio 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi</P>
</TD>
<TD VALIGN="TOP">
<P>Data not useable - not able to distinguish groups </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nakao-2001" TYPE="STUDY">Nakao 2001</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>ACEi and ARB</P>
</TD>
<TD>
<P>Data not useable</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Panichi-2000" TYPE="STUDY">Panichi 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi and ARB</P>
</TD>
<TD VALIGN="TOP">
<P>Crossover RCT - data not separate thus not useable</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Roccatello-2000" TYPE="STUDY">Roccatello 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi</P>
</TD>
<TD VALIGN="TOP">
<P>Data not useable - not able to distinguish groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Russo-2001" TYPE="STUDY">Russo 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi and ARB</P>
</TD>
<TD VALIGN="TOP">
<P>Data not useable - not able to distinguish groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi</P>
</TD>
<TD VALIGN="TOP">
<P>Crossover RCT - data not separate thus not useable</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tesar-1999" TYPE="STUDY">Tesar 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi and ARB</P>
</TD>
<TD VALIGN="TOP">
<P>Complete data not given. Qualitative results only.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Antiplatelet/anticoagulant agents</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>Anticoagulant</P>
</TD>
<TD VALIGN="TOP">
<P>Numbers in treatment groups NS.<BR/>Attempt to contact authors - no response.<BR/>Unable to use data in MA.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Statins</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Buemi-2000" TYPE="STUDY">Buemi 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>Statin</P>
</TD>
<TD VALIGN="TOP">
<P>Data not useable &#8211; only interquartile ranges, no SD provided</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Other</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD VALIGN="TOP">
<P>Herbal: Dan Shao Tang<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chinese - abstract only in English - unable to translate rest. Not included in MA. Western medicine not defined.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Adamkova-1989" TYPE="STUDY">Adamkova 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>Phenytoin</P>
</TD>
<TD VALIGN="TOP">
<P>Journal paper with only abstract in English - unable to translate full article. Additional data re SE versus SD requested from authors - no response.<BR/>Unable to use data in MA</P>
</TD>
</TR>
</TABLE>
<P> N - number of participants</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-02-09 16:15:15 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<TITLE MODIFIED="2011-01-12 16:57:22 +1100" MODIFIED_BY="Narelle S Willis">Reports of adverse events in included studies</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-09 16:15:15 +1100" MODIFIED_BY="Narelle S Willis">
<P> </P>
<TABLE COLS="4" ROWS="33">
<TR>
<TH VALIGN="TOP">
<P>Study</P>
</TH>
<TH VALIGN="TOP">
<P>N</P>
</TH>
<TH VALIGN="TOP">
<P>Treatment group</P>
</TH>
<TH VALIGN="TOP">
<P>Other group</P>
</TH>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Fish oil</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Costanzi-2006" TYPE="STUDY">Costanzi 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>Fish oil+ARB+ACEi: No adverse events</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi or ARB: no adverse events</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Donadio-1994" TYPE="STUDY">Donadio 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>106</P>
</TD>
<TD VALIGN="TOP">
<P>Fish oil: fishy after taste (NS); no discontinuation because of adverse events</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Donadio-2001" TYPE="STUDY">Donadio 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>73</P>
</TD>
<TD VALIGN="TOP">
<P>High dose fish oil: GIT intolerance (1); " no serious adverse events"</P>
</TD>
<TD VALIGN="TOP">
<P>Low dose fish oil: GIT intolerance (1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pettersson-1994" TYPE="STUDY">Pettersson 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>Fish oil: belching occasionally (NS)</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo: belching occasionally (NS)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Antihypertensive agents (ACEi or ARB)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-IgACE-Study-2001" TYPE="STUDY">IgACE Study 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>66</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi: cough, temporary (1)</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi: "no severe adverse event was found"</P>
</TD>
<TD VALIGN="TOP">
<P>Shenle capsule: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>131</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi+Shenhua: "no severe adverse event occurred during treatment, and the occurrence in the two groups was similar"</P>
</TD>
<TD VALIGN="TOP">
<P>Shenhua: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HKVIN-Study-2006" TYPE="STUDY">HKVIN Study 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>109</P>
</TD>
<TD VALIGN="TOP">
<P>ARB: major adverse event (pregnancy, TB) (2); minor adverse event (dizzy, headache, palpitation, ankle oedema) (5)</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo: major adverse event (allergy, heart failure, pregnancy, nephrotic syndrome) (4); minor adverse event (dizzy, headache, palpitation, ankle oedema) (9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Horita-2004" TYPE="STUDY">Horita 2004</LINK>
</P>
<P>(3-arm study)</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi+ARB: dry cough (1); postural, dropped out because of side effects (1); unclear which group </P>
</TD>
<TD VALIGN="TOP">
<P>ACEi or ARB: dry cough (1); postural, dropped out because of side effects (1); unclear which group </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Horita-2007" TYPE="STUDY">Horita 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>ARB+steroid+anticoagulant: Postural hypotension (NS)</P>
</TD>
<TD VALIGN="TOP">
<P>Steroid+anticoagulant: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-JLIGHT-Study-2003" TYPE="STUDY">JLIGHT Study 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>ARB: No fatal adverse events in either group; increased ALT, AST (NS, incidence 'almost the same' across groups); hyperkalaemia (3); dizziness (2) TIA (1)</P>
</TD>
<TD VALIGN="TOP">
<P>CCB: No fatal adverse events in either group; increased ALT, AST (NS, but incidence 'almost the same' across groups); increased uric acid (2); hyperkalaemia (2); dizziness (2); TIA (1) </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>
</P>
<P>(3-arm study)</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>ARB: "fewer side effects with no obvious differences in the three groups"</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi; ARB+ACEi: "fewer side effects with no obvious differences in the three groups"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nakamura-2007" TYPE="STUDY">Nakamura 2007</LINK>
</P>
<P>(3-arm study)</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi: "we did not notice any adverse effects of the monotherapy and the combination therapy"</P>
</TD>
<TD VALIGN="TOP">
<P>ARB; ACEi+ARB: "we did not notice any adverse effects of the monotherapy and the combination therapy"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Praga-2003" TYPE="STUDY">Praga 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi: no withdrawals because of ACEi side effects, mild increase in K+ only (NS)</P>
</TD>
<TD VALIGN="TOP">
<P>Symptomatic treatment: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shi-2002" TYPE="STUDY">Shi 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>131</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi: minor dry cough (9; all except 1 remained on treatment); headache and dizziness (5; 1 withdrew from study); tolerable GIT side effects (3)</P>
</TD>
<TD VALIGN="TOP">
<P>Symptomatic treatment: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Woo-2000" TYPE="STUDY">Woo 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi or ARB or ACEi+ARB: cough (NS); dizzy (NS); hypotension (NS)</P>
</TD>
<TD VALIGN="TOP">
<P>Symptomatic treatment: NS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Woo-2008" TYPE="STUDY">Woo 2008</LINK>
</P>
<P>(4-arm study)</P>
</TD>
<TD VALIGN="TOP">
<P>226</P>
</TD>
<TD VALIGN="TOP">
<P>ARB groups (high and normal dose): cough (1), rash (1), dizzy (1)</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi groups (normal and low dose): cough (6), dizzy (1), low blood pressure (1)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Antiplatelet/anticoagulant agents</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Camara-1991" TYPE="STUDY">Camara 1991</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>Antiplatelet: transient headache (100%)</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo: NS</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Tonsillectomy</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kawasaki-2006" TYPE="STUDY">Kawasaki 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>Tonsillectomy+steroid+anticoagulant+antiplatelet: glaucoma (1, 8.3%); growth retardation (1, 8.3%); hypertension (1, 8.3%)</P>
</TD>
<TD VALIGN="TOP">
<P>Cytotoxic+steroid+anticoagulant+antiplatelet: glaucoma (2, 12.5%); growth retardation (1, 8.3%); hypertension (2, 12.5%); hyperuricaemia (3, 18.8%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Phenytoin</B> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Houssin-1984" TYPE="STUDY">Houssin 1984</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>Phenytoin: gastric (5); skin rash (1); gingival hyperplasia (1); increased liver enzyme (8)</P>
</TD>
<TD VALIGN="TOP">
<P>No treatment: gastric (0); skin rash (0); gingival hyperplasia (0); increased liver enzyme (3)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Herbal medicine</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bo-2000" TYPE="STUDY">Bo 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>Shenning Mixture: GIT reaction "burning sensation in the abdomen" (NS); irregular menstruation (NS)</P>
</TD>
<TD VALIGN="TOP">
<P>Steroid+Vitamin E+antiplatelet: no significant side effects</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Qian-1987" TYPE="STUDY">Qian 1987</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>Tripterygium Wilfordii Glycoside: Adverse reactions included nausea, pigmentation and leucocytopenia, that would disappear while the dosage was lowered</P>
</TD>
<TD VALIGN="TOP">
<P>No treatment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Urokinase</B> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen--2004" TYPE="STUDY">Chen 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>Urokinase+ACEi: bleeding, mild nose bleed (3); hyperkalaemia (3, 'due to ACEi but group NS)</P>
</TD>
<TD VALIGN="TOP">
<P>ACEi: hyperkalaemia (3, 'due to ACEi but group NS)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Vitamin E</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chan-2003" TYPE="STUDY">Chan 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>Vitamin E: no complaints or untoward complications from either group</P>
</TD>
<TD VALIGN="TOP">
<P>Placebo: no complaints or untoward complications from either group</P>
</TD>
</TR>
</TABLE>
<P> N - number of participants</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>